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ABSTRACT 
Introduction The process of sequestration involving specific cytoadhesion between parasite 
ligands expressed on the surface of the parasitised red blood cells (pRBC) and host vascular 
endothelium contributes to pathogenesis of severe falciparum malaria. A major polymorphic 
surface antigen implicated in cytoadhesion is the Plasmodium falciparum erythrocyte 
membrane protein 1 (PfEMP1). PfEMP1 is encoded by the var multigene family that is sub-
divided into three main groups: A, B and C, according to sequence similarities in coding and 
non-coding sequences. PfEMP1 has variant adhesive phenotypes, some of which interact with 
ABO blood groups to form rosettes and some involved in apparent formation of platelet-
mediated clumps of infected erythrocytes that are thought to contribute to disease severity. 
With heavy HIV burden concentrating in areas with high malaria rates, co-infections are 
common. Both HIV and malaria interact with the host immune system, resulting in a complex 
activation of immune cells and subsequent dysregulated production of cytokines and 
antibodies.  However, there is limited information on the molecular mechanisms of interaction 
between the two infections.  
Methods Real time PCR was used to: 1) compare abundance of the three main var groups and 
measure the level of cytokine production and receptor expression utilising the resources of a 
clinicopathological study of 20 Malawian fatal paediatric malaria patients divided into three 
diagnostic groups: circulating and sequestered parasites (CM1); circulating and sequestered 
parasites plus perivascular pathology (CM2) and parasitaemic control (PC)  groups; and 2) 
determine the effect of host ABO blood group on expression of var/PfEMP1 subtypes mediating 
platelet-mediating clumping in 65 Malawian paediatric patients with uncomplicated malaria 
(UM). 
Results While there were no significant associations between ABO blood antigen groups with 
the clumping phenotype in UM patients, an abundance of var upsA and C transcripts were 
expressed in CM2 and the PC (p ≤ 0.001) groups. However, a very different expression pattern 
was observed in the CM1 group, which were mostly HIV positive (80%), with var gene group 
upsB being more abundant than in the other two diagnostic groups ( p ≤ 0.001). This result was 
supported by different cytokine/receptor upregulation between HIV positive and HIV negative 
children, with significant upregulation of TNF in HIV negative children (p ≤ 0.05).  
Conclusions This data suggests that perivascular pathogenesis in naturally infected children is 
associated with differential var gene expression in the body. HIV disruption of cytokine release 
affects receptor regulation and influences parasite antigen expression. 
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Chapter 1 
 
1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Global Malaria Burden 
Malaria is a disease that has plagued the human race for centuries. The word malaria is 
derived from two medieval Italian words “mal” and “aria” which mean “bad air”.  It was 
believed to be caused from ghastly smells from swamps in the 14th century. Malaria is a vector-
borne infectious disease caused by a eukaryotic protozoan of the genus Plasmodium. It is 
widely spread in the tropics and subtropical regions, which include parts of the Americas, Asia, 
and Africa. 70% of malaria clinical attacks  occur in sub-Saharan Africa and 25% are in highly 
populated South East Asia (Snow, Guerra et al. 2005). 90% of the mortality from malaria occurs 
in Africa with poverty contributing to the high mortality.  
Malaria is regarded as one of the most important parasitic infections worldwide with 
approximately 40% of the world’s population being affected by the disease once or more in 
their lifetime.  Despite control measures aimed at decreasing disease burden, there has been a 
tremendous increase in the annual number of cases from 221 million in 2002 (Snow, Guerra et 
al. 2005) to approximately 500 million cases and with about one million fatalities annually in 
sub-Saharan Africa  alone (Hay, Guerra et al. 2009). In 2007, an estimate of 2.4 billion people 
were at risk of malaria with 60% of this population living in areas designated as having stable P. 
falciparum transmission; Central and South East Asia (CSE Asia) and Africa (Hay, Guerra et al. 
2009). In 2009, a study carried out in 81 of the most malaria prone countries with the aim of 
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estimating global Plasmodium falciparum infection (Hay, Guerra et al. 2009) found that of the 
1.38 billion people at risk of contracting P. falciparum malaria, the majority were found in CSE 
Asia, including Yemen and Saudi Arabia (0.69 billion) and Africa (0.66 billion), with the 
remainder in Latin America. Recently, the population at risk of P. falciparum malaria is 
estimated to be between 1.3-1.44 billion (Gething, Patil et al. 2011). According to the 2011 
World Malaria Report, malaria mortality rates have fallen by more than 25% globally since 2000 
and by 33% in Africa through concerted malaria control programmes. 
Malaria is geographically restricted to certain regions of the world and remains well 
established in areas with suitable transmission climates. There are three main climate factors 
that promote malaria: temperature, precipitation and humidity (Pampana 1969). Temperature 
affects many parts of the malaria cycle; temperatures of about 27˚C are favourable for the 
extrinsic cycle of the parasite. Higher temperatures also increase the number of blood meals 
which results in increased egg production (Martens, Niessen et al. 1995). Rainfall has 
proportional influence on humidity and temperature.  Different Anopheles species prefer 
different water bodies; some prefer shallow collections of fresh water such as puddles whereas 
others prefer salty or brackish water. The mosquito lifespan is long and transmission intensifies 
during and just after the rainy season (Martens, Niessen et al. 1995). Heavy rainfall washes 
away mosquito larvae. 
Urbanisation has also been identified as a potential factor influencing malaria 
transmission. For example, An. gambiae, which prefers to breed in clean water, is found 
breeding in polluted water in urban areas due to the mosquitoes’ ability to evolve and adapt to 
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natural or man-made environments (Keating, Macintyre et al. 2004; Sattler, Mtasiwa et al. 
2005; Klinkenberg, McCall et al. 2008). These mosquitoes have a local adaptation or phenotypic 
plasticity in these urban populations, resulting into an increase in malaria incidences in high 
density urban population (Donnelly, McCall et al. 2005; Klinkenberg, McCall et al. 2005). Thus, 
in additional to developing resistance to the insecticides used in the ITNs An. gambiae ss might 
adapt to the urban environment behaviourally which could comprise other control methods.  
The degree of P. falciparum endemicity also varies depending upon geographical 
location and socio-economic factors (Figure 1.1). In areas of high infection like the sub-Sahara, 
the greatest suffering is borne by children less than 5 years old and by pregnant women who 
together contribute approximately 3,000 deaths per day. By contrast, in areas of low 
transmission, all age groups are at equal but reduced risk of infection (WHO 2011). In 2002, as 
high as 70% of all clinical events attributable to P. falciparum were concentrated in the African 
region compared to only 25% in South East Asia (Snow, Guerra et al. 2005). It has been 
estimated that the annual incidence of severe malaria was 10.7 million in Africa and only about 
a third of that in Asia and the Americas (Hay, Guerra et al. 2009). Such high prevalence of the 
disease in Africa has led to malaria being ranked as one of the major killers alongside HIV/AIDS. 
The distribution of malaria in endemic countries is further sub-divided according to the 
degree of endemicity. Areas in which the infection prevalence is less than 10% are said to be 
hypoendemic, and those where the infection prevalence is between 11-50% are referred to as 
mesoendemic. Regions are described as holoendemic and hyperendemic if the prevalence is 
above 50% (Hay, Guerra et al. 2009).  
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Figure 1.1. The 2010 Spatial Distribution of P. falciparum malaria by endemicity 
(From Gething et al. Malar J. 2011: 10 (378))
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1.2 Malaria transmission  
Malaria is caused by protozoa of the genus Plasmodium, family Plasmodiidae. 
There are over 120 species of Plasmodium that can infect mammals, reptiles and birds. 
Human malaria is transmitted by female anopheline mosquitoes during a blood meal, a 
source of protein for egg development and maturation. Not all Anopheles species 
transmit malaria, and only about 30-40 different Anopheles mosquitoes are of local 
clinical importance. The major malaria vectors in sub-Saharan African are An. gambiae 
s.s, An. arabiensis and An. funestus (Gillies 1968). Currently, there is no vaccine 
available for malaria, therefore vector control is one of the most important methods 
for malaria prevention. However, over the years the main vectors have evolved 
resistance to commonly used insecticides, increasing their chances of survival such that 
control of these vectors is a challenge (Greenwood and Mutabingwa 2002). 
There are four Plasmodium species that cause human malaria: P. falciparum, 
P. vivax, P. ovale (which is actually two species), and P. malariae; the latter can also 
cause disease in primates. Recently, Plasmodium knowlesi, a primate malaria pathogen 
has also been identified to cause clinical malaria in humans (Singh, Kim Sung et al. 
2004).  The most virulent disease is caused by P. falciparum which contributes greatly 
to child mortality annually. The special disease presentation of this species, compared 
to other Plasmodium that infect humans, has been attributed to the ability of 
P. falciparum to cause organ specific diseases such cerebral malaria and placental 
malaria (Pongponratn, Riganti et al. 1991; Berendt, Tumer et al. 1994; Turner, Morrison 
et al. 1994).  
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1.3 Malaria transmission and control in Malawi 
1.3.1 Transmission 
In Malawi, malaria is endemic and continues to be a major public health 
problem, with no reduction in disease incidence observed over the past decade despite 
a change of first-line anti-malarial treatment in 2007 and intensification of vector 
control programmes (Roca-Feltrer, Kwizombe et al. 2012). There has been a gradual 
increase in the number of outpatient visits between 2001 and 2010 (Figure 1.2). 
 
 
  
 
 
 
 
 
 
Figure 1.2. Temporal trends of total monthly outpatient visits, malaria slides taken, 
and parasitaemia-positive slides. Data was recorded from the Pediatric Accident and 
Emergency Unit at Queen Elizabeth Central Hospital, Blantyre, Malawi, 2001–2010 
(From Roca-Feltrer et al. Emerg Infect Dis 18(2) 2012 272-8) 
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An estimated 6 million cases occur annually with 98% of malaria infections 
caused by P. falciparum and transmitted by An. funestus, An. gambiae, and An. 
arabiensis (PMI 2012). About 40% of all hospitalisation of children less than five years 
old and 34% of all outpatient visits across all ages are due to malaria (PMI 2012). Nearly 
60% of all hospital deaths in children less than five years old are attributed to malaria 
and anaemia. There are several potential independent etiological factors associated 
with severe anaemia in Malawian children; bacteremia, malaria, hookworm, HIV 
infection, vitamins A and B12 deficiency (Calis, Phiri et al. 2008). The underlying cause  
was identified as failure of red cell production (Boele van Hensbroek, Calis et al. 2010).  
Transmission rates are intense all year round, especially during the rainy season 
between November- April for areas lying within metres of sea level.  In other areas, 
transmission lessens during the dry season (October to November) and peaks again in 
the rainy season. Highland regions (>1500m) of Africa historically have been considered 
free of malaria, until the late 1980s when concern arose that high elevation malaria 
transmission may be increasing (Lepers, Deloron et al. 1988; Some 1994; Malakooti, 
Biomndo et al. 1998; Lindblade, Walker et al. 1999). Hypotheses about the reasons for 
this include changes in climate, land use and demographic patterns (Bouma, Baeza et 
al. 2011; Chaves, Hashizume et al. 2012; Ermert, Fink et al. 2012).  
Figure 1.3 shows an example of Anopheles distribution in Tsekera area which is 
close to the river, has a lot of water pools and hosts a lot of livestock compared to 
Mwingama, an area further from the river, has less water pools and livestock, both 
found in Chikwawa district. 
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Figure 1.3. Anopheles mosquito species abundance in two sentinel sites and monthly 
rainfall distribution for Chikwawa district. While annual rainfall pattern is constant 
throughout the district, there has been a significant reduction of all Anopheles 
mosquitoes since the introduction of IRS (Benjamin Nyoni, Unpublished data). 
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1.3.2 Control Interventions 
Malawi has adopted two major malaria control interventions: treatment and 
vector control. 
 
1.3.2.1 Chemoprophylaxis and Chemotherapy 
1.3.2.1.1 Medication and treatment 
For several years, African countries have used drugs comprising of quinoline and 
antifolate types to treat malaria. In Malawi, chloroquine was used as a first-line drug to 
treat P. falciparum infections until world-wide in vivo resistance was detected. In 1993 
Malawi switched to  sulfadoxine-pyrimethamine (SP) as first-line treatment and quinine 
as the second-line drug to treat malaria, depending on disease severity. While the 
latter remains efficacious and is still used to treat severe cases, the parasite has long 
developed resistance for chloroquine and SP, leading to an increase in malaria-related 
mortality (Trape, Pison et al. 1998; Korenromp, Williams et al. 2003). However, recent 
research suggests that chloroquine may again be effective following the decline in 
prevalence of chloroquine-resistant  P. falciparum in Malawi by 2001 (Laufer, Thesing 
et al. 2006). 
In 2007, Malawi adopted artemisinin-based combination therapy (ACT) as the 
first-line therapy for fighting P. falciparum infections as recommended by WHO for 
endemic countries. By 2009, another 42 malaria endemic African countries also 
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changed their treatment regime to ACT and 20 countries adopted the use of rapid 
diagnostic tests (RDTs) for all-age groups (WHO 2009). 
 
1.3.2.1.2 Intermittent Preventative Treatment (IPT) 
In areas of high malaria transmission, the population most at risk comprises 
pregnant women and children less than five years of age (Greenwood, Fidock et al. 
2008). In 1998, WHO recommended the use of IPT which involves administering a 
predetermined curative dose of antimalarials at specific intervals to individuals in 
endemic areas before they are parasitaemic (Garner and Gulmezoglu 2006; Briand, 
Cottrell et al. 2007) in order to control for gestational malaria in pregnant women.  
The importance of IPT usage in Malawi was confirmed by clinical trials which 
reported reduced incidence of gestational malaria, anaemia and low birth weight in 
pregnant women and their babies (Luxemburger, Ricci et al. 1997; Nosten, McGready 
et al. 2007), and reduced rates of hospital re-admittance due to malaria and/or severe 
anaemia in children (Phiri, Esan et al. 2012).  
 
1.3.2.2 Vector control 
Vector control is regarded as one of the most successful methods to reduce 
malaria transmission at the community level. The two most effective vector control 
methods that Malawi has adopted are: 
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1.3.2.2.1 Insecticide treated nets (ITNs) and long lasting insecticide treated nets (LLIN) 
ITNs decrease malaria transmission by mass killing of Anopheline vectors 
(Takken 2002). ITNs provide 17% protective efficacy compared to no nets and save 
about 5.5 children each year for every 1000 children protected with ITNs (Lengeler 
2004). ITNs reduced the incidence of uncomplicated malarial episodes of P. falciparum 
by 50% and 62% compared to no nets in areas with stable malaria and areas with 
unstable malaria, respectively (Lengeler 2006). Recently, WHO has recommended LLIN 
which have insecticide incorporated into the net fibres rather than soaked into the net 
at regular intervals as for ITNs (Norris and Norris 2011).  
In Malawi, the current National Malaria Control Programme (NMCP) supported 
a three-pronged approach to ITN distribution: 1) routine distribution of free pyrethroid-
treated LLINs through antenatal care and expanded programmes in immunisation 
clinics, 2) periodic mass campaigns covering the entire population, and 3) traditional 
social marketing through private sector outlets. NMCP hopes to achieve universal 
coverage with ITNs which is defined as one net per two people (PMI 2012). According 
to the 2010 Malaria Indicator Survey (MIS), nearly 60% of households in Malawi owned 
one or more ITNs and that 55% of children less than five and 49% of pregnant women 
slept under an ITN the previous night (PMI 2012). 
 
1.3.2.2.2 Indoor spraying with residual insecticides 
The use of indoor residual spraying (IRS) to reduce malaria has been adopted 
since the 1940s and 1950s (De Mellion 1936; Russell 1955.; Alilio, Bygbjerg et al. 2004) 
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and it is now widely used as one of the primary interventions of malaria control as 
recommended by WHO. 
 
Figure 1.4. Progress in vector control coverage in sub-Saharan Africa from 2000 to 2010 
with adjustments from Global Malaria Programme (WHO 2011). 
 
Pyrethroid IRS is included in the Malawi Malaria Strategic Plan of 2011-2015 as 
a key malaria prevention strategy (PMI 2012). In the years 2007-2009, the President’s 
Malaria Initiative (PMI) supported two initial spraying rounds covering 27,000 houses in 
the Nkhotakota district. Based on the success of these efforts (Skarbinski 2012), the 
Malawi Ministry of Health expanded IRS to a total of 7 districts: Chikhwawa, Karonga, 
Salima, Mangochi, Nkhotakota, Nsanje and Salima, covering 500,000 houses and 
protecting an estimated 2.5 million people (PMI 2012).  
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However, the Cinderella story does not seem to last as the first evidence of 
insecticide resistance in An. funestus were reported on one of the islands in Lake 
Malawi (Hunt, Edwardes et al. 2010). Other cases of possible pyrethroid resistance in 
An. funestus have been reported in some areas where IRS has been implemented (PMI 
2010). In spite of this, NMCP is planning to intensify IRS to 12 high malaria burden 
districts by 2015.  
 
1.3.2.2.3 Larvicides 
The future in malaria control is now heading towards integrated vector 
management, targeting both larval and adult mosquitoes (WHO 2003; Townson H 
2005; WHO 2007). While ITN and IRS use is currently the priority, there is growing 
interest in arresting aquatic stages of malaria vectors with microbial larvicides (Shililu, 
Maier et al. 1998; Killeen, Fillinger et al. 2002; Killeen, Fillinger et al. 2002; Utzinger, 
Tanner et al. 2002; Fillinger, Sonye et al. 2004; Fillinger and Lindsay 2006; Gu, Utzinger 
et al. 2008). So far, microbial larvicides are only being used in Tanzania (Geissbuhler, 
Chaki et al. 2007; Fillinger, Kannady et al. 2008). However, there are plans to expand 
larvicide usage to 17 countries included in the PMI.  
Malawi is in the process of investigating options for larviciding in 10 districts 
along the lakeshore and Shire Valley areas. Seven out of the 10 earmarked districts for 
larviciding are currently designated as IRS districts. 
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1.4 THE PLASMODIUM FALCIPARUM PARASITE  
1.4.1 P. falciparum life cycle 
 
 
Figure 1.5. P. falciparum life cycle.  
 
P. falciparum has a complicated life cycle with asexual reproduction occurring in 
the mammalian host and sexual reproduction in the anopheline mosquito vector. Host 
infection commences upon the dermal inoculation of sporozoites by an infected female 
mosquito. The sporozoites circulate for up to 45 minutes before invading liver 
hepatocytes where they undergo asexual reproduction for approximately one week to 
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form large intracellular hepatic schizonts containing thousands of merozoites. P. vivax 
and P. ovale infections can lie dormant in the liver for weeks or months before 
reactivating and forming a hepatic schizont. The entire pre-eryhrocytic phase lasts 
about 5–16 days depending on the parasite species: an average 5-6 days for P. 
falciparum, 8 days for P. vivax, 9 days for P. ovale, and 13 days for P. malariae and 8-9 
days for P. knowlesi.  
The pathogenic process begins when the swollen hepatocytes eventually rupture, 
discharging merozoites into the bloodstream where they rapidly invade erythrocytes. 
The merozoite recognises, attaches and then enters RBCs by multiple receptor–ligand 
interactions in as little as 60 seconds. This quick invasion minimises exposure of the 
parasite surface antigens from the host immune response. P. vivax invades only Duffy 
blood group-positive RBC, using the Duffy-binding protein and the reticulocyte 
homology protein, expressed mostly on the reticulocytes. On the other hand, P. 
falciparum uses several different receptor families and alternate invasion pathways 
that are highly redundant. The merozoite has special apical secretory organelles: 
micronemes, rhoptries, and dense granules that help the invasion process. The 
merozoite attaches to the surface of the RBC forming a stable parasite–host cell 
junction. Following this, the parasite pushes its way through the erythrocyte bilayer 
and creates a parasitophorous vacuole to seal itself from the host cell cytoplasm. 
The parasite develops within a membrane-bound parasitophorous vacuole first 
as a trophozoite and then, during multiple nuclear divisions known as schizogony, as a 
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schizont. When the schizont matures, it ruptures the host erythrocyte, releasing 
merozoites that rapidly invade fresh erythrocytes in circulation, thereby continuing the 
asexual life cycle. A small proportion of merozoites develop into sexual forms (male and 
female gametocytes). The gametocytes starts as a round body measuring 2 µm across 
and then mature into twin crescent shapes found in the peripheral blood or in the 
spleen. The gametocytes enter the peripheral blood approximately 8 to 11 days after 
the initial infection (Garnham, 1966). Crescents can persist for up to 3 months or even 
longer. Initially, females outnumber the males 3:1 but towards the end of the infection 
their numbers become more or less equal (Baker 2010; Kuehn and Pradel 2010). The 
mature male gametocyte or microgamete measures 9-11 µm in length, and the female 
gametocyte or macrogametes measuring 12-14 µm in length, are taken into the 
mosquito gut with a blood meal.      
Sexual reproduction occurs in the mosquito, leading to new genetic 
combinations, before inoculation into new hosts.  Inside the gut of the mosquito, the 
gametocytes undergo sporogony where the gametes fuse to form a zygote, which then 
undergo meiosis within 12 – 18 hrs after the blood meal to form first an ookinete and 
five days later develops into an oocyst in the gut wall. The oocyst rapidly divides and 
bursts, releasing large numbers of sporozoites that migrate to the salivary glands of the 
mosquito to await injection into a human host during the next blood meal. 
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1.5. Plasmodium falciparum disease and clinical features in African children 
The impact of P. falciparum infection in endemic African countries is highlighted 
by the socio-economic burden these countries experience. Children less than five years 
of age, which this thesis will concentrate on, and pregnant women bear the brunt of 
the infection although all age groups can be infected. The high disease burden in 
malaria endemic areas results in individuals acquiring malaria-specific antibodies with 
age. These antibodies are able to recognise and thus protect individuals against a range 
of parasite isolate, potentially including those that cause severe forms of disease. 
Parasites are able to sequester in the placenta of pregnant women causing what is 
referred to as placental malaria (PM) (Steketee, Nahlen et al. 2001; Guyatt and Snow 
2004). PM is risky to both the mother and child as it can lead to severe malarial anemia 
in the mother and low birth weight for the baby (Murphy and Breman 2001). PM is 
more common in women who are pregnant for the first time (primigravid) than those 
who have been pregnant before (multigravid) as the primigravida lack antibodies to 
placental binding parasites (Fried, Nosten et al. 1998; Beeson, Brown et al. 1999; 
Beeson and Rogerson 2004). 
Malaria is classified into three categories: asymptomatic malaria (AM) mild or 
uncomplicated malaria (UM) and severe malaria (SM).  UM is mainly characterised by 
persistence, but not worsening, of the initial symptoms such as fever that are observed 
approximately 8 days after the introduction of the parasite in the human host. These 
symptoms are suggested to be due to the release of parasite toxins during erythrocytic 
rupture (Bates, Berendt et al. 1992; Berendt, McDowall et al. 1992).  
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The causes of complicated malaria, commonly known as SM, are complex and 
not yet fully understood. Severe falciparum malaria can cause acute febrile illness 
characterised by fever, chills, headache, severe anaemia and splenomegaly, which 
usually respond promptly to appropriate anti-malarial therapy. SM is sub-divided into 
three clinical syndromes: cerebral malaria (CM), severe malarial anaemia (SMA) and 
severe respiratory distress (SRD) (Marsh et al., 1995). Left untreated, the patient will 
either die in the acute attack or survive but with minimal development of immunity 
against the next infection, in the case of a first attack. Substantial immunity only 
develops after an individual has been exposed to malarial antigen in multiple episodes 
over a number of years (Ho and White 1999). CM has been associated with 
sequestration of pRBC in brain microvasculature which leads to the blocking of cerebral 
post-capillary venules that can eventually lead to rupture and haemorrhage. Other 
mechanisms attributed to CM are cytokine induction of secondary mediator production 
such as nitric oxide (NO), which is thought to cause decrease of  intracranial pressure 
due to vasodilation (Clark and Rockett 1994). Tumor necrosis factor (TNF), one of the 
pro-inflammatory cytokines, has been implicated in CM as it causes up-regulation of 
adhesion receptors as well as modulating effects of NO.  
Approximately 5-10 million infected individuals per year develop complications 
during the acute infection. These complications are manifested differently between 
adults and children (Table 1.1), with either coma, with metabolic acidosis and 
hypoglycemia in SRD, as SMA or as renal failure and pulmonary edema in adults (White 
and Ho 1992; Bejon, Berkley et al. 2007). Disease progression is influenced by both host 
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and parasite factors. Various cellular and molecular strategies allow the parasite to 
evade the human immune response (White and Breman 1998).  In African children, the 
commonest presenting syndromes associated with mortality are CM; recurrent 
convulsions; metabolic dysfunction, which manifests itself as hypoglycaemia or lactic 
acidosis; or symptomatic anaemia (Marsh, Forster et al. 1995; Newton and Krishna 
1998). The overall case fatality rate from severe falciparum malaria varies from 15 to 
20%, with the highest mortality resulting from CM with coma or respiratory distress 
(Newton and Krishna 1998; Newton, Hien et al. 2000).  
 
Table 1.1. Differences in clinical presentation of falciparum malaria infections 
between adults and children in Africa 
Signs/Symptoms Adult Children 
Anaemia Common Very common 
Convulsions Common Very common 
Pre-treatment hypoglycaemia Less common Common 
Metabolic acidosis Less common Common 
History of cough Uncommon Common 
Jaundice Very common Common 
Renal failure  Common Less common 
Pulmonary oedema Less common Rare 
Duration of illness 5 – 7 days 1 – 2 days 
Resolution of coma 2 – 4 days 1 – 2 days 
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Malaria retinopathy is a diagnostic tool for CM using a set of five retinal 
abnormalities: retinal whitening, discolouration of the retinal vessels to orange or 
white, haemorrhages and papilledema (reviewed in (Lewallen, Harding et al. 1999; 
Beare, Taylor et al. 2006)) that are unique to SM and common in children with cerebral 
malaria, and have been linked to risk of death and length of coma. Retinopathy has 
been shown to be 95% sensitive and shows specificity of 90%. In agreement with other 
studies (Taylor, Fu et al. 2004; White, Lewallen et al. 2009) and in support of 
mathematical models and immunological evidence (Gupta, Maiden et al. 1996; Bull, 
Lowe et al. 1998; Craig and Scherf 2001; Kyes, Horrocks et al. 2001; Ofori, Dodoo et al. 
2002; Peters, Fowler et al. 2002; Lavstsen, Magistrado et al. 2005), Malawian children 
with CM confirmed by retinopathy show less genetically mixed parasites compared to 
retinopathy negative children (Milner, Valim et al. 2012). 
 
1.6 Parasite population and genotypes 
It is necessary to study parasite populations in order to better understand the 
factors that have an impact on the development of immunity in different endemic 
areas. In the 1960s, it was suggested that many people in malaria endemic areas carry  
genetically variant parasites in an active infection (Wilson, McGregor et al. 1969). Proof 
of heterogenous parasite populations was later provided through enzyme typing, by 
which variations in three parasite enzymes: glucose-6-phosphate isomerase (G6PI), 
lactate dehydrogenase (LDH) and 6-phosphogluconate dehydrogenase (6PGD) were 
found in the peripheral blood samples of P. falciparum-infected women and children. 
   
21 
 
Each enzyme variant represented a different allele of a single gene (Carter and 
McGregor 1973). There is now clear evidence that an individual can carry a mixture of 
parasites of different genetic background (Kun, Missinou et al. 2002). The challenge lies 
in the identification of these genotypes as some parasite subpopulations may “hide” 
from the circulation by sequestering in the different organs of the host during latter 
stages of their asexual cycle. Research in this area has taken a new turn in trying to 
uncover potential competition between genotypically different clones in the human 
host, in which the situation is complicated when parasites are faced with treatment 
and the host immune system.  
The most common and simple method used for parasite genotyping is 
performed using three single-copy genes, the glutamate rich protein (glurp) gene, 
located on chromosome 10 (Borre, Dziegiel et al. 1991) and the merozoite surface 
membrane proteins 1 and 2 (msp1 and msp2) located on chromosome 9 (Tanabe, 
Mackay et al. 1987) and 2 (Smythe, Peterson et al. 1990), respectively. These highly 
polymorphic loci are convenient typing markers (Felger, Tavul et al. 1994; Contamin, 
Fandeur et al. 1995; Ntoumi, Contamin et al. 1995; Ntoumi, Rogier et al. 1997) because 
they possess numerous alleles. The glurp alleles are identified by size polymorphism of 
one domain, due to variable copy number of sequence repeats (Borre, Dziegiel et al. 
1991). The various msp1 alleles are grouped into three families: K1, MAD20 and RO33 
according to their reference isolates, based on variable nucleotide sequence and copy 
number of repeats in their block 2 region (Tanabe, Mackay et al. 1987; Zwetyenga, 
Rogier et al. 1998).  msp2 has two allelic families, 3D7 and FC27, which differ in 
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nucleotide sequence and copy number of repeats of the central domain of the gene 
(Smythe, Peterson et al. 1990; Zwetyenga, Rogier et al. 1998; Snounou, Zhu et al. 
1999). Another major use of msp genotyping in antimalarial trials is to distinguish 
recrudescence from new infection due to treatment failure (Mugittu, Adjuik et al. 
2006). 
Severity of malaria has been associated with the occurrence of parasite 
genotypes described by the above described polymorphic genetic markers of the genes 
for merozoite surface protein 1 and 2 (Tanabe, Mackay et al. 1987). The distribution of 
these allelic variants has also been shown to vary with geographical location. RO33 was 
observed in P. falciparum infected Brazilians and Senegalese (Kimura, Mattei et al. 
1990), while in Gabon RO33 was observed in asymptomatic cases and the allelic marker 
K1 was observed in severe cases (Kun, Schmidt-Ott et al. 1998). On the other hand, K1 
is common in asymptomatic cases in East Africa (Babiker, Ranford-Cartwright et al. 
1994). msp2’s 3D7 and FC27 alleles have been associated with severe malaria, higher 
parasite density and increased multiplicity of infection in a hyperendemic area of India 
(Ranjit, Das et al. 2005).  
  The possibility that specific parasite characteristics contribute to severity of 
disease was initially investigated in a hypoendemic area in French Guiana (Ariey, 
Hommel et al. 2001). Parasite genotyping in geographically and temporally matched 
patients with mild and severe disease showed the association of a specific MSP1 allele 
(B-K1) with the presence of a particular var antigen (a member of a P. falciparum 
multigene family discussed below). var-D was over-represented among patients with 
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severe versus mild disease (47% vs. 3% respectively). These findings suggest an 
association between parasites possessing certain genes and virulence of disease. 
  Kun et al. 2002 demonstrated that the appearance of a new genotype in a 
previously steady pattern of asymptomatic infection within a single host coincides with 
clinical symptoms. However, the same group claims to have shown for the first time 
that there is no apparent change in P. falciparum subpopulations in individual patients 
during an episode of malaria (Kun, Missinou et al. 2002). They suggest that although an 
individual in high transmission areas is usually infected by multiple parasite genotypes, 
the malaria symptoms are caused by one presumably virulent dominant parasite 
genotype which probably multiplies rapidly and inhibits the growth of concurrent 
parasites present in the host (Figure 1.6). Some parasite clones more sensitive to the 
treatment administered to patients during infection are likely to disappear earlier from 
the circulating blood. The remaining genotypes may be hard to detect if parasitaemia is 
effectively reduced by the drug (Farnert, Rooth et al. 1999; Franks, Koram et al. 2001; 
Missinou, Kun et al. 2004).  
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Figure 1.6. Parasite density and genotyping analysis of finger-prick blood sample from 
an individual child (80S).  The upper panel shows the course of the parasitaemia 
(parasite/µL over time (days). The middle and lower panel shows the results of the PCR 
products specific for two different mps2 alleles; 3D7 family and the FC27 respectively. A 
molecular size kilobase (kb) ladder was also used. + indicates the positive control for 
the respective isolate; - indicates the negative control. Lane 9 represents the 
symptomatic phase. This child experienced 8 days of asymptomatic infection with only 
one parasite of the FC27 family. On day 9 the child became symptomatic and a unique 
FC27 variant and an additional 3D7 strain appeared. The arrow points to a band 
representing a minor fraction of 3D7 parasites. (From Kun et al. Am J Trop Med Hyg 
66(6) 2002 653-8) 
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Most longitudinal studies on parasite subpopulations in individual patients have 
been carried out on asymptomatic parasite carriers. Färnert et al. 1997 studied the 
daily dynamics of P. falciparum subpopulations in asymptomatic children in Tanzania 
and reported highly complex changes in parasite density and genotype patterns over 
time (Farnert, Snounou et al. 1997). This led to the conclusion that the parasites 
observed in any single blood sample represent only a part of the total body-parasite 
mass, because the genetic make-up of the parasite population can be very mixed and 
some parasites are removed from circulation by sequestering in the tissues.  
Furthermore, the distribution of some msp1 alleles has been shown to be 
influenced by age (Ntoumi, Rogier et al. 1997). These results are consistent with the 
interpretation that acquired anti-P. falciparum immunity reduces parasite density, 
limits the number of parasite genotypes infecting an individual at any given time, and 
controls parasites against which a strong immune response has been mounted 
(Zwetyenga, Rogier et al. 1998). 
 
1.6.1 Parasite population and genetics in Malawi 
Most P. falciparum infections are comprised of multiple genetically distinct 
parasite variants arising from more than one infectious mosquito bite, or a single blood 
meal transmitting multiple parasite variants (Talisuna, Okello et al. 2007). Infections 
with a single to a few variants are common in low transmission areas such Asia and 
Latin America (Juliano, Ariey et al. 2009). In areas of high transmission such as sub-
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Saharan Africa, individuals can be detected having more than 10 genetic variants 
(Greenhouse, Myrick et al. 2006; Kwiek, Alker et al. 2007).  
Malawi is one of many sub-Saharan countries with a high burden of malaria, 
where transmission is perennial and, despite the up-scaling of malaria control 
measures, there has been no decrease in the incidence of childhood malaria (Roca-
Feltrer, Kwizombe et al. 2012). Malawian paediatric P. falciparum infections are 
dominated by clones which persist in both circulation and in parasites sequestered in 
the tissues (Dembo, Phiri et al. 2006; Montgomery, Milner Jr. et al. 2006) as shown by 
data generated from other countries using peripheral blood samples (Missinou, Kun et 
al. 2004). The specific genetic populations defined in terms of msp1 and 2 genotypes 
are not associated with preferential sequestration in the brain in children with malaria. 
These results have been confirmed by other genotyping methods using a 24 single 
nucleotide polymorphism assay (Milner, Valim et al. 2012) and massively parallel 
pyrosequencing (Juliano, Porter et al. 2010). The latter method has revealed up to six-
fold more variants per infection, exceeding the results from the currently 
recommended msp1 and 2 genotyping.  
Other high resolution methods have also shown that genotypes isolated from 
Malawian children are conserved within the population with about 15% extreme 
relatedness within a single patient with heterogeneous infection compared to 21.1% 
relatedness in parasites from Thailand (Nkhoma, Nair et al. 2012). These results for 
Malawi are comparable to other highly malaria endemic countries like Tanzania which 
also show higher mean multiplicity of infection (MOI) for both markers of msp1 and msp2 
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genes and increased genetic diversity (Schoepflin, Valsangiacomo et al. 2009). 
However, the genetic diversity was also not very different from PNG which has low 
malaria endemicity. Considering the different inoculation rate of >300 infective bites 
per person per year (Smith, Charlwood et al. 1993; Charlwood, Smith et al. 1998) and 
average of 5 detected infections per child (Felger, Irion et al. 1999) for Tanzania versus 
35 infective bites for PNG (Smith, Hii et al. 2001), this indicates that there was little 
genetic differentiation between parasite populations in Tanzania and PNG, suggesting 
that the observed pattern of allele frequencies are independent of transmission 
intensity (Schoepflin, Valsangiacomo et al. 2009). 
The complexity of P. falciparum genetic diversity can also be influenced by age 
(Bendixen, Msangeni et al. 2001). Farnert et al showed that while most laboratories 
might have the same sensitivity and specificity with the msp1/2 genotyping method, 
technical differences can also lead to results that show variation rather than 
epidemiological differences  (Farnert, Arez et al. 2001). Increased intensity of malaria 
control programmes are also likely to have an effect on parasite genetic diversity. For 
example, Chikwawa, one of the districts in Malawi with highest malaria transmission 
shows a significant reduction in moderate anaemia, from 10% to almost 0% due to 
constant use of IRS for a year (Figure 1.7; Sanie Seseye, personal communication). 
There was also a reduction of sporozoite infection rate, from 6.4% to almost 0% for An. 
funestus and from 6.1% to 0% for An. gambiae after IRS intervention, compared to a 
sporozoite rate of 10.2% in 2005 before IRS intervention (Benjamin Nyoni, personal 
communication).   
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Figure 1.7. Intervention coverage and prevalence of P. falciparum parasitaemia and 
anaemia in children at the study site in Chikwawa district from 2010 to 2012. The 
study area consists of 50 villages. Since the introduction of IRS in March 2011, 
parasitaemia in children has dropped to about 10% and malaria–associated anaemia is 
almost non-existent at 0% prevalence. (Sanie Sasey, unpublished data) 
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1.7 Malaria pathogenesis 
1.7.1 Sequestration and cytoadherence 
The pathogenicity of P. falciparum is thought to result in part from the unique 
ability of pRBC to adhere to, and activate, vascular endothelium. Mature trophozoites 
and schizonts are removed from the peripheral circulation (Bignami and Bastianelli 
1889), due to adhesion of the infected erythrocytes (Miller 1969) to post-capillary 
venules, leading to sequestration of pRBC in the tissues. The parasite remodels the 
pRBC both inside and outside to facilitate its protein trafficking pathways, which result 
in the deformation of the erythrocyte plasma membrane. Not all of the remodelling 
proteins are antigens.  Some lie underneath the knobs and some remodel the 
trafficking pathways internally. The antigenic proteins mediate cytoadherence to 
variety of host endothelial receptors (Luse and Miller 1971).  
Cytoadherence can cause occlusion of small vessels, impaired oxygen delivery and 
hence can contribute to organ failure in the host (Miller, Good et al. 1994). It is also 
suggested that cytoadhesion aids parasite maturation due to their preference for the 
microaerophilic venous atmosphere and it allows the parasite to escape clearance by 
the spleen (Saul 1999). The spleen removes erythrocytes with reduced deformability, 
such as parasite-infected cells (Looareesuwan, Ho et al. 1987), during acute falciparum 
malaria as well as selectively extracting parasites from their erythrocytes and leaving 
the residual cells within the circulation, a mechanism also known as “pitting” 
(Schnitzer, Sodeman et al. 1972; Anyona, Schrier et al. 2006). 
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As has been stated above, P. falciparum infections are commonly composed of 
multiple subpopulations of parasites with varied adhesive properties.  Variants have 
been revealed to differ in their efficiency of binding to a range of host receptors and 
will compete for adhesion to endothelia, suggesting that a mixed infection will not 
show uniform cytoadherence properties and so parasite variants may vary in their 
ability to cause pathology (Phiri, Montgomery et al. 2009).  
Cytoadherence can activate intracellular signaling pathways in both endothelial 
cells and pRBC, leading to expression of immune mediators such as cytokines, which 
can modify the outcome of the infection through monocyte and platelet recruitment, 
additional cytokine release, and fibrin deposition that aggravates inflammation (Turner, 
Morrison et al. 1994; Miller, Hudson-Taylor et al. 2002). Furthermore, there has been 
some evidence of an association between clinical syndromes and adhesion to these 
receptors (Udomsangpetch, Taylor et al. 1996; Newbold, Warn et al. 1997). Therefore, 
understanding the molecular events involved in these adhesive interactions is critical in 
terms of both the pathogenesis and implications for therapeutic intervention. 
 
1.7.2 Variant proteins expressed on the surface of pRBC and their functions 
When P. falciparum infects the host erythrocyte, it deposits protein on the 
surface of the pRBC. These proteins are exported from the intracellular parasite 
through the erythrocyte cytoplasm to the surface via a complex system of vesicle 
trafficking pathways (Pouvelle, Gormley et al. 1994). There is an array of parasite-
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derived proteins identified as being associated with the pRBC cell membrane at various 
stages of the developmental cycle. P. falciparum erythrocyte membrane proteins 1, 
2 and 3 (PfEMP1, PfEMP2 and PfEMP3), P. falciparum histidine-rich protein (PfHRP1) 
and knob-associated histidine-rich protein (KAHRP) are associated with knobs. Of these, 
PfEMP1 is the only protein that extends beyond the cell surface to mediate 
cytoadherence (Magowan, Wollish et al. 1988), whereas PfEMP2 , PfEMP3 and PfHRP1 
or KAHRP remain on the internal face of the erythrocyte membrane in association with 
electron-dense material.  
 
 
 
 
 
 
 
 
Figure 1.8. Schematic diagram of P. falciparum protein distribution on the surface 
membrane of infected erythrocytes. Lipid bilayer of red blood cell (RBC) membrane  is 
indicated, together with the cytoskeleton and electron-dense material (EDM) under the 
knob. P. falciparum erythrocyte membrane proteins 1 and 2 (PfEMP1 and PfEMP2) and 
P. falciparum histidine-rich protein (PfHRP1) or knob-associated histidine-rich (KAHRP) 
are associated with knobs. RESA is the ring-infected erythrocyte surface antigen. 
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The role of these proteins is not fully known; however, PfEMP2 is presumed to 
have a structural function (Howard, Barnwell et al. 1988). PfEMP3, also found on the 
surface of sporozoites and in the cytoplasm of mature hepatic stages (Gruner, Brahimi 
et al. 2001), is thought to be involved in sporozoite invasion.  PfEMP3 may also 
facilitate PfEMP1 function as its mutation can result in the disruption of PfEMP1 
transfer to the RBC surface (Waterkeyn, Wickham et al. 2000). On the other hand, 
because of its ability to produce vesicles, HRP1 is presumed to destabilise the 
cytoskeleton to allow lateral movements of some membrane components necessary 
for inward expansion and the formation of the parasitophorous vacuole membrane 
(Hommel and Semoff 1988). 
There are two other parasite proteins associated with the erythrocyte 
membrane that are not localised specifically to the knobs: ring-infected erythrocyte 
surface antigen (RESA) and P. falciparum histidine-rich protein 2 (PfHRP2). PfHRP2 is 
secreted into the circulation and is currently being exploited for diagnostic assays 
(Gamboa, Ho et al. 2010). The RESA antigen is transferred from the merozoite to the 
erythrocyte membrane during invasion where it is thought to be entirely sub-
membranous (Aikawa, Torii et al. 1990). RESA is potential ligand for cytoadherence 
mediated by CD36 (Cranston, Boylan et al. 1984). More recently, RESA has been shown 
to reduce ring-stage deformability in static conditions (Mills, Diez-Silva et al. 2007), 
protect the ring stage from vesiculation damaged induced at high temperatures (Silva, 
Cooke et al. 2005; Pei, Guo et al. 2007) and thus ensuring survival of the parasite (Diez-
Silva, Park et al. 2012). 
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1.7.3 Plasmodium falciparum multigene families 
 Multigene families (Figure 1.9) encode for P. falciparum variant proteins and 
are considered as potential contributors to antigenic variation which will be discussed 
in detail in section 1.8. These include the repetitive interspersed family (rif); the 
subtelomeric, variable open reading frames (stevor); P. falciparum Maurer’s Cleft-2 
Transmembrane family (Pfmc-2TM) and var genes (Weber 1988; Cheng, Cloonan et al. 
1998).  
 
1.7.3.1 The rif multigene family 
RIFIN proteins are encoded by the rif (repetitive interspersed family) multigene 
family, ranging between 30-40 kDa in size (Fernandez, Hommel et al. 1999; Kyes, 
Christodoulou et al. 2003). RIFINS are divided into A and B types. A-type RIFINs are 
associated with MC while B-type RIFINs are restricted to the parasitic cytosol (Gardner, 
Hall et al. 2002; Petter, Haeggstrom et al. 2007). Bioinformatic analysis of rif genes 
reveals a sequence conservation of its several members cross HB3, 3D7, IT and Dd2 
isolates, with 30 to 50% amino acid identity for any two random RIFINs and >90% 
amino acid identity between at least one pair of those found in at least three out of the 
four isolates (Claessens, Ghumra et al. 2011). Like var genes (discussed in section 
1.7.3.5), rif genes undergo switching and clonal expression to produce polymorphic 
display of RIFINs in the merozoite stages that are fundamental for the parasite to 
establish a chronic infection (Cabral and Wunderlich 2009; Wang, Magistrado et al. 
2009). In vitro, rif genes transcription switches faster than var genes transcription, at a 
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rate of 45% per generation (Cabral and Wunderlich 2009) and similar to var genes, rif 
gene silencing is dependent on the histone deacetylase, with silent rif loci associated to 
histone 3 lysine 9 trimethylation (Lopez-Rubio, Mancio-Silva et al. 2009; Salcedo-
Amaya, van Driel et al. 2009).
 Initially, RIFINS were correlated with erythrocyte rosetting using the CD31 
receptor (reviewed in (Sherman, Eda et al. 2003), which was later shown to be 
mediated on the parasite by PfEMP1 (Rowe, Moulds et al. 1997; Chen, Barragan et al. 
1998). RIFINs initiate a naturally acquired immune response that has been correlated 
with a significant rapid parasite clearance from circulation upon treatment in Gabon 
(Abdel-Latif, Dietz et al. 2003). The presence of high levels of anti-RIFIN antibodies in 
asymptomatic children from the same population provides some evidence that anti-
RIFIN antibodies provide a certain degree of protein against malaria infection (Abdel-
Latif, Khattab et al. 2002; Abdel-Latif, Dietz et al. 2003).  
 
1.7.3.2 SURFIN 
The SURFINs, encoded by the surf multigene family are related to the P. vivax 
subtelomeric transmembrane protein 1 (PvSTP1). Other members of this protein are 
expressed on the surface of merozoites and other erythrocytic stages (Winter, Kawai et 
al. 2005) and are suggested to be involved adhesion (Tanabe, Mackay et al. 1987) and 
erythrocyte invasion (Mphande, Ribacke et al. 2008). 
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Figure 1.9. Structure and arrangement of variant antigen genes in P. falciparum. 
A. The gene structure of each of the four major antigen families. The rifs , stevors and 
Pfmc-2TM all have a two-exon structure with the small first exon encoding the signal 
peptide, while the second exon contains the PEXEL/VTS motif responsible for 
erythrocyte trafficking. While var genes also have a two-exon structure, they do not 
contain a signal peptide. In addition, var genes have two promoters, the first upstream 
of exon one and responsible for transcription of the mRNA and the second in the 
intron, leading to transcription of anti-sense ‘sterile’ transcripts.  
B. Location and arrangement of the var, rif , stevor and Pfmc-2TM  gene families on a 
typical P. falciparum chromosome. Within the subtelomeric regions, var genes are 
typically located closest to the telomeric repeats, followed by interspersed rifs and 
stevors, and lastly by members of the Pfmc-2TM family.  
 
   
 
   
36 
 
1.7.3.3 The stevor multigene family  
The stevor (subtelomeric variable open reading frame) multigene family 
originally named 7h8 (Limpaiboon, Shirley et al. 1991) consists of 30–40 genes, 
depending on the parasite isolate, located within rif-containing subtelomeric regions on 
all P. falciparum chromosomes. The stevor genes are more conserved between parasite 
isolates than RIFINs. Apart from ultimately being associated with the erythrocyte 
membrane like RIFINs and PfEMP1, STEVOR are associated with the Maurer's clefts 
(MC), a unique feature of pRBC that consist of a flat vesicular membranous structure 
within the erythrocyte cytoplasm that transports proteins across the cytoplasm of the 
host cell to the surface of the plasma membrane. It is possible that the MC are not the 
final destination of STEVOR proteins as it has been recently shown that, similar to 
PfEMP1, they are trafficked through the MC to the surface of the merozoite (Khattab 
and Meri 2011) and the erythrocyte surface in asexual stages (Kaviratne, Khan et al. 
2002; Kissinger, Souza et al. 2002; Lavazec, Sanyal et al. 2006; Blythe, Yam et al. 2008; 
Khattab, Bonow et al. 2008; Niang, Yan Yam et al. 2009). Stevors are also associated 
with a tubovesicular membrane network that extends from the parasitophorous 
vacuole through the erythrocyte cytoplasm. These structures have been suggested to 
be involved in the trafficking of proteins from the parasite to the surface of the pRBC 
(Przyborski, Wickert et al. 2003).  
Although the function of stevor remains enigmatic, their localisation within MC 
suggests their possible functionality within this organelle (Blythe, Surentheran et al. 
2004). Their highly variable loop between the two TM domains has already been 
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implicated in antigenic variation in the face of immune pressure at the erythrocyte 
surface. Synthetic STEVOR peptides have been shown to bind with high affinity to 
human erythrocytes (Garcia 2005), suggesting a possible role in forming rosettes and 
also impacts the deformabilty of pRBC as a tool for sequestration (Sanyal, Egee et al. 
2011) 
 
1.7.3.4 The Pfmc-2TM multigene family 
The catalogue of 2 transmembrane (2TM) proteins includes several smaller 
families of paralogous genes (Marti, Baum et al. 2005; Templeton and Deitsch 2005; 
Sargeant, Marti et al. 2006), most notable of which are 13 genes that encode the Pfmc-
2TM proteins (Sam-Yellowe, Florens et al. 2004). The Pfmc-2TM proteins are highly 
conserved across paralogues within their N-terminal, transmembrane and positively 
charged C-terminal regions. Indirect immunofluorescence studies have shown that the 
Pfmc-2TM proteins are localised to the MC (Sam-Yellowe, Florens et al. 2004); 
however, it is yet to be determined whether the erythrocyte surface is the ultimate, 
perhaps functional destination of the Pfmc-2TM. 
 
1.7.3.5 The var multigene family 
By far, the most evident contributors to antigenic variation with biological 
relevance and also the focus of this study are the var genes. One of the success stories 
in the study of P. falciparum is the annotation of the complete genome sequence of the 
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laboratory P. falciparum isolate 3D7 (Gardner, Hall et al. 2002). This achievement and 
the partial genome sequence of other P. falciparum clones HB3 (Volkman, Sabeti et al. 
2007) and IT4/25/5 (IT4) permitted the comparison of var gene repertoires, with each 
of the parasite clones representing Africa, Central America, and Southeast Asia, 
respectively (Kraemer, Kyes et al. 2007). Initially, 61 var genes were sequence in 3D7, 
HB3 had 54 full and partially sequenced var genes (including six pseudogenes), and IT4 
had 48 full and partially sequenced var genes  (Kyes, Kraemer et al. 2007) and this data 
has been matched by recent studies (Rask, Hansen et al. 2010; Claessens, Ghumra et al. 
2011). 
The var genes are scattered on all chromosomes, and the majority of the var 
genes are located in the subtelomeric regions with 22 genes arranged in clusters of 
tandem repeats in the internal regions in the chromosomes, except chromosome 14 for 
3D7  (Gardner, Hall et al. 2002). The three isolates share seven protein architectural 
types and most var genes have overall amino acid sequence identity of <50% within 
individual domains, even those within the same architectural type. However, three var 
genes (var1csa, var2csa, and Type 3 var) are highly conserved  at >75% identity over 
multiple domains (Kraemer, Kyes et al. 2007).   
Overall, all var genes have a similar structure, consisting of a long exon 1 that 
encodes the variable extracellular portion of the PfEMP1 protein (discussed in section 
1.7.3.5.2 below), exhibiting both sequence diversity by varying combinations of the 
Duffy-Binding Ligand (DBL) and Cysteine Rich Inter-domain Region (CIDR) domains. 
Each pRBC expresses only one PfEMP1 variant by one var gene out of the possible 60 
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var genes present in the parasite genome. However, the parasite is able to switch its 
PfEMP1 variant though antigenic variation (discussed in section 1.8) by switching var 
gene expression at each new asexual blood stage, potentially giving rise to a phenotype 
with different adhesive properties. PfEMP1 variants are elevated on the surface of the 
host erythrocytes through knobs, which are protuberances on infected erythrocyte 
membrane that appear in early trophozoites stages of the asexual life cycle of the 
parasite containing various malaria proteins. 
 All var genes also possess an intron that has a highly conserved nucleotide 
sequence, and a short exon2 that encodes a short intracellular domain that is thought 
to anchor the protein within the knob structure at the cytoplasmic face of the 
erythrocyte membrane (Baruch, Pasloske et al. 1995; Su, Heatwole et al. 1995). Each 
var gene possesses two separate promoters, one upstream of exon 1 that is 
responsible for expression of the messenger ribonucleic acid (mRNA) and is active early 
in the cell cycle, from 12 to 18 h after invasion and a second promoter within the intron 
that leads to expression of a non-coding anti-sense RNA mainly by the late-stage 
parasites and is also thought to regulate gene expression (Calderwood, Gannoun-Zaki 
et al. 2003; Kyes, Christodoulou et al. 2003). More experimental data is required to 
elucidate the possible role of the non-coding RNAs in var regulation. However, it is 
speculated that the non-coding RNAs could be involved in chromatin assembly, as has 
been shown for non-coding RNAs in other systems (Morey and Avner 2004).  
 
   
40 
 
1.7.3.5.1 Var grouping and classification 
Sequence analysis of the upstream regulatory regions of all 3D7 isolate var 
genes have identified three main subgroups of the family: A, B and C and two 
intermediate groups (A/B and B/C) depending upon sequence motifs in their 5’ non-
coding regions (ups); and their chromosomal location and orientation of transcription 
(Kraemer, Gupta et al. 2003; Kraemer and Smith 2003; Lavstsen, Salanti et al. 2003). 
Rask et al has also been able to match all previously described ups subgroups (upsA1–
2, upsB1–4, upsC1–2 and upsE) and identified four additional subgroups (upsA3 and 
upsB5–7) (Rask, Hansen et al. 2010). The three major group classifications based on ups 
sequence also correspond to HB3, Dd2 and IT4 var genes but differences in 
chromosomal location between isolates argue for a modification of the sub-groupings. 
For example, the HB3 UpsA1-associated var gene (HB3var6) is located in a central 
chromosomal cluster rather than the typical sub-telomeric location.  
Group A var genes are generally longer and more structurally diverse, with 2-7 
DBL domains (Figure 1.10A). However, they also include some of the shortest genes like 
the Type 3 var, which consist of an unusual DBL1DBL2 domain combination and 
share almost no sequence identity with other members of the var gene family 
(Gardner, Hall et al. 2002; Kraemer, Kyes et al. 2007).  The proportion of var genes in 
each ups type is similar between 3D7, HB3 and IT4. However, the differences in 
chromosomal location between isolates call for a modification of the sub-groupings.  
Due to these difference Kraemer et al devised a naming system based on both var gene 
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location and ups sequence to allow for the future addition of 'atypical' genes (Kraemer, 
Kyes et al. 2007).  
The largest var group is Group B, with 22-27 genes in the P. falciparum isolates 
sequenced so far (Lavstsen, Salanti et al. 2003).  They are mostly located in 
subtelomeric regions, where they are translated towards the centromere, or in central 
chromosomal regions.  Most genes in this group consist of a typical DBL1α-CIDR1α 
head structure followed by a single DBL2δ and a non-α CIDR2 domain (Figure 1.10B).  
Group B genes can be further divided into 4 sub-types (B1-4) based on upsB sequence 
variations (Kraemer, Kyes et al. 2007).  
Group C var genes also exhibit the common DBL1CIDR1DBL2CIDR2non-
gene structure and they are exclusively located in centromeric regions (Figure 1.10 C) 
(Kraemer, Kyes et al. 2007). Their upstream sequences (upsC) are diverged from the 
other gene groups and found in 2 variations (C1-2).  Interestingly, genes containing the 
upsC upstream sequences have been shown to also be expressed during gametocyte 
development (Sharp, Lavstsen et al. 2006). 
Initially, two other var gene groups, D and E, were identified. These were 
represented by one gene each in 3D7 and paralogues shared over 75% identity in 
multiple domains and over 90% in some stretches (Gardner, Hall et al. 2002; Kraemer, 
Kyes et al. 2007).  Group D was represented by the longest gene identified thus far as 
the var1csa pseudogene.   Its upstream sequence has since been shown to cluster 
phylogenetically with upsA sequences and thus this group has been reclassified as the 
A2 group, whereas all other upsA genes are A1 type (Kyes, Christodoulou et al. 2003).    
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Group E is the var2csa gene, found at 1 copy in the 3D7 and IT4 isolates and in 2 
copies in HB3.  It is unusually structured with 3 DBLx domains followed by 3 DBL 
domains (Figure 1.10) (Gardner, Hall et al. 2002).  Var2csa have very little to no 
sequence identity with other members of the var gene family. This gene is expressed at 
high levels in placental-associated malaria and is thought to be the main ligand used in 
interacting with CSA, expressed on syncytiotrophoblasts in the placenta and is a major 
vaccine candidate for this form of malaria (Salanti, Dahlback et al. 2004).   
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Figure 1.10. Var groups and their domains. A. Group A var genes are generally longer 
and more structurally diverse, with 2-7 DBL domains. They do consist of some of the 
shortest genes like the Type 3 var, which consist of an unusual DBL1DBL2 domain 
combination.  B. Group B is mostly located in subtelomeric regions where they are 
translated towards the centromere. Most genes in this group consist of a typical 
DBL1α-CIDR1α head structure followed by a single DBL2δ and a non-α CIDR2 domain.  
C. Group C var genes also exhibit the common DBL1CIDR1DBL2CIDR2 non-
gene structure and they are exclusively located in centromeric regions. E. Var2csa 
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1.7.3.5.2 P. falciparum erythrocyte membrane protein 1 (PfEMP1) 
PfEMP1 are highly polymorphic antigens displayed within electron dense knobs 
on the surface of pRBC (Leech, Barnwell et al. 1984; Magowan, Wollish et al. 1988; 
Baruch, Pasloske et al. 1995). They are large proteins ranging between 200-350 kDa 
and are encoded by a multicopy gene family collectively named var. Each parasite 
genome contains about 60 var genes (Baruch, Pasloske et al. 1995; Smith, Chitnis et al. 
1995; Su, Heatwole et al. 1995; Gardner, Hall et al. 2002). PfEMP1 molecules (Figure 
1.11) have a general structure that is composed of a long extracellular region 
containing several conserved structural features: an N-terminal segment (NTS); Duffy-
Binding-Like-Domains (DBL; α-ζ); cysteine rich inter-domain regions (CIDR; α-γ); a 
transmembrane domain (TM) and a conserved intracellular acidic terminal segment 
(ATS) (Su, Heatwole et al. 1995; Smith, Subramanian et al. 2000). According to the 
classifications by Rask et al the DBL domain has five smaller distinct classes; four of 
which are based on the N-terminal DBL domains of var2csa (Lavstsen, Salanti et al. 
2003), and the DBLα of var3. The CIDR domain has two additional classes; δ, and pam 
which include the inter-domain 2 of var2csa. NTS sequences are divided into three 
classes, NTSA, NTSB, and NTSpam  while ATS sequences are divided into ATSA, ATSB, 
ATSpam, ATSvar1, and ATSvar3 (Rask, Hansen et al. 2010). 
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Figure 1.11. Schematic structure of PfEMP1 showing the major domains some of the 
proposed host receptors they bind. Duffy-Binding-Like-Domains (DBL; α-ε), cysteine 
rich inter-domain regions (CIDR; α,β), N-terminal segment (NTS), constant region  (C2), 
Transmembrane (TM) and acidic terminal segment (ATS).(Adapted from Smith et al, 
Trends in Parasitol 17(11) 2001 538-545)  
 
All the CIDR1α from the general PfEMP1 sequences bind to the CD36 receptor 
(Baruch, Ma et al. 1997; Gamain, Smith et al. 2001; Robinson, Welch et al. 2003). The 
most conserved domains of the PfEMP1 structure are the DBL1 and the C-terminal ATS 
region. The overall similarity in amino acid sequence of the DBL1 domain is >53%. 
However, sequences of domains of DBL1α are more common and more diverse while 
those of rarer DBL1α1 domains are more closely related which could be an indication of 
functional differences (Robinson, Welch et al. 2003). Although all var genes maintain 
the basic architecture, the amino acid sequence is highly variable when comparing 
PfEMP1 proteins among paralogues and across parasites isolates, indicating that there 
exists a virtually unlimited repertoire of PfEMP1 variants depending upon transmission 
intensity and geographical location (Kyes, Taylor et al. 1997; Fowler, Peters et al. 2002; 
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Trimnell, Kraemer et al. 2006). This high level of sequence diversity is thought to be 
maintained through gene conversion and recombination events within the family 
(Deitsch, del Pinal et al. 1999; Freitas-Junior, Bottius et al. 2000; Flick and Chen 2004).  
PfEMP1 has been identified as one of the major ligands to mediate the unique 
ability of the mature blood stage parasites of P. falciparum to adhere to capillary and 
post-capillary venular endothelia during the second half of the 48 hour life cycle 
(MacPherson, Warrell et al. 1985). Their adhesive properties are considered to be one 
of the major contributors to virulence, as isolates with minimal capacity to bind to host 
receptors cause mild or unapparent infections in animal models (Langreth and 
Peterson 1985). The role of the spleen to control parasite burden and protect against 
severe manifestations of malaria is well-appreciated in splenectomised malaria patients 
who develop actute P. falciparum malaria with high parasitaemia (Pongponratn, 
Viriyavejakul et al. 2000; Demar, Legrand et al. 2004; Bach, Baier et al. 2005). In 
addition, the blood film miscoscopy reveals the presence of mature asexual stages 
which that do not sequester would otherwise be removed from circulation by a 
functional spleen if present (Bach, Baier et al. 2005; Bachmann, Esser et al. 2009) and 
by the spleen modulating sequestration by unknown mechanisms (David, Hommel et 
al. 1983; Pongponratn, Viriyavejakul et al. 2000; Buffet, Safeukui et al. 2011). Some 
PfEMP1 adhesion interactions are proposed to lead to severe disease manifestations. A 
good example of this is the var2csa that has been identified as the main receptor 
mediating parasite sequestration in placental malaria (Silamut, Phu et al. 1999; Chen, 
Schlichtherle et al. 2000).  
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The position of the PfEMP1 on the pRBC enables the antigen to interact with 
various receptors, thus mediating adhesion with their multiple binding domains. 
However, this also makes it particularly vulnerable to recognition by antibodies 
produced by the host. Each var gene encodes an antigenically distinct form of PfEMP1, 
and supports adhesion to a range of possible endothelial receptors (Gardner, Pinches 
et al. 1996; Chen, Heddini et al. 2000). The extremely high level of PfEMP1 sequence 
diversity is a highly effective strategy to avoid host immune evasion and parasite 
clearance by the spleen, thus ensuring the survival of blood stage infections 
(Looareesuwan, Ho et al. 1987; Anyona, Schrier et al. 2006).  
 
1.8 Antigenic variation 
Bacterial, protozoan and fungal pathogens have evolved similar mechanisms of 
antigenic variation to avoid eradication by their host immune system and to maintain 
persistent infections (reviewed in (Deitsch, Lukehart et al. 2009). In Plasmodium spp., 
the first indications of antigenic variation were mentioned by Cox (Cox 1959) after 
observation of relapse in parasite populations in P. berghei-infected mice. Years later, 
antigenically variant P. knowlesi was described (Brown and Brown 1965), with the  
protein responsible for antigenic variation on the surface of infected erythrocytes 
identified in 1983 (Howard et al. 1983). Primarily, antigenic variation  was 
demonstrated in other Plasmodium species that possess a range of antigenic families 
with different properties:  in P. falciparum (Langreth and Reese 1979), P. fragile 
(Handunnetti, Mendis et al. 1987), P. chabaudi  (McLean, Pearson et al. 1982), and in P. 
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vivax (Mendis, Ihalamulla et al. 1988; Cole-Tobian and King 2003; Ntumngia, McHenry 
et al. 2009).  
Of all the malaria species that cause disease in humans, only P. falciparum can 
be maintained in in vitro culture long enough to allow extensive study of its variant 
surface proteins. Var genes have been shown to be expressed in a mutually exclusive 
manner at both the mRNA (Scherf, Hernandez-Rivas et al. 1998; Voss, Healer et al. 
2006) and protein levels (Dzikowski, Frank et al. 2006). The paradigm of mutually 
exclusive expression is a key element that underlies the process of antigenic variation 
and the ability of parasites to evade the host immune response, ensure blood-stage 
parasite survival and thereby promote transmission to additional hosts. Only one var 
gene is dominantly expressed in the mature stages of the parasite. A small 
subpopulation of parasites switch expression of its PfEMP1 variant (Smith, Chitnis et al. 
1995) and they find an advantageous niche (while the immune system is distracted by 
the major variant) and expand, thus resulting in the persistent nature of the disease as 
well as the waves of parasitaemia frequently involved in P. falciparum infections 
(Miller, Good et al. 1994).  
Mature erythrocytes provide an ideal atmosphere for the parasite to hide from 
the immune system of the host because of their simple morphology. They do not 
contain internal mechanisms of synthesis or traffic of proteins. They also do not 
express class I or II MHC molecules on their surface. 
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Figure 1.12. Schematic model of antigenic variation of PfEMP1. Each PfEMP1-
expressing pRBC is represented by a different colour. Each wave of parasite load is 
dominated by a single type of PfEMP1 (light blue) at 24 hours. The population switches 
to a different major PfEMP1 (green) at 48 hours due to host immune response (and 
possibly drugs). Antigenic variation continues during the course of the disease until all 
parasites are eliminated. 
 
 
The host immune system initially develops antibodies against the predominant 
form of PfEMP1 antigen and then consequently selects for subpopulations that arise 
from switching of expression between var genes. Seemingly, from the 60 var genes 
rises variant PfEMP1s that result in long term persistence of a single infection that 
varies in magnitude from undetectable levels to high parasite burdens (Miller, Good et 
al. 1994). After 18 hours of invasion by P. falciparum, these surface antigens mediate 
adhesion to receptors on the host endothelium, preventing the infected erythrocytes 
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from passing through the spleen. In doing so, the erythrocyte surface proteins make 
the parasite “visible” to the host immune system at the same time as they withdraw 
from circulation (Newbold, Craig et al. 1999).  
 
1.9 Host receptors implicated in cytoadherence  
The process of cytoadherence involves specific interactions between parasite 
ligands expressed on the surface of the pRBC and receptors on the host vascular 
endothelium. A number of endothelial receptors have been identified based on their 
ability to support the adhesion of laboratory-selected parasite isolates in in vitro 
adhesion assays.  Individual receptors are discussed below: 
 
1.9.1 Thrombospondin 
One of the first receptors to be identified was thrombospondin (TSP), a protein 
known to adhere to pRBC in a dose-dependent manner (Roberts, Sherwood et al. 1985; 
Sherwood, Roberts et al. 1987). There are three potential ligands for TSP: PfEMP1 
(Baruch, Gormely et al. 1996), red-cell-derived phosphatidylserine (Eda and Sherman 
2002) and altered band 3 protein (Eda, Lawler et al. 1999). Although TSP contributes to 
cytoadherence, it was later found insufficient to support the process by itself due to 
low affinity of binding under flow conditions (Panton, Leech et al. 1987).  
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1.9.2 CD36 
CD36 or platelet glycoprotein IV, commonly found on endothelial cells and 
blood monocytes, is described as one of the main host cytoadherence receptors for 
pRBC (Barnwell, Asch et al. 1989; Ockenhouse, Ho et al. 1991). CD36 is capable of 
binding almost all parasites from infected patients (Hasler, Handunnetti et al. 1990; 
Newbold, Warn et al. 1997) by using CIDRα domains of PfEMP1, encoded by group B 
and C var genes (Robinson, Welch et al. 2003). The ability to bind to TSP and CD36 is 
highly correlated; however, pRBC adherence to CD36 is a firmer attachment (Asch, Liu 
et al. 1993). The role of CD36 in malaria pathogenesis is unclear (Serghides, Smith et al. 
2003). In African subjects, there has mostly been no difference in CD36 binding ability 
between parasites isolates from SM and UM patients (Marsh, Marsh et al. 1988; 
Newbold, Warn et al. 1997; Rogerson, Tembenu et al. 1999; Heddini, Chen et al. 2001). 
The bulk of current evidence leans towards supporting the role of CD36 in UM (Ochola, 
Siddondo et al. 2011). A positive correlation was shown between CD36 binding and SM 
in Thailand (Ho, Singh et al. 1991; Ockenhouse, Ho et al. 1991) but this was not 
confirmed in a more recent study (Omi, Ohashi et al. 2003). Based on human genetic 
studies, there is some evidence that CD36 might have a role in SM development but 
more studies are required (Cserti-Gazdewich, Dhabangi et al. 2012). 
 
1.9.3 ICAM-1 
Intercellular adhesion molecule-1 (ICAM-1), an immunoglobulin superfamily 
adhesion molecule, is another host cytoadherence receptor that adheres to 80% of 
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isolates. ICAM-1 is distributed widely on vascular endothelium from a range of organs 
and is the proposed receptor for PfEMP1 in cerebral microvessels because they do not 
express CD36 (Berendt, Simmons et al. 1989). In support of a role for ICAM-1 in 
cerebral cytoadherence, pRBC ICAM-1 binding ability has recently been associated with 
cerebral malaria in Kenya (Ochola, Siddondo et al. 2011).  Such associations have never 
been observed in Asian field isolates (Ockenhouse, Ho et al. 1991; Udomsangpetch, 
Taylor et al. 1996). In one immunopathological study, co-localisation of sequestered 
pRBC with ICAM-1 expression was noted, particularly in the brain (Turner, Morrison et 
al. 1994). However, post-mortem studies need to be interpreted with caution, as 
adhesion molecules could be expressed as a consequence of the circulatory disturbance 
and metabolic abnormalities resulting from death rather than being its cause. For 
example, oxidant damage by adherent sickle cells has been shown to induce the 
expression of ICAM-1, E-selectin, and VCAM-1 on vascular endothelium (Sultana, Shen 
et al. 1998).  
 ICAM-1 is widely upregulated by cytokines: tumor necrosis factor (TNF), 
interleukin-1 (IL-1) and interferon-γ (IFN-γ) (Pober 1987). It binds the DBL2βC2 domain 
of PfEMP1 (Smith, Craig et al. 2000; Chattopadhyay, Taneja et al. 2004; Springer, Smith 
et al. 2004) mostly encoded by the group B var genes (Howell, Levin et al. 2008).  
 
1.9.4 CSA 
Chondrotin sulphate A (CSA), a carbohydrate expressed on syncytiotrophoblasts 
that line the placental intervillous space and found in association with 
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thrombomodulin, has been identified as the main receptor for placental sequestration 
in PM (Fried and Duffy 1996). CSA is also widely expressed at different levels 
throughout the human body but displays weak adherence to pRBC.  The blood flow in 
the placental intervillious space is very slow, an advantage for the parasite to firmly 
adhere to var2csa as the major ligand (Salanti, Staalsoe et al. 2003). 
 Hyaluronic acid (HA) has also been suggested as an additional receptor for 
sequestration of pRBCs in the placenta. However, it has shown low affinity binding 
under flow conditions which suggest that it might not be the main cause of pRBC 
accumulation in the placenta (Beeson, Rogerson et al. 2000). The involvement of  HA in 
placental sequestration is controversial, with claims that the original HA extracts 
showing adhesion were contaminated with CSA while others claim that the 
contamination was very minute to cause a significant effect. Recently, both CSA and HA 
have shown to bind P. vivax under static and flow conditions (Chotivanich, 
Udomsangpetch et al. 2012). 
 
1.9.5 Immunoglobulin-like receptors 
Other  members of the immunoglobulin superfamily are implicated in pRBC 
binding: vascular adhesion molecule-1 (VCAM-1; also known as CD106), platelet 
endothelial cell adhesion molecule 1 (PECAM-1; also known as CD31), E-selectin 
(CD62E) and P-selectin (CD62P) (Ockenhouse, Tegoshi et al. 1992; Newbold, Warn et al. 
1997; Treutiger, Heddini et al. 1997; Chen, Heddini et al. 2000). VCAM-1 and E-selectin 
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are not constitutively expressed on endothelial cells but rather are induced by IL-1 and 
TNF. The parasite ligands responsible for adhering to them remain unclear. In African 
isolates, both VCAM-1 and E-selectin showed low binding and are not associated with 
disease severity (Newbold, Warn et al. 1997).  
P-selectin is expressed on activated platelets and endothelia and is important 
for leukocyte trafficking. It has been shown to facilitate CD36 binding of Thai field 
isolates (Udomsangpetch, Reinhardt et al. 1997; Ho, Schollaardt et al. 1998; Yipp, 
Hickey et al. 2007). PECAM-1 is widely found on endothelia, platelets, monocytes and 
other immune system cells. The binding of certain field isolates from Kenya to PECAM-1 
does not show a significant correlation with SM (Newbold, Warn et al. 1997), whereas a 
PECAM-1 polymorphism in Thailand isolates showed an increased risked of CM 
(Kikuchi, Looareesuwan et al. 2001). An analysis of PECAM-1 polymorphisms revealed 
that the frequencies of certain variants are a risk factor for cerebral malaria (Kikuchi, 
Looareesuwan et al. 2001). The parasite ligand for both P-selectin and PECAM-1 is 
unknown but is thought to be PfEMP1 because purified PfEMP1 can bind to P-selectin 
in vitro (Treutiger, Heddini et al. 1997; Senczuk, Reeder et al. 2001) and both CIDRα and 
DBL2δ domains of PfEMP1 mediate PECAM-1 binding (Chen, Heddini et al. 2000; Yipp, 
Hickey et al. 2007).  
 
1.9.6 Other potential receptors for cytoadhesion 
Although their involvement in cytoadherence is debatable, other potential 
receptors for P. falciparum are collagen (Tandon, Kralisz et al. 1989), high molecular 
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weight glycoprotein fibronectin (Eda and Sherman 2004), some high and low density 
lipoproteins. Heparan sulphate has been shown to mediate rosetting and possible 
binding to CD31 (Calvo, Gomez-Coronado et al. 1998; Chen, Heddini et al. 2000). 
PfEMP1 also binds to complement receptor (CR1/CD35), found on the surface of non-
infected erythrocytes, and ABO blood group antigens to form rosettes which are 
thought to impair circulation and potentially cause ischemic complications in malaria 
(Kaul, Roth et al. 1991; Dondorp, Pongponratn et al. 2004). P. falciparum rosetting 
parasites bind IgM natural antibodies (“non-immune” IgM) from normal human 
plasma/serum (Scholander, Treutiger et al. 1996; Rowe, Shafi et al. 2002). Other 
endothelial receptors for P. falciparum but whose ligands are not yet known include 
cytokine protein fractalkine (Hatabu, Kawazu et al. 2003), alpha(v)beta3 receptor 
(Siano, Grady et al. 1998), neural cell adhesion molecule (NCAM or CD56) (Pouvelle, 
Matarazzo et al. 2007) and gC1qR-HABP1-p32 (Biswas, Hafiz et al. 2007). 
 
1.10 Molecular mechanisms of cytoadhesion  
It has been established that the adhesion of pRBC to microvascular endothelium 
is a central event in the pathogenesis of falciparum malaria. The molecular mechanisms 
and rheological characteristics of this interaction are of profound importance. Early 
studies of cytoadhesion were carried out using static adhesion assays, not taking into 
consideration that in vivo pRBC adhesion to vascular endothelial cells is likely to be 
influenced by the shear forces induced by flowing blood and the kinetics of receptor-
ligand coupling. The now widely used flow-based conditions closely mimic the 
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microcirculation in vivo (Nash, Cooke et al. 1992; Cooke, Berendt et al. 1994; Cooke and 
Coppel 1995).  
Studies that have used these techniques have demonstrated the strong 
dependence of adhesion on flow stress and have also shown clinical parasite isolates 
interacting with endothelial receptors in a stepwise process; tethering, rolling (slow, 
end-over-end movement in direct contact with the endothelial surface) and firm 
adhesion (no detectable movement) (Figure 1.13).  Significantly firmer adhesion is 
observed to CD36 than to ICAM-1 (Nash, Cooke et al. 1992; Cooke, Berendt et al. 1994; 
Cooke and Coppel 1995). This stepwise process tends to differ depending on the type 
of receptor. However, the strength of the rolling and interaction with each receptor 
molecule varies. Some pRBC bypass the rolling event and rest on CD36 immediately 
after tethering (Udomsangpetch, Reinhardt et al. 1997).  
 
 
Figure 1.13. Schematic diagram of the different phases of infected erythrocyte 
interaction with endothelium under physiological flow conditions. The tethering of 
one parasite (red) provide local disturbance in flow rates allowing the infected 
erythrocyte with reduced binding ability (blue)to adhere to the endothelium efficiently 
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P. falciparum variants have been shown to compete for adhesion to endothelia 
based on their efficiency of binding and it has been assumed that ‘efficient’ binders will 
cause severe disease. There are several studies showing correlation between the level 
of adhesion and the severity of the disease, with severe malaria isolates showing a 
stronger adhesion to endothelial receptors  (Newbold, Warn et al. 1997; Heddini, 
Pettersson et al. 2001; Phiri, Montgomery et al. 2009) (except for Stephen Rogerson 
who shows the opposite (Rogerson, Tembenu et al. 1999)). This suggests that variants 
from a genetically mixed infection will not display uniform cytoadherence and so may 
vary in their level of pathology in different organs depending on receptor expression.  
To determine the relative importance of cytoadherence, pRBC taken directly 
from the peripheral blood of the patients with acute falciparum malaria have been 
examined in a number of studies using static and flow binding assays (Hasler, 
Handunnetti et al. 1990; Ho, Singh et al. 1991; Ockenhouse, Ho et al. 1991; Chaiyaroj, 
Angkasekwinai et al. 1996; Newbold, Craig et al. 1997; Udomsangpetch, Reinhardt et al. 
1997). The degree of adhesion to CD36 is at least 10 fold higher than adhesion to ICAM-
1. Minimal or no adhesion to E-selectin, VCAM-1, or CSA is seen with most paediatric 
isolates. When the degree of cytoadherence to CD36 is compared at a fixed 
parasitemia, a range of intrinsic cytoadherent capabilities among different isolates 
becomes evident and in some instances correlates positively with the clinical severity 
of the infection (Ho, Singh et al. 1991; Ockenhouse, Ho et al. 1991). The high 
percentage of null cells observed in in vitro studies are unlikely in vivo, in that mature 
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parasites are seldom seen in the peripheral blood, yet multiplication is remarkably 
efficient even in the face of splenic clearance.  
P-selectin has been shown to be important for mediating the capture and fast 
rolling of pRBC followed by slower rolling and attachment to CD36 (Moore, Patel et al. 
1995). A likely scenario is that pRBC may need to interact with a number of endothelial 
receptor molecules for optimal adhesion. The rolling interactions with molecules such 
as ICAM-1 and P-selectin appear to facilitate adhesion to CD36, even if individually they 
are of much lower avidity than that required to allow attachment. This is the first 
demonstration of synergism among receptor molecules for cytoadherence under flow 
conditions. There is also synergism between CD36 and ICAM-1 in mediating 
cytoadherence to human dermal microvascular endothelial cells under static conditions 
and flow-based assays (McCormick, Craig et al. 1997; Gray, McCormick et al. 2003; 
Phiri, Montgomery et al. 2009).  
To date, parasite-host interactions show a complex pattern, with the parasite 
having a plethora of different host receptors to cytoadhere to. However, field isolates 
have shown restricted binding, with pronounced differences in host receptor specificity 
and extent of cytoadherence. These differences provide a scenario where different 
receptors can act synergistically. Adherence to one receptor can increase binding 
efficiency to other receptors (McCormick, Craig et al. 1997; Yipp, Anand et al. 2000; 
Gray, McCormick et al. 2003; Phiri, Montgomery et al. 2009). Synergism may be 
particularly important in view of the fact that CD36 expression on microvascular 
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endothelium does not appear to be upregulatable (Petzelbauer, Bender et al. 1993). 
Therefore, the degree of cytoadherence of P. falciparum on vascular endothelium may 
be regulated at the level of expression of adhesion molecules such as P-selectin and 
ICAM-1 rather than that of CD36. 
 
1.10.1 Rosetting 
Rosetting, the binding of pRBC to uninfected RBC, has been associated with high 
parasite density in numerous geographic areas and with severe malaria in Africa (Kun, 
Schmidt-Ott et al. 1998; Rowe, Kyes et al. 2002; Normark, Nilsson et al. 2007). 
Rosetting is viewed to contribute to pathogenesis due to the occlusion of the 
microvessels by the resulting agglutinates. The main host parasite ligands suggested for 
this phenomenon are var group A PfEMP1 (Bull, Berriman et al. 2005; Kaestli, Cockburn 
et al. 2006; Claessens, Ghumra et al. 2011). P. falciparum rosetting parasites are placed 
into two distinct phenotypes: those that bind IgM natural antibodies from normal 
human plasma/serum onto the surface of IEs (Scholander, Treutiger et al. 1996; Rowe, 
Shafi et al. 2002) and those that do not. IgM-binding rosetting isolates are common in 
parasites isolated from children, in whom they are associated with severe disease 
(Rowe, Shafi et al. 2002). IgM-binding of rosetting parasites is also thought to 
strengthen the infected-uninfected erythrocyte interaction in rosettes (Scholander, 
Treutiger et al. 1996; Clough, Atilola et al. 1998; Somner, Black et al. 2000), and also 
possibly aid parasites in evading immunity by masking key epitopes (Barfod, Dalgaard 
et al. 2011).  
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Previous studies have also shown RIFINs to rosette via CR1, heparan sulphate 
and CD31 (Calvo, Gomez-Coronado et al. 1998; Chen, Heddini et al. 2000). In contrast, 
Claessens et al observed a few rif genes highly expressed in a rosetting P. falciparum 
isolate, IT/R29 but their expression was not correlated to the high rosetting frequency 
(Claessens, Ghumra et al. 2011). 
 
1.10.2 Clumping 
The ability of P. falciparum clinical isolates to form platelet-mediated clumps 
has been associated with severe malaria in most studies, and accumulation of platelets 
in cerebral microvasculature was shown in CM patients but not in those who died of 
severe malarial anaemia (Pain, Ferguson et al. 2001; Grau, Mackenzie et al. 2003; 
Chotivanich, Sritabal et al. 2004; Arman, Raza et al. 2007). PfEMP1 has been suggested 
as the parasite ligand involved in clumping, the aggregation of pRBC and platelets (Pain, 
Ferguson et al. 2001).  Although the molecular binding mechanisms between pRBC and 
platelets is not yet fully understood, CD36 was originally shown to be the host receptor 
mediating this interaction, and the ability of CIDR domains to bind this receptor is well 
defined (Baruch, Ma et al. 1997; Smith, Kyes et al. 1998; Robinson, Welch et al. 2003).  
A recent hypothesis suggests that CD36-expressing platelets act as a bridge between 
pRBC and brain endothelia. The CIDR1 of group B and C PfEMP1 variants are likely to 
bind to CD36 in contrast to CIDR domains of group A variants (Robinson, Welch et al. 
2003).  
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Figure 1.14. Cytoadhesion of erythrocytes with P. falciparum to human cell. (From 
Expert Rev Mol Med 2009 26(11) e16) 
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A novel mechanism that supports pRBC adhesion in vitro is platelet-decorated 
von Willebrand factor (vWF). vWF is a glycoprotein constitutively produced by the 
Weibel-Palade bodies in the endothelium and megakaryocytes present in the blood 
plasma that is important for blood clotting. Liberation of vWF multimers tethered to 
ECs into circulation is triggered by EC activation brought by inflammation responses. 
During P. falciparum infection, vWF levels are elevated in both CM and UM patients 
(Phiri, Bridges et al. 2011), which unravel under flow and accumulate platelets on their 
surface by binding to platelet receptors such as thrombin. The vWF is cleaved and 
regulated by protease ADAMTS 13 that has significantly reduced activity during malaria 
infection. The accumulation of platelets offers the opportunity for increased pRBC 
adhesion, thus permitting vWF to play a role in malaria pathogenesis (Bridges, Bunn et 
al. 2010). 
Other receptors shown to mediate clumping are: P-selectin, expressed on the 
surface of activated platelets, especially in combination with CD36 (Wassmer, Taylor et 
al. 2008) and globular C1q receptor (gC1qR-HABP1-p32), expressed on the surface of 
diverse cell types including endothelial cells and activated platelets. gCIqR-HABP1-p32 
has been shown to facilitate pRBC-platelet clumping as well as potentially acting as a 
direct cytoadherence receptor through expression on brain endothelia (Biswas, Hafiz et 
al. 2007).  The parasite ligands that interact with P-selectin and gC1qR-HABP1-p32 have 
not yet been identified.  
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1.11 Regulation and control of var gene expression 
Knowledge of the molecular mechanisms regulating antigenic variation has 
advanced considerably; however, some inconsistencies and unanswered questions 
remain. There are different schools of thought with regard to control of var gene 
expression. Reverse transcription (RT)–PCR studies indicate the presence of multiple 
var transcripts in ring-stage parasites, but only a single var transcript in mature 
trophozoites. This has led to some groups believing that several var genes are 
transcribed during ring stages and only one var gene is expressed in mature stages such 
as trophozoites, from approximately 16 hours post-invasion. This has been accredited 
to the detection of only one full-length mRNA message in these mature stages (Chen, 
Fernandez et al. 1998; Scherf, Hernandez-Rivas et al. 1998; Kyes, Christodoulou et al. 
2007). Several lines of evidence have emerged that contradict this model of relaxed 
transcription of all var followed by exclusive transcription of a single var. This raised the 
question of a possibility of complete transcription of many var genes in trophozoite 
stages with a rapid and selective 3’ to 5’ degradation of the products not predestined 
for expression (Taylor, Kyes et al. 2000). This theory is backed-up by the analysis on 
synchronised mature parasites selected for adhesion to a certain receptor which has 
shown the detection of multiple full-length var genes transcripts (Noviyanti, Brown et 
al. 2001; Duffy, Brown et al. 2002), although one might argue that these arise from 
cytoplasmic remnants of promiscuous ring stage transcription.  
 It has also been argued that a bias towards transcription of the gene dominant 
in the previous asexual erythrocyte life cycle results in the same single var evading 
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silencing in the mature trophozoite (Chen, Fernandez et al. 1998). The process of 
exclusive transcription might be reset to a default var following transmission through 
the mosquito (Peters, Fowler et al. 2002).  Initially, Chen et al identified FCR3S1.2var1 as 
the dominant transcript belonging to group A-var genes transcribed in rosetting 
trophozoites of FCR3s1.2 parasite strains (Chen, Barragan et al. 1998). However using 
three sets of primer-pairs generated for the amplification of unknown DBL1α-
sequences lead to the identification of a different dominantly transcribed var gene 
(FCR3S1.2var2) in the same strain (Albrecht, Moll et al. 2011). These two studies 
highlight the importance of using more in-depth approach in the design of degenerate 
primers for detection of group A1. Regardless of whether only one full-length as 
opposed to several full-length var mRNA messages are present in mature asexual blood 
stages, the fact still remains that there is clonal expression of PfEMP1 proteins 
displaying different adhesive phenotypes by individually infected erythrocytes. The 
association of phenotypes with binding to particular tissues or disease outcome in field 
studies is evidence for transcription initiation control of gene expression. 
Investigations pertaining to the molecular basis for transcriptional regulation of 
the multicopy gene families of P. falciparum, with emphasis on the var gene family, 
have particularly centred on the roles that chromatin structure, subnuclear localisation 
and DNA regulatory elements play in var gene silencing, activation and mutually 
exclusive expression (reviewed in (Dzikowski, Templeton et al. 2006). The concepts 
likely also apply to the other multicopy gene families found in the malaria genome, 
such as the 2TM gene family members, of which little is known.  
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Antigenic variation in microorganisms is created by two general types of 
mechanisms: genetic events that involve gene recombination and/or mutations, and 
epigenetic mechanisms that affect the expression of a gene without altering its primary 
nucleotide sequence. However, for P. falciparum var genes, transcription occurs in situ 
and does not require specific gene shuffling, deletions or altering the DNA sequence of 
its regulatory elements (Kyes, Horrocks et al. 2001) as is the case in other organisms 
(Scherf, Hernandez-Rivas et al. 1998). These results suggest that var gene activation or 
repression occurs under epigenetic control. Whether antigen variation is governed by 
genetics or epigenetics, the studies that have performed thorough investigations on 
the subject generally point towards the fact that antigenic variation is not random but 
occurs with a certain order at specific loci. Earlier work by (Scherf, Hernandez-Rivas et 
al. 1998; Deitsch, del Pinal et al. 1999) supported the idea that switching between 
expressed PfEMP1 forms is controlled by epigenetic mechanisms rather than genetic 
rearrangements as shown by (Smith, Chitnis et al. 1995). In vitro studies with P. 
falciparum isolates verified that the rate of antigenic switching of a certain variant was 
estimated as high as 2% per generation, with immune selection presumably restricting 
the expressed PfEMP1 repertoire in vivo (Biggs, Gooze et al. 1991; Roberts, Craig et al. 
1992). In other words, at the end of each asexual erythrocytic cycle, 98% of schizonts 
express the original PfEMP1 type in the newly infected erythrocyte.   
The molecular mechanisms for var switching remain elusive.  Some data have 
suggested that regulation of var genes consists of 2 activities: interaction of the 5’ 
promoter and the intron promoter, and chromatin modification, specifically histone 
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methylation and deacytelation (Deitsch, Calderwood et al. 2001; Calderwood, 
Gannoun-Zaki et al. 2003), and yet the mechanism underlying this interaction is 
unclear.  Silent genes are characterised by a specific methylation of histone H3, 
H3K9me3 (Chookajorn, Dzikowski et al. 2007; Lopez-Rubio, Gontijo et al. 2007) 
whereas active genes are associated with the presence of H3K4me2 and H3K4me3. This 
selective modification of histones is believed to be involved in the highly structured var 
switching described by Recker et al (Recker, Buckee et al. 2011). 
One of the major draw backs of using in vitro methods to study var transcription 
is the possible bias in transcription profiles due to long term cultures. Recent studies 
clearly demonstrate that even after few cycles in a short term culture, the expression 
profile of var genes can change rapidly (Peters, Fowler et al. 2007). To overcome these 
limitations elaborate bioinformatics analyses are required where identification of var 
sequences can be achieved by special algorithms of mere tags of semi-conserved 
domains like the DBL1α (Normark, Nilsson et al. 2007). In spite of this, the var 
regulation studies have been consistent in identifying the order governed by var 
switching.  Thus, long term cultures in the absence of selective pressure rapidly result 
in extremely heterogenous var expression. Horrocks et al. were the first to show that 
var switching rates vary between isolates and are controlled by the individual genes 
intrinsic factor (Horrocks, Pinches et al. 2004).  These rates were later proposed to be 
associated with chromosomal location, with var genes located in the centromere being 
stable and rarely undergoing transcriptional switches with low off rates ranging from 0-
0.3% per generation, while var genes in the subtelomere readily switch with high off 
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rates 1-2% (Frank, Dzikowski et al. 2007). Mathematical models also predict 
substantially lower rates (0.03% per generation) of some variants (Paget-McNicol, 
Gatton et al. 2002) or faster (18%) for others (Gatton, Peters et al. 2003).  
Recent models by Recker et al have shown that a non-random highly structured 
switching pathway utilises the different on and off rates of the variants to prevent 
exposure of the entire var repertoire to the host immune system during the early 
stages of infection (Recker, Buckee et al. 2011). In order for P. falciparum to limit 
antigen exposure to the host immunity, the variant switching needs to occur often 
enough to generate parasite subpopulations that escape the host immune response 
and at the same time tightly controlled in order to avoid premature expenditure of the 
60 different proteins. Wang et al. have shown that parasites isolated from non-immune 
individuals express all var genes and let growth advantages select for those parasites 
best adapted to their hosts adhesion surfaces at onset of infection (Wang, Hermsen et 
al. 2009), as is the case in pregnancy malaria where the dominant variant in circulation 
is different from  the parasite population sequestering in the placenta.  .  
The general control of var gene transcription is governed by two promoters 
(Figure 1.9A), one located upstream and regulated var expression; the second 
promoter is on the introns and is responsible for sterile transcripts. The same promoter 
was also shown to function in both directions (Calderwood, Gannoun-Zaki et al. 2003), 
hence the prospect that its anti-sense transcripts may play a role in var2csar regulation 
in CSA-selected parasites (Ralph, Bischoff et al. 2005). Widespread antisense transcripts 
are also believed to be involved in the modulation of gene expression in humans (Yelin, 
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Dahary et al. 2003), rice (Osato, Yamada et al. 2003; Yamada, Lim et al. 2003; Yelin, 
Dahary et al. 2003), and Arabidopsis (Yamada, Lim et al. 2003). Non-protein coding RNA 
is also reported to play a role antigenic variation and potentially regulate P. falciparum 
gene expression at all levels (Raabe, Sanchez et al. 2010). 
 
1.12 Human acquired immunity and antibody reactivity to Plasmodium falciparum 
1.12.1 Memory B cells 
In theory, immunity to malaria parasite could be directed at any point in the life 
cycle, from the time the mosquito injects the sporozoites into the skin, to the pre-
erythrocytic and erythrocytic stages (reviewed in (Langhorne, Ndungu et al. 2008)). 
Mouse models have demonstrated killing of the pre-erythrocytic stages in the 
hepatocytes using CD8+ effect cells producing IFN-γ (Schofield, Villaquiran et al. 1987). 
However some longitudinal studies have disputed these findings suggesting that 
immunity involvement of these stages is limited (Owusu-Agyei, Koram et al. 2001). 
During blood stages, humoral response is presumed to play a key role as shown by 
mouse models, which demonstrate parasite clearance at this stage of infection is 
mediated by antibodies, B cells (Langhorne, Cross et al. 1998) and T-cell-mediated 
release of IFN-γ from macrophages (Pombo, Lawrence et al. 2002).  
People exposed to malaria do accumulate memory B cell specific for malaria 
antigens with exposure (Langhorne, Ndungu et al. 2008; Weiss, Traore et al. 2010; 
Wipasa, Suphavilai et al. 2010; Nduati, Gwela et al. 2011), however, studies 
investigating malaria-specific memory B cells in malaria-exposed people are limited. 
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One study reported a persistence of anti-P. falciparum memory B cells for over 8 years 
in adults without evident re-exposure (Migot, Chougnet et al. 1993) while another 
study reported low memory B cell in malaria-exposed children (Dorfman, Bejon et al. 
2005). In addition, children and adults living in malaria-endemic areas have shown 
altered distribution of B-cell subset (Asito, Moormann et al. 2008; Weiss, Traore et al. 
2010), suggesting some dysfunction of the B-cell compartment during acute and 
chronic P. falciparum malaria infection.  
 
1.12.2 T-cells 
Memory CD4+ T cells are also thought to be important in regulating pathology 
through cytokine production and inducing rapid secondary antibody responses 
(Langhorne, Ndungu et al. 2008). During malaria infections, memory CD4+ T cells are 
induced naturally, however, it has been difficult to demonstrate the function of CD4+ T 
cells in natural human infection due to low frequencies and the associated short-lived 
memory and regulatory activity (Langhorne, Ndungu et al. 2008; Todryk, Walther et al. 
2009). Currently, very little is known about CD4+ T-cells on parasite surface antigens 
such as PfEMP-1. One study used DBLα-tags to investigate CD4+ T-cell response to 
PfEMP-1 dominantly expressed in children with SM and UM during acute infection and 
found antigen-type dependent T-cell responses difference between var group A 
PfEMP1 and non-group A var/PfEMP-1 (Gitau, Tuju et al. 2012). 
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1.12.3 Dendritic Cells 
At the centre of both the T-cells and B cells responses are the dendritic cells 
(DC), which initiate and regulated the adaptive immune response.  DCs specialize in the 
uptake, processing and presentation of antigens to T cells. Malaria parasites can impair 
and suppress DC function, thus enabling parasite to invade the immune system 
(reviewed in (Wykes, Keighley et al. 2007; Bousheri and Cao 2008; Todryk and Urban 
2008)). DCs activate and mature during Plasmodium infection (Coban, Ishii et al. 2002; 
Leisewitz, Rockett et al. 2004; Sponaas, Cadman et al. 2006; Wilson, Behrens et al. 
2006) however, their activity is suppressed by haemozoin, a by-product of the malaria 
infection (Skorokhod, Alessio et al. 2004; Millington, Di Lorenzo et al. 2006) resulting in 
unstable interactions with T-cell (Millington, Gibson et al. 2007). 
 
1.12.4 Antibodies 
Immunity to malaria is acquired as a result of antigenic stimulation through 
repeated infections from early childhood onwards (McGregor 1987). This concept is 
demonstrated by the fact that in areas where malaria is endemic, the age-specific 
burden of P. falciparum infection and clinical disease are closely related to the level of 
malaria transmission. In high-transmission areas, the youngest children suffer from 
frequent episodes of disease and high parasite loads, while older individuals are 
generally able to control parasitemia and only suffer from mild malaria symptoms. On 
the contrary, in low-transmission areas, the incidence and severity of clinical disease in 
adults remains similar to that of children (Snow, Bastos de Azevedo et al. 1994; Snow, 
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Omumbo et al. 1997; Greenwood and Mutabingwa 2002; Lusingu, Vestergaard et al. 
2004).   
Immunoglobulin G antibodies (IgG) are among the immune responses 
associated with protection against clinical malaria, including antibodies with specificity 
for variant surface antigens (VSA) expressed on the surface of pRBC (Marsh, Otoo et al. 
1989; Bull, Lowe et al. 1998; Giha, Staalsoe et al. 2000; Bull and Marsh 2002). P. 
falciparum can maintain a chronic infection despite the sequential immune clearance 
of phenotypically similar parasites, due to emergence of isogenic parasite populations 
expressing different variant antigens on the surface of the pRBC that are not 
recognised by the host immune system. Accumulated clinical immunity development 
coincides with the gradual acquisition of a broad repertoire of VSA-specific antibodies 
(Bull, Lowe et al. 1998; Hviid and Staalsoe 2004). An infection is accompanied by 
development of antibodies with specificity for the VSA expressed by the infecting 
parasite (Marsh, Otoo et al. 1989; Ofori, Dodoo et al. 2002; Staalsoe, Shulman et al. 
2004; Elliott, Brennan et al. 2005). This process is repeated following each new parasite 
infection and it appears to protect the host from future clinical episodes arising from 
parasites expressing antigenically similar VSA. Antibodies are effective presumably by 
blocking invasion of RBC by merozoites (Blackman, Heidrich et al. 1990) cellular killing 
of antibody-opsonised parasites (Bouharoun-Tayoun, Oeuvray et al. 1995) and/or 
binding of antibodied to parasite-induced molecules (Bull, Lowe et al. 1998). 
VSA expressed by parasites isolated from children with severe disease have 
been found to be more frequently recognised by plasma from the same (or different) 
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patient taken during and after infection in areas of moderate to high transmission (Bull, 
Lowe et al. 1999; Bull, Kortok et al. 2000; Nielsen, Staalsoe et al. 2002). Such events 
occur due to the antibodies ability to cross-react by recognising the same epitopes. 
Following these observations, it was later discovered that in high transmission areas, 
young children (who are more prone to severe disease) quickly acquire antibodies and 
protection against malaria parasites expressing VSA types associated with severe 
disease outcomes.   
The recent identification of specific VSA mediating parasite adherence to human 
brain endothelia (Avril, Tripathi et al. 2012; Claessens, Adams et al. 2012; Lavstsen, 
Turner et al. 2012) gives hope of a vaccine targeting SM-specific VSA. Parasite virulence 
may be linked to the expression of specific VSA that allows particularly effective pRBC 
sequestration through simultaneous interaction with several host receptors or strong 
and efficient adhesion to a single receptor (Chen, Heddini et al. 2000; Heddini, 
Pettersson et al. 2001). The necessity to express multiple adhesive domains ought to 
impose considerable constraints on the three-dimension structure of the VSA involved, 
suggesting that such VSA may intrinsically be more similar to each other (Nielsen, 
Vestergaard et al. 2004).  Although extensive sequence diversity of VSA between and 
within clones has been demonstrated by several studies, it does not necessarily 
translate into serological diversity (Nielsen, Vestergaard et al. 2004). 
Agglutination assays have been successful in describing antigenic variation in 
PfEMP1.  Previously, agglutination studies have shown that antibodies from acute or 
convalescent patients agglutinate with P. knowlesi (Brown and Brown 1965) and P. 
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falciparum (Newbold, Pinches et al. 1992) in a variant-specific manner, and switches in 
agglutinating phenotype have been correlated with switches in cytoadherence 
characteristics of the pRBC (Roberts, Craig et al. 1992). 
Surveys of agglutinating antibody responses to natural P. falciparum 
populations in Pakistan (Iqbal, Perlmann et al. 1993), The Gambia, (Marsh and Howard 
1986) Kenya (Bull, Lowe et al. 1999) and Papua New Guinea (Forsyth, Philip et al. 1989; 
Reeder, Rogerson et al. 1994) have indicated that PfEMP1 antigens are highly diverse 
since antibodies induced following an infection generally agglutinate only the 
homologous parasite isolate that caused that particular infection. These findings 
confirm VSA diversity and implicate these molecules as important targets for naturally 
acquired immunity.  
Pre-existing anti-PfEMP1 antibodies are passed from mother to child and last for 
about six months. These antibodies are able to recognise PfEMP1 variants that are 
expressed during a new infection of the infant and a subset of variants in the 
population. These results are supported by Bull et al. 1999 who found that plasma from 
a 3 month old child, presumably still carrying maternal antibodies, was able to 
agglutinate all isolates at the time of disease, apart from the homologous isolate. This 
gave rise to the concept that infection is due to a hole in the antibody repertoire. 
Despite the apparent role of anti-PfEMP1 antibodies in the development of anti-
disease immunity, their diversity is thought to limit their potential as vaccine 
candidates. Although the total pool of PfEMP1 epitopes is generally assumed to be 
large, Aguiar and co-workers have argued that antigenic diversity appears to be finite 
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because of the fact that semi-immune serum has been found to agglutinate parasites 
isolated in different continents and those isolated from a similar location up to 19 years 
in the past (Aguiar, Albrecht et al. 1992).  
Hviid et al propose that the specificity/cross-reactivity balance is determined by 
transmission intensity through its impact on acquisition of protective immunity (Hviid, 
Staalsoe et al. 2003).  After all, it has been shown that antibody recognition of VSA 
varies markedly between different parasite isolates (Bull, Lowe et al. 1999; Bull, Kortok 
et al. 2000; Nielsen, Staalsoe et al. 2002), with parasites expressing common VSA at a 
selective advantage in non-immune patients but the balance gradually tips in favour of 
rare VSA with the acquisition of protective immunity. This hypothesis helps to solve the 
long-standing but unresolved puzzle of why immunity to severe disease develops much 
more rapidly than immunity to parasitaemia per se. If the common VSA are more 
conserved (and cross-reactive) among isolates than rare VSA, then the differences 
between the above geographical data from India and Sudan on one hand and the 
Gambia, Ghana, and Kenya on the other, probably reflect differences in seasonality and 
intensity of malaria transmission.  
The var gene group A are highlighted as potential virulent PfEMP1 candidates 
for vaccines that can induce antibodies to inhibit rosetting (Discussed in section 1.10) 
and prevent severe malaria. The link between rosetting, group A vars and SM has been 
demonstrated in vitro where parasites selected to bind human brain endothelial cell 
line HBEC-5i consistently up-regulated group A-like var genes (Claessens, Adams et al. 
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2012). Further work from the same group links IgM-positive rosetting parasites and 
group A vars, showing that the rosetting group A type PfEMP1 have a similar head 
structure, with a distinct NTS (Ghumra, Semblat et al. 2012). Combinations of 
antibodies raised against the NTS segment and the various domains recognised live IEs 
(Ghumra, Khunrae et al. 2011) and blocked binding to HBEC-5i (Claessens, Adams et al. 
2012), inhibited rosette formation and induced phagocytosis of pRBCs against 
homologous parasites (Barfod, Dalgaard et al. 2011; Ghumra, Khunrae et al. 2011; 
Ghumra, Semblat et al. 2012). Furthermore, the antibodies displayed broad cross-
reactivity against heterologous parasite strains with the same rosetting phenotype, and 
clinical isolates from other sub-Saharan African countries (Ghumra, Semblat et al. 
2012). The studies described above provide some evidence that parasites with a 
virulence-associated adhesion phenotype share pRBC surface epitopes that can be 
targeted by strain-transcending antibodies to PfEMP1, which potentially can be used in 
development of therapeutic interventions to prevent severe malaria. 
 
1.13 Vaccines 
Some high transmission areas in sub-Saharan Africa have experienced a 
significant reduction in malaria due to several efforts that have been put in place to 
control the disease. However, this success story is being threatened by the potential 
spread of artemisinin resistant strains of P. falciparum originating from Southeast Asia 
(White 2010) and the spread of An. gambiae strains that are resistant to pyrethroid 
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insecticides (WHO 2011). It is through such challenges that the idea of a vaccine seems 
essential, especially in areas where elimination is inconceivable.  
 
1.13.1 Pre-erythrocyte vaccines 
A vaccine targeting the sporozoite is very logical because only a small number of 
parasites (Sinden 2010)are inoculated at a time, thus creating a bottleneck in the 
parasite life cycle. The idea of designing a vaccine to target pre-erythrocytic stages 
started when UV-irradiated sporozoites of P. gallinaceum showed protection from 
avian malaria in chickens (Ceithaml and Evans 1946). Subsequently, vaccination of 
rodents with irradiated sporozoites of P. berghei showed maximum protection against 
challenge (Nussenzweig, Vanderberg et al. 1967). Since the identification of the 
sporozoite surface molecule circumsporozoite protein (CSP) as a target for antibodies 
(Sinden 2010), several efforts have used the CSP for vaccine development with some 
success in humans (Vanderberg, Nussenzweig et al. 1969; Clyde, Most et al. 1973; 
Patarroyo, Amador et al. 1988).  The required amount of attenuated sporozoites to 
elicit a response have been recently quantified, therefore it is hoped that clinical trials 
will proceed shortly (Hoffman, Billingsley et al. 2010). Other protective mechanisms in 
humans have been achieved by exposure to P. falciparum-infected mosquitoes 
followed by treatment with chloroquine (Roestenberg, Teirlinck et al. 2011).  
There is a potential synthetic vaccine RTS,S, made from CSP, with hepatitis B 
virus surface antigen and an adjuvant AS02 and AS01 (monophosphoryl lipid A , quil A 
and saponin or liposomes) (Casares, Brumeanu et al. 2010) which shows 30-50% 
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protection and that lasts longer than four years in some cases while in others, RTS,S has 
failed to elicit high enough immune response to some antigens (Casares, Brumeanu et 
al. 2010; Greenwood and Targett 2011; Garcia-Basteiro, Bassat et al. 2012). Phase 3 
trials of this vaccine are currently underway at eleven sites in seven countries, including 
Malawi.  
 
1.13.2 Blood stage vaccine 
Efforts in blood stage vaccines to block erythrocyte invasion or inhibit parasite 
replication have mostly been based on the following antigens: the apical membrane 
protein 1 (AMA-1), MSP1, 2 and 3, GLURP, RESA, serine repeat antigen 5 (SERA5) and 
the erythrocyte-binding antigen 175 (EBA-175) (WHO 2010) with minimal success in 
humans (Genton, Betuela et al. 2002; Ellis, Sagara et al. 2010; WHO 2010; Thera, 
Doumbo et al. 2011). In other attempts, infections induced by bouts of P. falciparum 
erythrocytes that are treated before manifestation of the erythrocytic stages show 
protection from subsequent challenge and elicit a strong T-cell proliferation (McCarthy 
and Good 2010).  
 
1.13.3 Vaccines that impact transmission 
Other vaccines designed to control transmission, P320, P48/45 and HAP2, have 
been based on gametocyte surface antigens and prevent fertilisation in the mosquito 
midgut.  Alternatively, P25 and P28 vaccines induce antibodies that prevent zygote or 
ookinete migration from the midgut (Arevalo-Herrera, Solarte et al. 2011). Only P25, 
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based on the ookinete antigens of P. falciparum and P. vivax, has reached the clinical 
phase of development (Malkin, Durbin et al. 2005; Wu, Ellis et al. 2008; Arevalo-
Herrera, Chitnis et al. 2010; Arevalo-Herrera, Solarte et al. 2011) but no large clinical 
trials have yet been undertaken.  
 
1.13.4 PfEMP1 based-vaccines 
 Variant specific anti-PfEMP1 antibodies are thought to contribute to the 
regulation of parasite density in a manner that decreases the incidence of clinical 
disease (Marsh and Howard 1986; Forsyth, Philip et al. 1989; Gupta, Hill et al. 1994; 
Bull, Lowe et al. 1998). As previously discussed in section 1.12.4, immunity to PfEMP1 
can thereby influence transmission by regulating the density of asexual blood stages 
with the potential to become transmission stages, and to directly target early 
gametocytes to prevent their maturation into transmission stages (Piper, Roberts et al. 
1999). On the other hand vaccine against variant-specific PfEMP1 epitopes might be 
unrealistic due to complex variability in these antigens but there is some hope as 
selected PfEMP1 variants have been associated with severe malaria. Therefore, 
subgroups of these antigens, such as the var2csa important in PM have the potential to 
make good vaccine candidates for specific aspects of the disease (Hviid 2010; Avril, 
Cartwright et al. 2011). Alternatively,  targeting the relatively conserved DBL1 domain 
to generate cross-reacting antibodies may also circumvent the problem of variant 
PfEMP1 (reviewed in (Ho and White 1999)).  
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The CIDR1 domain of PfEMP1 is highly variable (Smith, Subramanian et al. 
2000). Although the CIDR1 domain was unable to elicit high antibody titers during 
infection (Baruch, Gormely et al. 1996; Baruch, Ma et al. 1997), monoclonal antibodies 
produced against different regions of this domain have reacted with several isolates 
(90% of those tested) expressing different PfEMP1 variants except those that do not 
bind to CD36 (Gamain, Smith et al. 2001), presumably because the monoclonal 
antibodies were raised to a CIDRα and not a CIDRα1 type domain. Some immunisation 
experiments in monkeys using a 179-amino acid region of the CIDR domain induced 
protection against homologous challenge (Baruch, Gamain et al. 2002). Furthermore, 
immunisation of mice with three different CIDR1 that have the critical function of 
binding to CD36 also induced cross-reactive antibodies (Gratepanche, Gamain et al. 
2003). Thus, CIDR1α-based general malaria vaccines have served the proof-of-principle 
of the possibilities of developing vaccines against variant antigens and other PfEMP1 
domains are also being exploited for this purpose (Chen, Pettersson et al. 2004). 
 
1.14 Var gene studies in field isolates 
Advances in the study of var gene expression in field isolates have been made 
due to the availability of robust molecular techniques which have allowed the 
determination of various surface antigens expressed on the surface of an infected 
erythrocyte in relation to cytoadherence and disease severity. A highly dynamic and 
variable picture of simultaneously expressed var transcripts has been observed  in field 
isolate samples confirming the recombinogenic nature of var genes, with a correlation 
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between the number of var transcripts and the number of infecting strains (Kaestli, 
Cortes et al. 2004; Kaestli, Cockburn et al. 2006). This has raised a common challenge of 
identifying several non-identical sequences between different isolates. This 
complication poses challenges in how the enormous amount of data that has already 
been generated can be meticulously analysed and fully understood. This problem is 
well pointed out by (Barry, Leliwa-Sytek et al. 2007) who observed a vast diversity of 
DBL1α domains of var genes in the genome of parasites sampled from widespread 
geographic origins compared to parasites from a single malaria endemic area of Papua 
New Guinea (PNG).  
The vast var gene diversity is largely responsible for the inherent difficulties in 
population genomic analysis of highly diverse multigene families of Plasmodium spp. 
Individual P. falciparum genomes have repertoires of var genes that can recombine 
with other repertoires during the sexual phase of the life cycle in the mosquito (Su, 
Ferdig et al. 1999). There is also circumstantial evidence for ectopic recombination 
among var genes within the same genome, possibly during both meiosis and mitosis, 
creating a possibility to generate diversity even among closely related genomes (Ward, 
Clottey et al. 1999; Freitas-Junior, Bottius et al. 2000; Taylor, Kyes et al. 2000). 
Additional complications in the P. falciparum genome are the several unusual features 
such as extreme AT bias, large tracts of non-unique sequences and several large 
families of polymorphic genes (Gardner, Hall et al. 2002).  
Parasite populations are generally distinct based on geographical location. For 
example, South American and Asia-Pacific isolates commonly amplified identical DBL1α 
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sequences from multiple patients, whereas this is a rare occurrence in sub-Saharan 
African samplings of circulating populations (Nogueira, Wunderlich et al. 2001; Fowler, 
Peters et al. 2002; Bull, Berriman et al. 2005; Albrecht, Merino et al. 2006; Fowler, 
Chavchich et al. 2006; Barry, Leliwa-Sytek et al. 2007).  Bull et al. have shown that var 
genes from Kenyan field isolates and laboratory isolates can be classified into 
biologically meaningful subsets based on cysteine-containing small blocks of semi-
conserved sequences, such as the DBL domain cassette classification described by 
Lavstsen et al (Rask, Hansen et al. 2010) thus providing some evidence of the existence 
of var gene semi-structuring  (Bull, Berriman et al. 2005). However, there was variation 
in expression of these semi-conserved sequences in parasites. In most of the isolates 
there were clear dominant sequences present at high frequencies expressed by the 
parasite in different infections that were consistent with those found in field isolates of 
other studies. Further, Warimwe et al. from the same group showed that expression of 
a minor component of all genomic var repertoires of semi-conserved blocks with two 
cysteine residues, “cys2”, were associated with parasites from young children with 
severe malaria and low immunity against malaria (Warimwe, Keane et al. 2009). The 
var genes with the 2 cysteine structure mostly belong to group A var genes. Therefore, 
the results are compatible with the hypothesis that the genomic var gene repertoire is 
organised such that PfEMP1 molecules that confer the most virulence to the parasite 
belong to group A vars (Kyriacou, Stone et al. 2006). 
So far, var gene studies have employed the use of polymerase chain reaction 
(PCR) techniques for the amplification of parasite DNA. A conserved DBL1domain is 
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targeted using “universal” primers to amplify a tag of variable sequence and length 
with which to identify each transcript distinct. These primers were subsequently shown 
to exhibit bias for a subset of var genes, affecting sequence abundances by leaving  
other var sequences untargeted (Taylor, Kyes et al. 2000).  A new set of universal 
primers designed by Kyes et al. in 1997, revised by Taylor in 2000 and again by Bull in 
2005, are the most utilised for field studies of all the primer sets developed so far 
(Kyes, Taylor et al. 1997; Taylor, Kyes et al. 2000; Bull, Pain et al. 2005). 
 Studies on circulating parasites have demonstrated that there is high turnover 
in the antigens expressed during infection with most studies linking high expression of 
group A var genes in peripheral blood to severe disease syndromes (Bull, Berriman et 
al. 2005; Kaestli, Cockburn et al. 2006; Kyriacou, Stone et al. 2006; Rottmann, Lavstsen 
et al. 2006; Warimwe, Keane et al. 2009).  Examination of postmortem samples of 
severe infections has shown a reduced genetic diversity compared to mild and 
asymptomatic paediatric malaria (Montgomery, Milner Jr. et al. 2006; Milner, Valim et 
al. 2012).  Their pattern of antigen expression is, however, largely unknown. 
Nonetheless, Dobano et al used immunofluorescence antibody typing for MSP 1 and 2 
alleles to compare circulating parasites and sequestered parasites in the brain and 
other tissues in the same Malawian children with fatal malaria (Dobano, Rogerson et al. 
2007). They found concordance between parasite serotypes in peripheral blood and 
parasite serotypes in tissues and no difference in the serotype distributions in the 
different tissues. Previous studies of sequestered parasites have utilised purified 
receptors or cultured endothelium from particular organs, plus clinical isolates and 
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laboratory-adapted lines selected for specific adhesive behaviour, to model and 
investigate potential host-parasite interactions (Gay, Robert et al. 1995; Prudhomme, 
Sherman et al. 1996; Xiao, Yang et al. 1996; Traore, Muanza et al. 2000). 
There is evidence that the inflammatory responses seen at the blood-brain 
barrier in cases of CM involves the increased systematic production of pro- 
inflammatory cytokines such as TNF, lymphotoxin, IFN -γ and IL1β (Kwiatkowski, Hill et 
al. 1990; Newton and Krishna 1998; Brown, Turner et al. 1999) induced by the immune 
response to the malaria parasites. The overproduction of cytokines such as TNF results 
in up-regulation on cerebral EC of ICAM-1,  VCAM-1 and E-selectin that facilitates the 
sticking of pRBC to host receptors when they are expressing the appropriate ligands 
(Ockenhouse, Ho et al. 1991; Turner, Morrison et al. 1994; Rogerson, Tembenu et al. 
1999; Silamut, Phu et al. 1999). In accordance with this, a recent study on paediatric 
malaria in Ghana also showed staining for ICAM-1, VCAM-1 and E-selectin in 
association with pRBC in brain microvasculature of fatal CM patients (Armah, Dodoo et 
al. 2005).  However, the specific ligands used by the pRBC during in vivo interactions 
are unknown, largely due to the immense diversity and complexity of these antigens, 
and the inaccessibility of sequestered parasites.  
As previously mentioned, several adhesive phenotypes that do not utilise 
endothelia such as rosetting, sequestration of pRBC in the  placenta (Miller, Baruch et 
al. 2002), formation of platelet-mediated clumps (Pain, Ferguson et al. 2001), and pRBC 
adhesion to vWF (Bridges, Bunn et al. 2010) are all thought to contribute to pathology. 
Such pRBC adhesion mechanisms are supported by post-mortem histological studies 
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that have shown pRBC accumulating in the microvasculature (Grau, Mackenzie et al. 
2003; Wassmer, Combes et al. 2006).  
Malawi has a high burden of malaria with no reduction in disease incidence 
observed over the past decade despite a change of first-line anti-malarial treatment in 
2007 and intensification of vector control programmes (Roca-Feltrer, Kwizombe et al. 
2012). As such, there is a local malaria surveillance at the QECH and the paediatric  
clinicopathological study of fatal malaria patients in Blantyre, Malawi, with more than 
100 study cases of fatal malaria, including controls, from 1996-2011.  The availability of 
such resources has allowed investigation of host-parasite clumping mechanism and 
examination of antigen properties of sequestered populations of pRBC in the brain, 
heart and gut and their interactions with the host.  
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PROJECT AIMS  
The purpose of this work is to study tissue samples from a malaria clinicopathology 
study of fatal pediatric malaria patients. The main aims of the study are to:  
1. Determine which var gene groups are expressed by parasites in severe malaria 
and sequestered in cerebral microvasculature 
2. Determine the expression of putative sequestration receptors and cytokines in 
different paediatric malaria diagnostic groups and organs from fatal cases of P. 
falciparum paediatric malaria 
3. Determine which particular var/PfEMP1 subtypes and ABO blood groups 
mediate platelet-mediating clumping 
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Chapter 2 
 
2. STUDY PARTICIPANTS, MATERIALS AND METHODS 
2.1 Study location 
2.1.1 Malawi 
The republic of Malawi is a landlocked country located in south-east Africa, 
bordered by Zambia in the west, Tanzania in the north-east and Mozambique on the 
south-west and east. Much of the country is separated from Tanzania and Mozambique 
by the physical barrier of Lake Malawi. Malawi covers over 118,000 km2 (45,560 sq mi) 
with an estimated population of more than 15.3 million as of 2009 
(http://www.who.int/countries/mwi/en/). The country is divided into three main 
regions: Northern, Central and Southern Regions which are further sub-divided into a 
total of 24 districts comprising of several ethnic groups with English and Nyanja as the 
official languages. The largest and capital city is Lilongwe, located in the Central Region. 
The main commercial city of the country, Blantyre is located in the Southern Region.  
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Figure 2.1. Study location in Malawi. 
 
Malawi is one of the least developed countries in the world with a Gross 
National Capita income of USD810 per annum. Agriculture is the main driving force of 
the economy, accounting for at least 90% of export revenue with tobacco being the 
main export crop. Malawi has a major burden of disease including HIV/AIDS, 
pneumonia, tuberculosis and diarrhoea with malaria being the leading cause of death 
in children under five years (http://www.who.int/countries/mwi/en/).  
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Figure 2.2. Distribution of causes of death in children less than five years. 
These are figures from 2008 adapted from http://www.who.int/countries/mwi/en/  
Malaria was listed as the main cause of under-5 death 
 
2.1.2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme  
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW), 
located in Blantyre, was established in 1995 for the purpose of conducting research on 
diseases of local importance and providing training for clinical and laboratory staff. The 
programme operates in collaboration with the College of Medicine, University of 
Malawi (COM) and the Liverpool School of Tropical Medicine  and University of 
Liverpool, UK, via the Wellcome Trust Tropical Centre.  Clinical research performed at 
MLW is based in the wards and clinics of the Queen Elizabeth Central Hospital (QECH) 
and in health centres in the peri-urban and rural areas.  
Malaria 
Other 
Pneumonia 
Diarrhoea 
Prematurity 
Birth asphyxia 
Neonatal sepsis 
Congenital abnormalities 
Injuries 
Measles 
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QECH is a 1000 bed referral hospital for the Southern Region, is the largest 
hospital in Malawi and also serves as a local hospital for residents of Blantyre and 
surrounding areas, a population of 728,285 (www.world-gazetteer.com 2012). This 
study was conducted at the MLW laboratories which have successfully passed both 
internal and external quality control. Ethical approval was obtained from the College of 
Medicine Research and Ethics Committee (COMREC) under the University of Malawi, as 
detailed below. All clinical procedures were undertaken by experienced and Good 
Clinical and Laboratory Practice (GPLC) trained nurses and clinicians.  
 
2.1.3 Malaria surveillance in Malawi 
Malaria is responsible for approximately 40% of hospitalisation of children 
under the age of five (WHO report 2010). The Ministry of Health in collaboration with 
its partners implemented the National Malaria Strategic Plan from 2005–2010 with the 
goal to scale up malaria interventions towards the national vision of “Malaria-free 
Malawi.” There were four main areas of focus: effective antimalarial treatment, ITNs, 
IRS and prevention of malaria in pregnancy (MIS report 2010).  
  Some of the highlighted interventions included a change in treatment policy 
from sulfadoxine-pyrimethamine (SP) to artemisinin-based combination therapy (ACT) 
in 2007 for P. falciparum infection. All severe cases are still treated with quinine. In 
pregnant women, malaria prevention relies both on the use of ITNs and IPT with SP for 
women during pregnancy (PMI report 2012; MIS report 2010). 
   
91 
 
The use of ITNs when sleeping is the primary control strategy for preventing 
malaria in Malawi. Results from the 2010 Malawi Malaria Indicator Survey (MIS) 
indicate that 58.2% of households possess at least one ITN and among these houses, 
80.7% of children under the age of five slept under an ITN the night before the survey. 
ITNs are distributed freely to all age groups since 2010 (MIS report 2010). 
According to the MIS 2010, although IRS was approved since 2007, it has not yet 
been fully implemented as a malaria prevention method. Initially, IRS activities were 
limited to private spraying in Blantyre city, with less than 2% of all households sprayed 
in a year and pilot IRS spraying was started in Nkhotakota district. Based on the success 
of these efforts (Skarbinski 2012), the Malawi Ministry of Health have expanded IRS to 
a total of 7 districts (discussed in Chapter 1 section 3.2.2).  
 
2.2 Study population 
2.2.1 Clinical samples 
This study utilises clinical samples collected under a clinicopathological study of 
fatal paediatric malaria in Blantyre, Malawi, that aimed to collect  samples from 100 
patients and did so between 1996-2009 (Taylor, Fu et al. 2004). Patients were admitted 
to the paediatric research ward at QECH and were classified during life as having CM 
(Blantyre coma score of ⩽2, peripheral P. falciparum parasitaemia, and no other 
identifiable cause of coma); SMA (peripheral P. falciparum parasitaemia, a hematocrit 
level of <15% at any time during hospitalization, and consciousness until ⩽2 hrs before 
   
92 
 
death); or cerebral malaria and anemia (CM + SMA; symptoms of CM plus a hematocrit 
level of ⩽15%). These classifications were confirmed by autopsy.  
The time between admission and death ranged between 15 ±8 hrs, and 
autopsies were performed approximately 8 ±4 hrs after death. Tissue samples were 
placed in either tissue matrix (OCT compound; Tissue-Tek) or RNAlater (Ambion) at the 
time of autopsy, snap frozen in liquid nitrogen and stored at −80°C. Tissue was also 
fixed in 10% buffered formalin and processed using routine paraffin embedding for 
histological examination. The clinicopathological study was reviewed and approved by 
COMREC and ethics committees at Michigan State University and the University of 
Liverpool. 
This project used frozen archived samples from between January 1999 – 
December 2008. The fatal malaria cases were divided into three diagnostic groups 
which had clinically defined CM with the following histological findings: 
1. CM2 – classic CM, with high parasite burden in cerebral microvasculature 
and associated pathology such as ring haemorrhages, thrombi and 
infiltration of monocytes 
2. CM1 – clinically high parasite burden in the brain but with no associated 
pathology 
3. PC – parasitaemic controls are children who died with a mild or 
asymptomatic P. falciparum infection but with another identified cause of 
death 
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All patients had their HIV status determined with two rapid tests; Uni-Gold (Trinity 
Biotech, Carlsbad, CA) and Determine (Inverness Medical, Orlando, Florida). In the 
event of a discordant HIV result a PCR was performed. CM2 accounted for 
approximately half of the cohort and a quarter each of CM1 and PC cases (Taylor, Fu et 
al. 2004). The project was reviewed and approved by COMREC (Ref: P.06/07/560 and 
P.02/10/867). Details of these patients are described in Chapter 3.  
 
2.2.2 P. falciparum platelet-mediated clumping study  
2.2.2.1 Blood sample collection  
Paediatric malaria patients under the age of 12 years were recruited after 
obtaining informed consent from their parents or guardians at the accident and 
emergency (A&E) ward at QECH. The summary of the patient characteristics are given 
in Table 2.1 and the full details are listed in Table 2.2. The study was approved by 
COMREC (Ref: P.02/10/867). 
3 mL of whole blood was collected via venepuncture into sodium citrate tubes 
(BD vacutainer, product number 366395) and processed immediately. 
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Figure 2.3. Flow chart of the P. falciparum platelet-mediated clumping study design. 
Infected erythrocytes were isolated from 100 P. falciparum-infected children and 
cultured to maturity. RNA was extracted from both the platelet-mediated clumping and 
non-clumping pRBC for determination of var gene group expression.   
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Table 2.1. Summary of the selected characteristics of the study population (n=100) 
Characteristic  No. (%) 
Age in months 
       Average 
      Median 
      Range 
 
64 
60 
10-138 
 
Sex   
      Female 48 58.9 
      Male 52 41.1 
Blood group   
        A+ 17 23.2 
        B+ 21 28.8 
        AB+ 3 4.1 
        O+ 21 28.8 
        O- 10 13.7 
parasitaemia   
       ++ 11 15.1 
       +++ 17 23.3 
       ++++ 45 61.6 
+ 1 - 10 parasites per 100 thick film fields                       
= approx  40 - 100/µL 
+ + 11 - 100 parasites per 100 thick film fields                           
= approx  100 – 1,000/µL 
+ + + 1-10 parasites per single thick film field                   
=approx 1,000 - 10,000/µL 
+ + + + > 10 parasites per single thick film field                                
= approx  10,000-100,000/µL 
+ + + + + >100 parasites per single thick film field 
=>100,000/µL 
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Table 2.2. Clinical characteristics of patients in the study. 
Sample No. Age in 
months 
Gender Parasitaemia PCV Blood* 
group 
1 36 Female 3+ 18  
2 54 Female 3+ 34  
3 96 Female 4+ 21  
4 7 Female 4+ 24  
5 18 Female 4+ 30  
6 120 Male 2+ 39  
7 78 Male 3+ 22  
8 19 Female 4+ 20  
9 97 Female 4+ 30  
10 29 Female 2+ 36  
11 93 Female 4+ 35  
12 107 Male 4+ 38  
13 84 Female 3+ -  
14 68 Female 2+ 21  
15 32 Male 2+ 22  
16 84 Female 3+ 30  
17 108 Male 3+ -  
18 95 Female 3+ 30  
19 67 Female 4+ 21  
20 24 Male 4+ 32  
21 60 Male 3+ 22  
22 33 Male 2+ 34  
23 55 Female 2+ 27  
24 10 Female 4+ 27  
25 53 Female 2+ 28  
26 48 Male 2+ 30  
27 48 Male 4+ 38 A+ 
28 84 Male 4+ 30 A+ 
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29 132 Male 4+ 30 O+ 
30 84 Male 4+ 39 O+ 
31 108 Male 4+ 40 O+ 
32 84 Male 4+ 35 O+ 
33 84 Male 4+ 40 A+ 
34 72 Male 4+ 41 O+ 
35 72 Female 4+ 32 O+ 
36 27 Male 4+ 37 B+ 
37 132 Female 3+ 39 O+ 
38 35 Female 3+ 34 O+ 
39 78 Male 4+ 37 B+ 
40 84 Male 4+ 32 A+ 
41 25 Female 4+ 30 AB+ 
42 96 Female 3+ 30 B+ 
43 60 Male 4+ 30 A+ 
44 132 Female 4+ 38 A+ 
45 53 Female 4+ 22 A+ 
46 53 Male 4+ 25 A+ 
47 81 Female 4+ 21 O- 
48 48 Female 2+ 26 B+ 
49 36 Male 4+ 33 O- 
50 43 Female 3+ 20 A+ 
51 54 Female 3+ 30 A+ 
52 108 Male 4+ 41 O+ 
53 84 Male 3+ 37 O- 
54 72 Male 2+ 39 O+ 
55 132 Female 4+ 38 B+ 
56 60 Male 3+ 33 AB+ 
57 17 Female - 26 - 
58 48 Female 3+ 30 B+ 
59 108 Male 3+ 36 A+ 
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60 8 Female 2+ 18 O- 
61 96 Male 4+ 29 B+ 
62 108 Male 4+ 30 O- 
63 60 Male 3+ 32 B+ 
64 108 Male 4+  B+ 
65 108 Male 3+ 45 B+ 
66 63 Female 4+ 35 - 
67 84 Male 4+ 33 B+ 
68 96 Female 3+ 35 O- 
69 69 Male 2+ 25 O- 
70 96 Male 3+ 35 O- 
71 72 Male 4+ 30 B+ 
72 30 Female 4+  O- 
73 10 Female 3+ 26 B+ 
74 44 Male 4+ 36 B+ 
75 60 Female 4+ 20 B+ 
76 138 Male 4+ 31 O- 
77 48 Female 2+ 36 A+ 
78 15 Male 4+ 36 B+ 
79 17 Female 4+ 33 B+ 
80 18 Female 4+ 23 A+ 
81 24 Female 4+ 31 B+ 
82 23 Male 3+ 28 O+ 
83 24 Male 4+ 29 A+ 
84 36 Male 4+ 27 O+ 
85 72 Female 2+ 35 O+ 
86 24 Female 2+ 30 O+ 
87 132 Female 4+ 34 B+ 
88 26 Male 3+ 28 O+ 
89 8 Male 4+ 24 B+ 
90 84 Male 3+ 34 A+ 
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91 6 Female 2+ 35 AB+ 
92 120 Female 2+ 28 O+ 
93 47 Male 4+ 28 O+ 
94 27 Male 4+ 27 O+ 
95 21 Female 4+ 32 A+ 
96 48 Male 4+ 28 O+ 
97 41 Female 2+ 30 B+ 
98 19 Male 2+ 37 O+ 
99 48 Male 4+ 38 O+ 
100 120 Male 4+ 34 A+ 
Note: PVC represents packed cell volume; *patient with missing blood groups were 
used for the platelet-mediated clumping assay 
 
2.2.2.2 Inclusion and exclusion criteria 
A patient was recruited into the study if they were a child less than 12 years of 
age with a positive microscopy result of ≥ ++ (100-1000 parasites/µL) and whose 
parent/guardian had given informed consent for their child to participate. A patient 
was excluded from the study if they had severe anaemia (<15% packed cell volume) in 
order to not further stress the patient by taking blood. Patients were also excluded 
from the “Clumping Study” if they had taken anti-malarial medication at least 48 hrs 
prior to coming to the hospital.  
 
2.2.2.3 ABO blood group typing 
ABO blood group antigens were tested by monoclonal ABO blood grouping 
reagents for Anti-A, Anti-B and Anti-AB (Fortress Diagnostics, product numbers 
   
100 
 
BGA00010, BGB00010 and BGAB0010). A drop (30-50 µL) of whole blood was mixed 
with a drop (30-50 µL) of ABO grouping reagent on a grouping microplate. The plate 
contexts were mixed by tilting at 70˚ angle while gently swirling with care to avoid 
contamination. Each reaction was observed for at least three minutes for signs of 
streaming. Anti-A is coloured with acid blue dye, Anti-B coloured with acid yellow dye 
and Anti-AB is uncoloured. All positive reactions remained as distinct buttons either on 
the bottom of the well or occasionally sliding down the side. 
 
2.2.3 RNA and DNA extraction from P. falciparum infected post-mortem tissues 
Three tissues were selected for the purposes of this study: brain, heart and gut. 
To extract RNA and genomic deoxyribonucleic acid (gDNA), the tissue was weighed and 
pulverised into a powder with liquid nitrogen using pre-cooled mortar and pestle. Half 
of the powdered tissue was added to 10X volume Trizol at 1mL of Trizol per 50 – 100 
mg tissues for RNA. The remaining half of powdered tissues was placed into 10X 
volume of lysis buffer for DNA extraction. 
 
RNA preparation 
The tissue placed in Trizol was spun at 3,000 rpm for 10 min to pellet insoluble 
material. The supernatant was transferred into a new tube and incubate at room 
temperature (RT) for 5 min. 0.2X chloroform was added and the mixture was shaken 
vigorously for 15 sec, incubated at RT for 3 min, spun at 3,000 rpm for 30-40 min. The 
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aqueous phase was transferred to fresh tube, mixed gently with isopropanol at 0.5X 
original Trizol volume (OTV). Equal volumes of the mix was aliquoted into 1.5 mL tubes, 
incubate at RT for 10 min or left at 4˚C for several days. The tubes were spun at 13,000 
rpm for 15 min, aspirated and washed with 1X OTV of 75% ethanol by vortexing then 
spinning at 12,000 rpm for 5 min. After aspiration and air drying, RNA was resuspended 
into RNA-resuspension solution (Ambion, product number AM7010), incubated 55 – 
60˚C for 10 min, transferred to a new tube and stored -20˚C 
 
DNA preparation  
Tissue in the lysis buffer was incubated at 37˚C for 60 min.  Proteinase K (20 
mg/mL) was added and mixed by swirling at total final concentration of 0.1 mg/mL, 
then incubated in 50˚C water bath for 3 hrs while mixing occasionally. 1X the total 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added after the mixture 
was cooled to   RT and gently mixed on a wheel for 10 min to emulsify. The phases 
were separated by spinning at 3,000 rpm for 30 min. The aqueous was slowly 
transferred to a new tube.  1X the total volume of chloroform was added to the tube, 
mixed for 30 min and phases separated by spinning at 3,000 rpm for 30 min. The 
aqueous phase was slowly transferred to a new tube where 0.2X total volume of 10M 
ammonium acetate was added and mixed. A further 2X total volume of RT ethanol was 
added and mixed. The precipitated DNA was carefully removed with a sterile loop and 
transferred to a new tube. All fragment DNA was pelleted by spinning at 3,000 rpm. 
DNA was washed twice with 1 mL of 70% Ethanol by spinning at 3,000 rpm for 10 min.  
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After air drying, DNA was resuspend in appropriate volume of 1X Tris Buffer (TE) 
(10mM Tris, bring to pH 8.0 by HCl and 1mM EDTA), incubated on a rocking platform, 
12 – 24 hr to completely dissolve DNA and store at 4˚C  
 
2.2.3.1 DNA-Free RNA preparation 
This was done using a DNA free RNA kit (ZYMO research, product number 
R1013) according to manufacturer instructions.  5 μL 10x DNase I buffer, 2.5 μL RNase-
Free DNase I and 22.5 μLl RNase –free water was added to 20 μL of RNA sample was 
placed in a tube, gently mixed and incubated at 37°C for 10-15 min. RNA was bound to 
a Zymo-Spin column by centrifuging at 13,000 rpm for 30-60 seconds, followed by two 
times wash with 200 μL RNA buffer by centrifuging at 13,000 rpm for 30-60 seconds. 
RNA was eluted using 8-10 μL DNase/RNase-free water and stored at -80°C. 
 
2.2.3.2 cDNA synthesis 
Copy DNA (cDNA) was synthesised using a two step protocol from RETROscript 
reverse transcription kit (Ambion product number AM1710) as described by the 
manufacturer. 2 μL of random decamers were added to 2 μL RNA together with 8 μL of 
nuclease-free water to make a final volume of 12 μL. The mixture was heated for 3 min 
at 75 °C. 2 μL of 10X RT Buffer, 4 μL of deoxynucleotide triphosphates (dATP, dCTP, 
dGTP, dTTP), 1 μL of RNase inhibitor and 1 μL of Moloney Murine Leukemia Virus 
Reverse Transcriptase (MMLV-RT) were added to the mix on ice to make a final volume 
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of 20 μL. The mixture was incubated at 42 °C for an hour followed by a 10 min 
incubation at 92 °C. cDNA was stored at -20 °C . 
 
2.2.3.2.1. cDNA amplicon check using PCR 
cDNA amplicon was checked to confirm product formation using a nested PCR 
assay modified from Duffy et al., 2002. The following volumes and concentrations of 
reagents were added to the nested PCR reaction: 
 
Nest one 
2 μL 10X PCR buffer 
2.4 μL 25 mM MgCl  
1.6 μL 2.5mM dNTPs,  
1 μL 20 µM DBLα_dt1for (5’-GGIGCITGYGCICCRTWYMG-3’)  
1 μL 20 µM DBLα_dt1rev (5’-TCTTCIGYCCATTCCTCGAACCA-3’)  
0.1 μL Taq DNA polymerase (5 U/μL) 
1 μL of cDNA template   
10.9 μL distilled water 
Total reaction volume was 20 μL. PCR was conducted on a GeneAmp thermal 
cycler 2400 (Perkin-Elmer) or 9700 (Applied Biosystems) using the following conditions; 
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Initial denaturation: 95°C for 3 min  
Denaturation: 94°C for 30 sec 
Annealing: 55°C for 30 sec 
Extension: 72°C for 1 min 
50 cycles of steps 2 – 4  
Final extension of 72°C for 7 min 
 
Nest two 
 2 μL 10X PCR buffer 
2.4 μL 25 mM MgCl  
1.6 μL 2.5mM dNTPs,  
1 μL 20 µM DBLα_dt2for (5’-GCACGMAGTTTYGCIGATATAGG-3’)  
1 μL 20 µM DBLα_dt2rev (5’-ARATAYTGIGGSACRTARTCIARAT-3’)  
0.1 μL Taq DNA polymerase (5 U/μL) 
0.5 μL of nest one PCR product    
11.4 μL distilled water  
   
105 
 
Total reaction volume was 20 μL. PCR was conducted using the same 
thermocycler used for nest one PCR assays using the following conditions: 
1. Initial denaturation: 95°C for 3 min  
2. Denaturation: 94°C 30 for sec 
3. Annealing: 55°C for 30 sec 
4. Extension: 72°C 1 min  
5. 50 cycles of steps 2 – 4 
6. Final extension: 72°C for 7 min 
 
The formation of a DBL1 DNA fraction of 340-420bp was done by loading 5 μL of 
the PCR product on a 1% standard agarose gel containing 50 μg/mL ethidium bromide. 
The resolved bands were visualised under ultraviolet light using a UV-Transilluminator 
(GelDoc-It Imaging System, UVP, California, USA). 
 
2.2.3.2.2 Whole genome amplification 
Whole genome amplification was used to increase low concentrations of 
parasite DNA. gDNA was amplified using REPLI-g Midi kit (QIAGEN, product number 
150023) as described by the manufacturer. 2.5-5 μL of gDNA was placed in a 
microcentrifuge tube together with Buffer DBL1 and incubated at room temperature 
for 3 min.  Buffer N1 provided with the kit was added followed by 1 μL of DNA 
polymerase pre-diluted in 29μL reaction buffer on ice. The mixture was incubated at 
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30°C for 8-16 hours. The REPLI-g polymerase was inactivated by heating the reaction 
mix at 65°C for 3 min. The gDNA was stored at 4°C for short term use and -20°C for long 
term storage.  
 
2.3 P. falciparum isolates 
Two P. falciparum laboratory-adapted isolates were used: the genome 
reference isolate 3D7 (MLW parasite bank) (Gardner, Hall et al. 2002) and HB3 (kindly 
donated by Alister Craig, Liverpool School of Tropical Medicine, UK). 
 
2.3.1 P. falciparum isolation and culturing 
2.3.1.1. Preparation of human RBC 
Whole blood (type O+) obtained from non-immune volunteers was collected in 
ethylenediamine tetraacetic acid (EDTA) anti-coagulant at 1.5 mg per 1 mL of whole 
blood or in a sodium citrate tubes (BD vacutainer, product number 366395), washed 3 
times with RT protein-free culture medium (RPMI 1640 (Invitrogen, product number 
21875-091) supplemented with 25 mmol/L HEPES and 40 mg/mL gentamycin) by 
centrifugation for 5-8 min at 1,800 – 2,000 rpm. The RBCs were resuspended in an 
equal volume protein-free medium to give 50% RBC solution and stored at 4 ˚C to use 
within 7-10 days.  
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2.3.1.2. Thawing of glycerolyte-frozen parasites with NaCl 
Approximately 1 mL of blood containing 3% ring stage P. falciparum-infected 
erythrocytes (pRBC) was thawed to RT and the pRBC transferred to 50 mL centrifuge 
tubes with a sterile pipette.  200 μL of 12% NaCl was added slowly, drop-wise, with 
gentle shaking. After 5 min incubation 5 mL of 1.6% NaCl was added slowly, drop-wise 
with swirling followed by 5 mL of 0.9% NaCl.  The tube was centrifuged a 1,800 rpm at 
25 °C for 5 min, washed 2 times with protein-free medium by centrifuging at the same 
speed before placed in culture. 
 
2.3.1.3. In vitro culture of Plasmodium falciparum 
For short-term culture, pRBC from patients were pelleted and washed 3 times 
with 5-10 mL protein-free culture medium by centrifugation at 1,800 rpm for 5 min. 
The pRBC were placed in a T75 culture flask supplemented with standard malaria 
culture medium of RPMI 1640 supplemented with 25 mmol/L HEPES, 5% albumax and 
40 mg/mL gentamycin to achieve a 5% haematocrit. The flask was incubated for 24 - 36 
hrs in a 37 °C incubator. Parasite maturation was examined under a light microscope by 
a thin blood smear as described below.  
Long-term cultures or higher parasitemia were achieved by increasing the 
volumes of culture medium to 4 times the volume of the packed cell culture. 
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2.3.1.4 P. falciparum thin blood film slide preparation  
Thin blood smears are prepared by placing approximately 2 μL of blood on one 
end of a frosted glass slide resting on a flat surface. The blood was evenly spread across 
the edge of the second slide by gently touching the drop of blood with the edge of the 
slide. While holding the second slide at a 45° angle, quickly but gently, without exerting 
too much pressure on the first slide, slide the blood across the first slide to make a thin 
film of blood that is evenly spread. Slide was immersed in methanol for 10 seconds, air 
dried, then stained with 2% Giesma stain for at least 10 min.  The excess dye was rinsed 
with water, air dried and then examined under 90-100x oil emulsion lens on a light 
microscope 
 
2.3.1.5. Freezing of patient and laboratory isolates with glycerolyte 
All steps were carried out at RT unless otherwise specified. Cultures with 
parasitaemia of ≥5% young ring stages were pelleted by centrifuging at 1,800 rpm for 5 
min. 0.33X pellet volume of glycerolyte was added very slowly while gently mixing the 
tube. After 5 min incubation, 1.33X pellet volume of glycerolyte was added while gently 
mixing the tube. 1 mL of parasite mix was aliquoted per cryovial, frozen at -80 °C for at 
least 18 hrs and then transferred to liquid nitrogen tank for long-term storage 
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2.4 Real-time Polymerase Chain Reactions (RT-qPCR) 
2.4.1 Quantification of parasite DNA 
RT-qPCR was conducted using a laboratory  isolate P. falciparum 3D7 gDNA as a 
control for var gene expression as all primers were designed based on the var upstream 
region of this isolate which are found in known proportions, which has been shown to 
resemble the structure of var families in clinical isolates (Lavstsen, Salanti et al. 2003). 
Parasite DNA was quantified using a 519 bp region of gene PF07_0076, located on 
chromosome 7 and encoding a protein of unknown function (Daniels, Volkman et al. 
2008). Each reaction was carried out in a 10 μL volume using the following volumes and 
concentrations of reagents: 
5 μL 2X SYBR® Green PCR Master Mix  
1 μL 2 mM PF07_0076 _for (5’- CGACCCTGATGTTGTTGTTGGA -3’)  
1 μL 2 mM PF07_0076 _rev (5’-GGCTTTTTTCCATTTCTGTAGTTAAGATTCA -3’)  
2 μL distilled water  
1 μL DNA template 
Samples were run on an Applied Biosystems HT7900 real-time PCR System using the 
following conditions: 
1. Denaturation: 95°C for 15 sec 
2. Annealing and extension: 58°C for 1 min 
3. 50 cycles of steps 1 - 2  
   
110 
 
Product dissociation curve or melting temperature (Tm) was determined at the 
following conditions: 
1. Denaturation: 95°C for 15 sec 
2. Annealing: 60˚C  for 15 sec 
3. Extension: 95°C for 15 sec 
 
2.4.2. RT-qPCR for var group transcription analysis 
The procedure for differential var group transcriptional analysis was performed 
by quantitative real-time polymerase chain reaction (RT-qPCR) using primers (Table 2.3)  
specific for all 3 var gene groups and was adapted from (Kaestli, Cockburn et al. 2006). 
The oligonucleotides were designed according to alignments of 5’ untranslated region 
(UTR) var gene sequences from the 3D7 reference isolate and sequences from PNG 
clinical isolates from Joe Smith  (Seattle Biomedical Research Institute, Seattle, WA) and 
are available at http://www.plasmodb.org (Genbank accession numbers AY462581–
AY462851).   
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Table 2.3. Oligonucleotide primers for amplification of var gene regions 
var gene region (length of 
amplified product), name 
Primer sequence (5→3’) 
DBL1αreva CC(A/T)AT(A/G)(G/T)C(A/G/T)GCAAAACT(C/G/T)C(G/T)(A/T)GC 
 
var group A (150 bp) 
 
 
 upsA1_forb   
 
AACTTACCATAAATTATCATCAAA 
 upsAj_rev 
 
TCACCTACAACAAAT(A/G)TAATAAA 
var group B (360 bp) 
 
 
 17deg_for CTCAT(A/T)TATAATTTTA(C/G)AAAATA(A/T)A(A/T)AAAAC 
 
 RT-17.2_rev TTA(A/T)GGGAGTAT(A/T)GT(A/G/T)ATATGGTAGAAT 
 
var group C (240 bp) 
 
 
  RT-5B1.1_for   AATATTCATATTCCCACATT(A/G)TCATATAT 
 
5B1.4_rev ATTATGTGGTAATATCATGTAATGG 
 
NOTE: a Reverse primer used in the primary polymerase chain reaction (PCR). 
b Forward primers were identical in primary and real-time PCR. 
 
All parasite DNA was standardised to 0.001ng/µl before PCR analysis. Prior to 
RT-qPCR, 1 μL of DNA was amplified in a primary PCR, to increase sensitivity. DNA was 
amplified over the var 5’ UTR–DBL1α in 50 μL volume using the following volumes and 
concentrations of reagents: 
5 μL 10X PCR buffer 
3.75 μL 25 mM MgCl  
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4 μL 2.5mM dNTPs,  
1 μL 20 µM Forward primer for upsA, B or C (refer to Table 2.3 for sequence details) 
1 μL 20 µM DBL1αrev (refer to Table 2.3 for sequence details) 
0.25 μL Taq DNA polymerase (5 U/μL) 
1 μL of cDNA template   
33 μL distilled water 
 
PCR was conducted on a GeneAmp thermal cycler 2400 (Perkin-Elmer) or Veriti 
thermocycler model 9902 (Applied Biosystems) using the following conditions; 
1. Initial denaturation: 94°C for 5 min  
2. Denaturation: 95°C for 30 sec 
3. Annealing: 52°C for 1 min 
4. Extension: 64°C for 70 sec 
5. 14 cycles for gDNA and 16 cycles for cDNA  of steps 2 – 4 
 
The primary PCR product was checked using 1% standard agarose gel containing 
50 μg/mL ethidium bromide as described in section 2.2.1.5 to make sure that it did not 
exceed the linear range by no visible bands on an electrophoresis gel. 
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Reactions were done with 2 μL of primary PCR product in 10 μL volume using 5 
μL of 2X SYBR® Green PCR Master Mix (Applied Biosystems, product number 4364344),  
and 900 nmol/L primers per reaction for the respective sequences. RT-qPCR was 
performed over the var group A, B, and C 5’ UTR using the Applied Biosystems HT7900 
real-time PCR System using the following conditions: 
1. Initial denaturation: 94°C for 5 min  
2. Denaturation: 95°C for 30 sec 
3. Annealing: 54°C for 1 min 
4. Extension: 64°C for 70 sec 
5. 40 cycles of steps 2 – 4 
 
All runs included a dissociation curve as described in section 2.4.1. All DNA 
samples were run in triplicate with a cycle-threshold (CT) within the linear range 
between 15 and 31 and a melting temperature difference of 1˚C.  If all CT values of var 
group A, B, and C were >31, the sample was discarded and RT-qPCR was repeated. No-
template controls (NTC) were amplified in parallel with each reaction plate. If the NTC 
was positive, the plate was discarded and RT-qPCR repeated. var transcript abundance 
was expressed as proportion of total transcript of all var groups.  Comparison within 
groups was done by analysis of variance (ANOVA) and was corrected by the Bonferroni-
Dunn method. 
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2.4.2.1 RT-qPCR Standard curve  
Standard curves were linear over a dilution series of 5-6 different dilutions of 
3D7 gDNA with concentration ranging between 0.8 - 0.00008 ng/µL, each in triplicate. 
The PCR efficiency (E) was calculated using the formula E=10(1/-slope)-1. The slope was 
analysed close to -3.47 as recommended by the manufacturer (Applied Biosystems) to 
maintain maximum efficiency. The mean efficiencies of 3 independent standard curves 
with high reproducibility were 100% for var group A, 87% for var group B, and 96% for 
var group C.  
 
2.4.3 Microarray analysis of cytokine and receptor expression using RT-qPCR 
This part of the study was designed to use relative quantitative qPCR to look at 
genes involved in apoptosis, cytokine production and endothelial receptor expression 
and investigate any relationship to disease severity (Table 2.4). All primers were 
validated using 6 fold dilutions of 3D7 gDNA with concentration ranging 1 – 0.00001 
ng/μL until all primers amplified at the same melting temperature (Tm) as 3D7 gDNA. 
Primers had amplification efficiency (E) of between 1.85 and 2 [E= 10(-1/slope of 1 fold dilution 
of 3D7 gDNA)].  
All cDNA was adjusted to a concentration of 0.001 ng/μL and reactions were 
done in 10 μL volume using 5 μL of 2X SYBR® Green PCR Master Mix (Applied 
Biosystems, product number 4364344) and  900 nmol/L primers per reaction for the 
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respective sequences. qPCR was performed over the target genes using the Applied 
Biosystems 7900HT real-time PCR System using the following conditions; 
1. Denaturation: 95°C for 15 sec 
2. Annealing: 58°C for 1 min 
3. Extension: 60°C for 1 min 
4. 40 cycles  of 1 – 3 
 
Relative quantification was done using the comparative CT method which determines 
the change in expression of the target sequence relative to an endogenous control. All 
DNA samples were run in triplicate using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the endogenous control. Cycle threshold (CT) for each set of gene-specific 
primers was compared to those observed for GAPDH. The observed ΔCT was compared 
to the expected value from the target gene amplified from 3D7 gDNA. 
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Table 2.4. Oligonucleotides for target genes of cytokine production and receptor 
expression. 
TARGET GENE TARGET FUNCTION 
CD36 _fora  Hs CD36 TTT  CCT CTG ACA TT GCA CAA CTC AAG 
CD36 _revb Hs CD36 AAA GGC ATT GGC TGG AAG AA 
FASLG /CD95L _for Hs FAS ligand CAC TTT GGG ATT CTT TCC AT 
FASLG /CD95L _rev Hs FAS ligand GTG AGT TGA GGA GCT ACA GA 
GAPDH _for Hs GAP dehydrogenase TCA TCT CTG CCC CCT CTG CT 
GAPDH _rev Hs GAP dehydrogenase CGA CGC CTG CTT CAC CAC CT 
GP1BB /CD42c _for Hs glycoprotein 1b AGA ATC TCG ACA CCC TTC TCC 
GP1BB /CD42c _rev Hs glycoprotein 1b ATC TCA CAG TTG CAT AAC CAG G 
IFNG _for Hs interferon γ GCT CTG CAT CGT TTT GGG TTC TCT TG 
IFNG _rev Hs interferon γ CAT TCA TGT CTT CCT TGA TGG TCT CC 
ICAM-1 _for Hs ICAM-1 CTG CAG ACA GTG ACC ATC 
ICAM-1 _rev Hs ICAM-1 GTC CAG TTT CCC GGA CAA 
LICAM _for Hs L1 CAM GAA CCA TTG ACC TCC GGG 
LICAM _rev Hs L1 CAM CAG CGG TAC TCG CCA TCA T 
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NCAM /CD56 _for Hs neural CAM GTC CTG CTC CTG GTG GTT GT 
NCAM /CD56 _rev Hs neural CAM TGA CCG CAA TGC ACA TGA A 
PECAM-1 / CD31 _for Hs PECAM-1 GAG CCC AAT CAC GTT TCA GTT T 
PECAM-1 / CD31 _rev Hs PECAM-1 TCC TTC CTG CTT CTT GCT AGC T 
TFRC1/CD71_for Hs transferring receptor TGC TGT GAT CGT CTT TTT CTT GA 
TFRC1/CD71 _rev Hs transferring receptor TCA TCC CAA TAT AAG CGA CGT G 
TNF _for Hs TNF CCC AGG GAC CTC TCT CTA ATC A 
TNF _rev Hs TNF GCT ACA GGC TTG TCA CTC GG 
TNFR-1/CD120a _for Hs TNF receptor 1 TGC CTA CCC CAG ATT GAG AA 
TNFR-1/CD120a _rev Hs TNF receptor 1 ATT TCC CAC AAA CAA TGG AGT AG 
TNFR-2/CD120b_for Hs TNF receptor 2 CGC TCT TCC AGT TGG ACT GAT 
TNFR-2/CD120b_rev Hs TNF receptor 2 CAC AAG GGC TTC TTT TTC ACC T 
VCAM–1 _for Hs vascular CAM GCT GCT CAG ATT GGA GAC TCA 
VCAM-1 _rev Hs vascular CAM CGC TCA GAG GGC TGT CTA TC 
vWF _for Hs von Willebrand factor AGC CTT GTG AAA CTG AAG CAT  
vWF _rev Hs von Willebrand factor GGC CAT CCC AGT CCA TCT G 
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2.5 P. falciparum and platelet-mediated clumping 
 2.5.1 Enrichment of parasite mature forms 
Parasites were harvested when they had grown to the stage of pigmented 
trophozoites and the parasitaemia had reached 10-12%. The mature pRBC forms were 
enriched by plasmagel flotation. Briefly, parasite culture was transferred into a clean 
sterile 15 mL tube and the pRBC were pelleted by centrifugation at room temperature 
(RT) at 370 x g for 5 min. The supernatant was carefully removed and the pellet 
resuspended in a pre-warmed to 37°C solution of gelofusine (BBRAUN, product number 
FV41513) and RPMI 1640 medium as follows; RPMI making up 20% of total volume, 
gelofusine making up 30% of total volume and the remaining 50% is the parasite mix 
suspended in RPMI. The mixture was transferred into a sterile 15 mL tube and allowed 
to stand for 20 min in a 37°C incubator. The supernatant was transferred to a new 
sterile 15 mL tube and pelleted by centrifuging at 370 x g for 5 min. Parasitaemia and 
developmental stage was assessed by thin blood smear and examine under a light 
microscope as described in section 2.3.2. 
 
2.5.2 Preparation of Platelet-Rich Plasma (PRP) 
PRP was prepared from whole blood from a malaria naive host collected in 
sodium citrate vacutainers. The blood was centrifuged immediately at 250 g for 10 min 
to pellet erythrocytes and peripheral blood mononuclear cells. The cloudy supernatant 
containing PRP was carefully transferred in a clean 15 mL tube. The platelets were re-
suspended with saline phosphate buffer (PBS) at RT. The platelet were counted with a 
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Neubauer’s haematocytometer and their concentration was adjusted to >300 x 103 
platelets/μL. PRP was stored at 4 °C for up to a week. 
  
2.5.3 Preparation of Platelet-Poor Plasma (PPP) 
PPP was obtained by further centrifuging the supernatant from the PRP 
preparation from section 2.5.2 at 1500 g for 10 min. PPP was stored at 4 °C for up to a 
week.  
 
2.5.4 Platelet-mediated clumping assay 
  The clumping assay was performed with mature pRBC at the trophozoite stage 
resuspended in a 1.5 mL tube at 5% hematocrit. Acridine orange was added at 20 
μg/mL final concentration and PRP at 10% of the total volume. The tube was placed 
under gentle agitation on rollers at RT. Clump formation was checked by examining 10 
μL of pRBC/platelet mix on a slide with a cover slip under fluorescence at 5 min and 
then every 15 min for a total of 120 min. 
 
2.6 Platelet mobilisation assay 
The bottom of the glass petri dishes were soaked overnight in 70% nitric acid in 
order to provide binding substrate for the platelet-binding substrate 3-
aminopropyltriethoxysilane.  After rinsing with copious amounts of tap water, the 
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dishes were dried with anhydrous acetone, immersed twice in 4% solution of 3-
aminopropyltriethoxysilane (APES; Sigma), rinsed once with acetone, finally washed 
four times with distilled water and left overnight at 37°C to dry. PRP using sodium 
citrate collected blood was prepared as previously described and the platelet count 
was adjusted to 2 x 108 platelets/mL with RT PBS. The bottom of the petri dishes was 
covered with PRP and incubated for 30 min at room temperature to allow the platelets 
to settle and spread to form a confluent monolayer. The dishes were washed with 
room temperature parasite culture medium to remove unbound platelets.  The pRBC 
were enriched for mature forms using gelatin floatation as described in section 2.5.1 
and resuspended at 5% haematocrit with RPMI 1640. The pRBC resuspension was 
evenly added to the platelet-bound plates and co-incubated for an hour at RT. Plates 
were gently rinsed with PBS to remove unbound pRBC which were also used for RNA 
extraction. All the bound pRBC were rinsed with RPMI 1640 and RNA was extracted for 
qRT-PCR as described in section 2.2.1.2. 
 
2.7 Statistical analysis 
Statistical analysis was performed using Stata software (Intercooled Stata, 
version 10). var transcript abundance was expressed as the proportion of total 
transcripts for all three var gene groups A, B, and C. Comparison within groups was 
done by analysis of variance (ANOVA) and was corrected by the Bonferroni-Dunn 
method. Associations between var group proportions and clinical outcome were 
analyzed using the Kruskal-Wallis test or the Fisher’s exact test.  
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2.8 Chemicals and reagents 
Table 2.5. List of chemicals and reagents 
Item Product number Manufacturer/Supplier 
0.2 mL cap strips 732-3590 VWR 
0.2 mL tube strips 732-3588 VWR 
10 uL filter tips F104-96RS-10 Porex, WhiteSci 
10 uL filter tips F104-96RS-10 Porex, WhiteSci 
1000 uL filter tips F119-NXL-R100S-1000 Porex, WhiteSci 
100bp DNA ladder 15628-050 Invitrogen 
20 uL filter tips F114-R100S-20 Porex, WhiteSci 
200 uL filter tips F108-96RS-200 Porex, WhiteSci 
2-Propanol, 99%, Molecular 
Biology grade 
I9516-500ML Sigma 
3-aminopropyltriethoxysilane 15108500 Acros Organics 
Acridine orange stain P/L780/05 Fisher 
Adhesive PCR foil 732-4838 VWR 
Agarose, low melting BPE1360-100 Fisher 
Albumax II 11021-037 Invitrogen 
Anhydrous acetone, Molecular 
Biology grade 
A-0560-08 Fisher 
Butterfly needles, 21 g x 10 cm FSB458 NHS 
Cannula (IV) blue 22g x 25mm 
Jelco (4030) 
FSN017 NHS 
Centrifuge tubes , 50mL Falcon  358206 BD 
Centrifuge tubes,  15 mL  FB55950 Fisher 
Centrifuge tubes, 15ml Falcon  352097 BD 
Centrifuge tubes, 50 mL  FB55957 Fisher 
Culture flask, 175 cm2 TKT-130-215S Fisher 
   
122 
 
Culture flask, 25 cm2 TKT-130-150L Fisher 
Culture flask, 25 cm2, filtered TKT-130-170F Fisher 
Culture flask, 80 cm2 TKT-130-190W Fisher 
Culture flask, 80 cm2, filtered TKT-130-210T Fisher 
DNA-free RNA kit R1013 Cambridge Bioscience 
dNTPs set U1240 Promega 
Ethanol, absolute, Molecular 
Biology grade 
E7023 Sigma 
Ethidium Bromide, stain 2149846 Sigma 
Gentamicin, 50 mg/ml 15750-037 Invitrogen 
Giemsa stain, modified GS500-500ML Sigma 
Glass petri dishes PDS-100-011U Anumbra 
HEPES Buffer Solution 1M, liquid 15630-056 Invitrogen 
L-glutamine G7513 Sigma 
Lymphoprep NYC-1114545 Axis-Shield 
MicroAmp optical 384-well 
reaction plates 
4309849 Applied Biosystems 
MicroAmp optical 96-well 
reaction plates 
4306737 Applied Biosystems 
Needles, disposable, 21 gauge SZR-175-530R Fisher 
Nitric acid N1680CCo2500 Associated Chemical Ent. 
Nuclease-free water P1193 promega 
Pipettes, 1 mL PN1E1 ALP, WhiteSci 
Pipettes, 10 mL FB55484 Fisher 
Pipettes, 2 mL PN2E1 ALP, WhiteSci 
Pipettes, 5 mL FB51889 Fisher 
REPLI-g Mini kit 150023 Qiagen 
RETROscript cDNA synthesis kit AM1710 Ambion 
RPMI 1640 medium (1x) with L-
glutamine 
21875-091 Invitrogen 
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Sodium citrate tubes 366395 BD 
SYBR® Green PCR Master Mix 4364344 Applied Biosystems 
Taq Polymerase kit 201207 Qiagen 
TaqMan 4364338 Applied Biosystems 
Trizol 15596-026 Invitrogen 
Trypan blue T8154 Sigma 
Tubes, 1.5mL FB74031 Fisher 
Tubes, culture, 12 x 75 mm, PP TKV-182-035N Fisher 
Tubes, culture, 17 x 100 mm, PP TKV-182-081G Fisher 
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Chapter 3 
 
3.  DIFFERENTIAL EXPRESSION OF VAR GENE GROUPS IN P. FALCIPARUM INFECTIONS 
IN MALAWIAN PEDIATRIC MALARIA PATIENTS 
3.1 INTRODUCTION 
P. falciparum can affect the host in different ways.  The severity of the infection 
varies depending on host as well as parasitic factors. Infection can be asymptomatic or 
manifest via a range of signs and symptoms, including severe anaemia and cerebral 
dysfunction which can both be lethal to the patient. One of the factors contributing to 
the severity of pathology of P. falciparum is the ability of mature parasite forms to 
cytoadhere to various host endothelial receptors in deep vascular beds leading to 
microvessel obstruction and damage in various organs. This process is thought to be a 
host immunity avoidance strategy, allowing the parasite to circumvent splenic 
clearance (Smith, Chitnis et al. 1995; Kyes, Horrocks et al. 2001; Kaestli, Cortes et al. 
2004).  
Cytoadherence is mainly mediated by PfEMP1), a family of antigens with 
assemblies of semi-conserved DBL and CIDR adhesive domains. The ~60 encoding var 
genes are not all expressed simultaneously but instead one at a time in a mutually 
exclusive manner (discussed in Chapter 1, section 3.3.3). This allows the parasite to 
switch between surface expression of the various var gene products at rates as slow as 
0.03% per generation or fast as 18% per generation, resulting in antigenic variation, 
while maintaining or changing the adhesive properties. It is through this clonal 
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antigenic variation that the parasite is capable of evading the host immunity (Peters, 
Fowler et al. 2002; Kaestli, Cortes et al. 2004). 
As previously discussed in Chapter 1, in the P. falciparum reference genome 
3D7, var genes can be classified into three main groups: A, B and C according to their 5’ 
upstream and intron sequences (Voss, Thompson et al. 2000; Gardner, Hall et al. 2002).  
The majority of var genes (76%) belong to group B genes located subtelomerically, 
followed by the var group C (15%) arranged in clusters on chromosomes 4, 6, 7 and 8. 
The least numerous of the var genes (10%) belong to the more structurally diverse 
group A, which are mostly located subtelomerically, on most chromosomes, and have a 
distinct direction of transcription towards the telomeres (Voss, Thompson et al. 2000; 
Gardner, Hall et al. 2002; Lavstsen, Salanti et al. 2003).  
In the past, various studies using clinical isolates have tried to investigate the 
association between disease outcome and binding affinity for host endothelial 
receptors (Turner, Morrison et al. 1994; Fried and Duffy 1996; Newbold, Warn et al. 
1997). Bull et al (2000), using agglutination assays, showed that parasites isolated from 
children with  severe malaria had higher agglutination frequencies compared to 
isolates from children with mild malaria and the agglutination frequency decreased 
with age (Bull, Kortok et al. 2000). In 2005, the same group was able to class var genes 
from Kenyan field isolates and laboratory isolates into biologically meaningful subsets 
based on cysteine-containing small blocks of semi-conserved sequences, thus providing 
some evidence of the existence of var gene semi-structuring (Bull, Berriman et al. 
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2005). It was from these results that the question of the preferential involvement of 
var groups A, B and C in various clinical syndromes was raised. 
 
Table 3.1. Summary of outcome of clinical var gene group studies 
Author/year/locale var group A var group B var group C 
Bull et al/ 2005/Kenya no difference 
Kaestli et al/2006/PNG rosettes 
 
clinical malaria 
(severe & mild)  
asymptomatic  
 
Kyriacou et al /2006/Mali cerebral malaria hyperparasitaemia 
Rottmann et al /2006/Tanzania severe malaria 
 
clinical malaria 
(severe & mild)   
 
Warimwe et al/2009/Kenya severe malaria  
Kalmbach et al/2010/Gabon  cerebral malaria 
Avril et al/2012/Kenya cerebral malaria   
Lavstsen et al/2012/Tanzania severe malaria  
 
Two studies, one in Papua New Guinea (PNG) and the other in Tanzania, 
comparing asymptomatic infections to clinical malaria (mild, severe), found a 
preferential expression of var gene groups A or B in clinical cases (Kaestli, Cockburn et 
al. 2006; Rottmann, Lavstsen et al. 2006).  Kaestli et al. (2006) also found var group A to 
be associated with rosetting isolates (summarised in Table 3.1). Another study 
conducted in Kenya found no difference in var group expression between severe and 
mild disease (Bull, Berriman et al. 2005), and in Mali an association between var gene 
group and cerebral malaria was found in children (Kyriacou, Stone et al. 2006). var gene 
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group B was found to be associated with cerebral malaria in Gabon (Kalmbach, 
Rottmann et al. 2010) and both severe and uncomplicated malaria in PNG (Kaestli, 
Cockburn et al. 2006) and Tanzania (Rottmann, Lavstsen et al. 2006). var gene group B 
has also been associated with hyperparasitaemia in Mali (Kaestli, Cockburn et al. 2006).  
var gene group C has mainly been associated with asymptomatic malaria (Kaestli, 
Cockburn et al. 2006) but was found to be associated with hyperparasitaemia in Mali 
(Kyriacou, Stone et al. 2006) and cerebral malaria in Gabon (Kalmbach, Rottmann et al. 
2010). Interestingly, after classifying var genes from Kenyan field and laboratory 
isolates into biologically meaningful subsets based on small blocks of semi-conserved 
cysteine sequences, no association was found between the var groups and the various 
clinical presentations. However, an association was found between the presence of 
only 2 conserved cysteines in the DBLα domain and the rosetting phenotype (Bull, Pain 
et al. 2005). 
Although these studies have provided evidence that these var subtypes are 
associated with various disease outcomes, the results have been contradictory. No 
definite associations can be drawn. Several factors may contribute to these differences 
in findings: 1) all of the studies used peripheral blood samples which may not give an 
accurate representation of the sequestered parasite populations, 2) geographic (and 
potential endemnicity) differences resulting in var genes with different disease causing 
abilities 3) the use of different var gene group classifications and tools to study them, 
such as primer sets, and 4) differing definition of malaria disease states (Nogueira, 
Wunderlich et al. 2001; Fowler, Peters et al. 2002; Bull, Berriman et al. 2005; Albrecht, 
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Merino et al. 2006; Fowler, Chavchich et al. 2006; Barry, Leliwa-Sytek et al. 2007). The 
most consistent outcome has been identifying the association of var gene group A with 
severe forms of malaria (Table 3.1) which through recent findings supports the idea that 
specific subset of group A var genes mediates parasite adherence to human brain 
endothelia (Avril, Tripathi et al. 2012; Claessens, Adams et al. 2012; Lavstsen, Turner et 
al. 2012). Thus, CD36 binding is not a major factor and ICAM-1, although important in 
cerebral binding, is not necessary for widespread binding of pRBC to brain endothelia 
(Avril, Tripathi et al. 2012). 
All  var gene studies point to the general important fact that P. falciparum field 
isolates  are highly dynamic and variable in their var transcription, supporting the 
observation that certain var gene repertoires are able to recombine during the sexual 
phase of the life cycle in the mosquito (Su, Ferdig et al. 1999) and during both meiosis 
and mitosis, creating diversity even among closely related genomes (Ward, Clottey et 
al. 1999; Freitas-Junior, Bottius et al. 2000; Taylor, Kyes et al. 2000).  
We have been conducting a clinicopathological study of fatal paediatric malaria 
in Blantyre, Malawi, since 1996 (Taylor, Fu et al. 2004). In a previous study, we have 
shown that pRBC in the organs tend to be more genetically complex than in peripheral 
blood sample, which is a snapshot in time, and contains a subset of all parasite 
populations found in host. This study also demonstrated that, when compared to 
children with non-malarial causes of death, fatal CM patients have less complex 
infections, with genetically homologous parasites present in multiple organs 
(Montgomery, Milner Jr. et al. 2006). We have also shown that there is dominant 
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expression of particular set of var genes within a tissue; these dominant expression 
patterns vary between organs.  However, some of the dominant var gene patterns are 
detected in the same organs of other patients from the same malaria season 
(Montgomery, Mphande et al. 2007). This chapter describes the investigation of 
differential var gene group expression of P. falciparum in the organs and the relation of 
those expression patterns to clinical disease presentation. 
 
OBJECTIVES 
The objectives of this study are to: 
i. Determine the var group dominantly expressed by parasites that are found 
sequestered in the brain, heart and gut 
ii. Determine the dominant var group expressed in sequestered parasites isolated 
from children with different clinical presentations of cerebral malaria 
iii. Compare var transcripts in sequestered and circulating parasites  
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Study design, materials and methods 
A full description of all the methods used in this study has already been outlined 
in Chapter 2   
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3.3 RESULTS 
3.3.1 Parasite var gene distribution  
In total, 20 patients were selected for var gene group expression analysis. Patients 
were chosen based on diagnostic classification (Taylor, Fu et al. 2004) and from data 
extracted from the pilot study on var expression (Montgomery, Mphande et al. 2007).  
This had raised the suggestion of limited diversity of var genes within a malaria season, 
and so the patients were chosen at a fixed ratio over five malaria seasons. The ratio of 
2 CM2 : 1 CM1 : 1 PC was based on the observation that CM1 cases are found at half 
the rate of CM2 cases (Taylor, Fu et al. 2004).  One PC case was later revised as CM2 
based on histological examination, leaving us with a final selection of CM1 (n=5), CM2 
(n=11) or PC (n=4). 
All patients were recruited from four different malaria seasons between 1999 
and 2004 to allow comparison of parasite genetic make-up with seasonality (Table 3.2). 
There were no significant difference in age, time to death or parasitaemia, either at 
admission or death, between the three diagnostic groups (age and diagnostic group, 
p=0.37; time to death and diagnostic group, p=0.32; admission parasitaemia and 
diagnostic group, p=0.24; final parasitaemia and diagnostic group, p=0.95; Kruskal-
Wallis test).  
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3.3.2 Restricted genetic diversity of CM patients 
For each of the patients, var gene group expression was analysed in three 
tissues: brain, heart and gut. From our previous study (Montgomery, Milner Jr. et al. 
2006), using msp genotyping, we found no evidence of restricted P. falciparum genetic 
diversity in the brain or particular genetic variants specifically sequestered in this 
organ. This work is focused on determining whether parasites sequestering in the brain 
express a particular var gene group, which might be associated with CM. The heart is a 
reasonable comparative tissue as it displays less diversity of var transcripts than the 
brain (Montgomery, Mphande et al. 2007). The gut was examined because it is another 
organ of high parasite density (Montgomery, Milner Jr. et al. 2006).  
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Table 3.2. Clinical details of patients in main study 
Diagnosis Case 
no. 
Year of 
admission 
Agea HIV 
status 
Time to 
deathb 
Admission 
parasitaemiac 
Final 
parasitaemiac 
CEREBRAL MALARIA 
CM2 28 1999   61 - 00:30 424,000 424,000 
 34 1999 70 - 02:45   74,319   74,319 
 61 2002 26 - 04:15   42,027   42,027 
 62 2002 10 - 01:10      1,056,607      1,056,607 
 63 2002 79 - 16:10     8,212        400 
 64 2002 60 + 07:00   28,842   28,842 
 68 2003 156 + 15:25   28,080   4,680 
 75 2003 144 + 07:50 215,300   36,250 
 78 2003 15 - 02:00 637,000 637,000 
 82 2004 31 - 34:00 197,820            0 
 83 2004 26 - 13:45   22,000     6,000 
mean   61.6   09:32 247,837 210,011 
st dev   49.4  09:56 334,794 350,186 
CM1 37 1999 6 + 38:00 616,400 572,880 
 38 1999 84 - 35:40 782,320     5,474 
 74 2003 103 + 05:25 280,000 280,000 
 79 2003 79 + 04:40   34,400   34,400 
 84 2004 106 + 21:07 201,829       834 
mean   75.6  20:58 382,990 66,142 
st dev   40.6  16:55 307,769 120,250 
PARASITAEMIC CONTROLS 
  d 31 1999 39 + 22:00 159,434 188,432 
  d 45 2000 28 - 16:10 100,519        197 
 77 2003 7 - 04:05   66,844   66,844 
  e 80 2004 63 - 12:00   23,700   23,700 
mean   34.3  13:34 87,624 79,668 
st dev   23.3  07:32 57,274 78,700 
a months, b hours:minutes, c parasites/L in peripheral blood, d pneumonia 
(Streptococcus), e meningoencephalitis 
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Two different techniques were used to genetically characterise the infecting 
isolates: msp typing (provides the MOI without quantitatively identifying the VSA 
(Snounou, Zhu et al. 1999)) and a SNP assay called barcoding (detects the major 90% of 
genetic variants and classifies the infection as homo- or heterozygous (Daniels, 
Volkman et al. 2008)) on 16 of the 20 hosts. In accordance with other studies in Malawi 
(Dembo, Phiri et al. 2006; Bruce, Macheso et al. 2008), we found a mean of 2.3 ±0.7 
genetic variants per patient, and 1.6-1.8 ±0.9 variants per tissue, with no significant 
differences in MOI between tissues, diagnostic groups or season. CM infections 
commonly consisted of a single genetic variant that was the major isolate present in all 
three tissues in agreement with previous studies. Only 1/5 (20%) in CM1 and 3/8 
(37.5%) CM2 patients had evidently mixed infections. In contrast, 2/3 (67%) PC cases 
examined by msp genotyping contained more than one genetic variant and all three 
patients had major and minor alleles detected at at least one loci (Figure 3.1).  
In order to ensure that the genomic composition of the var subgroups was 
similar to the 3D7 reference genome and other sequenced genomes and to exclude 
primer bias, the ratio of var gene groups A, B and C in the gDNA of all the 20 malaria 
cases were quantified by qRT-PCR.  The genomic distribution of the three var 
subgroups was similar among hosts from different clinical diagnostic groups as well as 
between the brain, heart and gut tissues,  with 7% of the overall var genes amplified 
belonging to var group A, 76% to var group B and 16% to var group C, as shown in the 
brain (Figure 3.2A). This was in agreement with data from other sites and studies 
(Figure 3.2B) (Kaestli, Cockburn et al. 2006).   
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Figure 3.1. Distribution of P. falciparum merozoite surface protein (msp) 1 and 2 
genotypes in the tissues of 19 parasitaemic children. Each chart has the patient 
number above and tissue type on left and represents data from a single patient. A 
genotype detected by PCR is represented by each shaded square. Vertical alignment 
represents genotypes of the same electrophoretic mobility within a chart, but not 
between charts. Light gray shading denotes msp1 alleles, and dark gray shading 
denotes msp2 alleles. B-bg, brain basal ganglia (caudate); B-c, cerebellum (tonsils); B-fl, 
brain frontal lobe; B-p, pons (brain stem); B-pl, brain parietal lobe; Gut, jejunum and 
right colon of gut; Hrt, left ventricle of heart; Kdy, right kidney; Lng, right upper lung; 
Lvr, liver; PB, peripheral blood; PM, pectoralis muscle; Spl, spleen (From Montgomery 
et al. J Infect Dis (2006) 194 (1): 115-122) 
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Figure 3.2. Genomic distribution of var gene groups in parasites from children with 
different malaria diagnoses. (A) genomic var gene distribution in the brains of CM1 
(n=5), CM2 (n=11) and PC (n=4) patients (B) genomic var gene distribution in different 
malaria diagnostic groups determined by Kaestli et al. 2006. Both graphs display var 
gene group B as the majority in the tissue and the diagnostic group. The box plots 
outline 25th and 75th percentiles, with the median indicated as a line inside each box 
and the 5th and the 95th percentiles are illustrated by the whiskers. Outliers are 
indicated by the open circles. 
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3.3.3 Comparison of var transcripts between tissues and diagnostic groups 
After verification that the distribution of the three main var groups was similar to 
3D7, qRT-PCR was used to determine the levels of expression of the main var 
subgroups in parasites found sequestered in the tissues of the same 20 patients. Highly 
significant differences were observed in the expression levels of the 3 var subgroups in 
parasites from children with classical cerebral malaria (CM2), when compared with 
those found in children with cerebral malaria with sequestered parasites only (CM1). 
In CM2, group A var genes were expressed at high levels in the brain compared to 
group B and C genes (p=0.0001, ANOVA Bonferroni; Figure 3.3A), consistent with some 
peripheral blood studies linking group A expression with severe forms of disease 
(Kyriacou, Stone et al. 2006; Rottmann, Lavstsen et al. 2006).  Group A genes were also 
highly expressed in the heart and gut. The second most highly expressed were the 
group C vars with the group B vars being the least expressed (p=0.0001, ANOVA 
Bonferron; Figure 3.3A). A similar pattern of var expression was observed in 
parasitaemic controls (PC) cases (Figure 3.3B). 
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Figure 3.3. Transcript abundances of var gene groups in parasites found in the tissues of children in different diagnostic groups. 
Transcripts are shown as proportions of the total number of var gene transcription for parasites found in each tissue of the patients. 
Box plots of the proportion of var gene groups A, B and C in the brain, heart and gut of CM2 (n=11 for all tissues) (A), CM1 (n=5 for 
brain and gut, n=4 for heart) (B) and PC (n= 4 for all tissues) (C) patients. The box plots outline 25th and 75th percentiles, with the 
median indicated as a line inside each box and the 5th and the 95th percentiles are illustrated by the whiskers. Outliers are indicated 
by the open circles. (ANOVA; **p ≤ 0.001, *p ≤0 .05 after Bonferroni correction) 
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The pattern of expression in CM1 was different from CM2 and PC, with group B 
var being highly expressed (p=0.0001, ANOVA Bonferroni) and group C being the least 
expressed regardless of tissue (Figure 3.3C).  The difference in var expression between 
the CM1 and CM2 is not due to parasite density as there were no significant differences 
in parasite densities between these two diagnostic groups at admission or at the time 
of death (p=0.23 and p=0.77, respectively, ANOVA Bonferroni). Peripheral parasitaemia 
is not a good indicator of sequestered pRBC density.  However, Taylor et al have shown 
that both CM1 and CM2 have similar cerebral pRBC density compared to PC (Taylor, Fu 
et al. 2004). The parasitaemia between CM2 and PC was similar at admission and at 
death (p=0.80 and p=0.7, respectively, ANOVA Bonferroni) despite the outstanding 
differences in pathology. These results overall suggest that the distribution of var 
transcription is irrespective of the number of pRBC present or the severity of 
symptoms. 
 
3.3.4 Influence of HIV on var gene expression 
The results of the initial var gene group expression analysis of the 20 patients 
were intriguing, considering there were no significant differences in the clinical 
admission details of patients. CM1 accounts for approximately 25% of patients clinically 
diagnosed with cerebral malaria, and currently can be distinguished from CM2 only by 
post-mortem examination. Both CM1 and CM2 can be distinguished from PC by post-
mortem examination or malaria retinopathy, one of the entities of the ocular fundus 
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differences displayed in severe falciparum infections (reviewed in (Lewallen, Harding et 
al. 1999)) that  can precisely distinguish the different subsets of cerebral malaria 
(Taylor, Fu et al. 2004).  80% (n=4) in Table 3.3 and all patients in Table 3.4 (n=2) of the 
CM1 patients had a positive HIV status, a potential contributing factor.  This is 
characteristic of clinically diagnosed CM patients in the parent study in which 19% of 
CM2 and 6% of PC hosts were HIV+, whereas nearly two thirds (62%) of CM1 cases 
were infected (unpublished observations). 
In order to determine whether the presence of HIV in the patient influenced var 
expression, both data sets in Tables 3.3 were split according to HIV status. Eight out of 
the 20 patients (40%) were HIV positive and most belonged to the CM1 group (80%). 
Comparing age, time to death and parasitaemia, both at admission and at death, 
between HIV positive and HIV negative patients, there were no significant differences. 
(Age and HIV status, p=0.0521; time to death and HIV status, p=0.1863; admission 
parasitaemia and HIV status, p=0.8688; final parasitaemia and HIV status, p=0.3637; 
Kruskal-Wallis test).  
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Figure 3.4. Transcript abundance of var gene groups in parasites in the tissues in HIV positive and HIV negative cerebral malaria 
patients. Transcripts are shown as proportions of the total number of var gene group transcripts for parasites found in each tissue of 
each patient. Proportion of var gene groups A, B and C transcripts in the brain (A), heart (B) and gut (C). The box plots outline 25th 
and 75th percentiles, with the median indicated as a line inside each box and the 5th and the 95th percentiles are illustrated by the 
whiskers. Outliers are indicated by the open circles. (ANOVA; **P ≤ 0.001, *P ≤ 0.05 after Bonferroni correction) 
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The antigen expression pattern in HIV- cases closely resembled that of CM2 and 
PC in section 3.4.2 in all the tissues, with group A highly expressed and group B genes 
the least expressed (group A vs B, p=0.0001; group A vs C, p=0.001; ANOVA Bonferroni) 
(Figure 3.4).  There was substantial variation in the HIV+ data, with no major 
differences between var group expression in the brain and heart of HIV+ individuals. 
However, in the gut of HIV+ hosts,  similar patterns of var expression were observed as 
in HIV- hosts, with the group A vars being significantly higher expressed than group B 
(p=0.0001) and C (p=0.001).   
Comparing HIV+ versus HIV-, there were no differences in group A and C 
expression in all the tissues. However, significant differences were observed in group B, 
with expression being highest in HIV+ especially in the brain (p=0.046, ANOVA 
Bonferroni) and heart (p=0.034, ANOVA Bonferroni) as was seen in CM1. Group A was 
the least expressed and similar in the HIV+ and HIV- children. While expression of both 
B and C var gene groups were elevated, only var gene group B transcripts were 
significantly higher than var gene group C in the HIV+ (p=0.020, ANOVA Bonferroni). 
Unfortunately we do not have any measures of HIV disease severity in these 
patients, and so this data presumably spans a range of immunological deficiency.  
However, the significant differences in var expression in HIV negative patients suggest 
that HIV infection indirectly impacts pRBC var gene expression, perhaps through 
eliciting changes in the immune and inflammatory responses that upregulates the 
expression of certain receptors on the endothelial cells.  This in turn could influence the 
sequestration of certain parasites. 
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These results lead us to speculate that in the absence of HIV, CM patients are 
likely to develop into classical cerebral malaria as seen in CM2. The odds ratio indicated 
a marginal significance, with CM1 patients 12 times more likely to be HIV positive than 
CM2 (OR: 12.0 with 95% CI (1.0-136.7) p=0.05728 (Table 3.3)). Nevertheless, based on 
the small sample size, the study may not be powered to provide enough evidence. 
More information is also required on the severity of the HIV symptoms in both CM1 
and CM2 groups in terms of their CD4+ cells and viral load, as this could help explain 
the high parasitaemia and pathology, as has been previously shown (Migot, Ouedraogo 
et al. 1996; Mermin, Lule et al. 2004).  
 
Table 3.3. Patient HIV status in the CM1 and CM2 clinical diagnostic groups 
HIV status CM1 CM2 Total 
positive 6 4 10 
negative 1 8 9 
Total 7 12 19 
Note: The odds ratio (OR) calculated from the total number of children that were HIV 
positive and total number of children that were HIV negative. Children in CM1 are more 
likely be HIV positive OR: 12.0 with 95% CI (1.0-136.7) p=0.0573 and less likely to the 
HIV negative OR: 0.0833 with 95% CI (0.0073-0.9500) compared to CM2 
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3.4 Comparison of var transcripts: tissues versus peripheral blood: 
What is wrong with this picture? 
Unfortunately, there was no peripheral blood (PB) obtained from the 20 
patients to allow comparison of antigen expression between the tissues and PB due to 
post-mortem collection procedures of the parent study at this time. We therefore 
recruited 5 additional patients whose PB and tissue biopsies were both available for 
this analysis. The 5 patients were recruited between the 2006-2008 malaria seasons 
(Table 3.4) following the selection criteria described in section 3.3.1. We found no 
significant differences in age, time to death and parasitaemia, both at admission and 
death, between the three diagnostic groups (age and diagnostic group, p=0.8187; time 
to death and diagnostic group, p=0.2231; admission parasitaemia and diagnostic group, 
p=0.8187; final parasitaemia and diagnostic group, p=0.2231; Kruskal-Wallis test).  
 
Table 3.4 Patients in additional study with matched peripheral blood 
Diagnosis Case 
no. 
Year of 
admission 
Agea HIV 
status 
Time to 
deathb 
Time to 
autopsyb 
Admission 
parasitaemiac 
Final 
parasitaemiac 
CM2 96 2007 31 - 10:55 11:55 236 236 
 98 2008 96 + 32:40 10:40 471,056 17,610 
CM1 95 2007 11 + 04:00 08:20 688,867 688,867 
 99 2008 89 + 02:25 04:05 78,904 78,904 
PC 92 2006 39 - 30:40 11:50 90,960 90,960 
a months, b hours:minutes, c parasites/L in peripheral blood 
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As previously described, the relative proportion of genes in the three main var 
groups was measured in the genomic DNA to check similarity to the 3D7 genome. The 
var gene distribution was different from what was observed for the 20 patients; with 
no significant differences in the var gene group distribution between CM1 and CM2 
(Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Genomic distribution of var gene groups amplifications of parasites 
isolated from the brain, heart, gut and peripheral blood of children with different 
malaria diagnoses. The box plots outline 25th and 75th percentiles, with the median 
indicated as a line inside each box and the 5th and the 95th percentiles are illustrated by 
the whiskers. Outliers are indicated by the open circles. (ANOVA; *p ≤ 0.05 after 
Bonferroni correction). 
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Only PC showed a significantly high distribution of group B (p=0.0001, ANOVA 
Bonferroni) compared to the group A and B. However, the number of group B was 
much more pronounced in the tissues, especially the brain (A vs B, p=.041) and heart (A 
vs B p=0.028, ANOVA Bonferroni) while Group C numbers were slightly raised in CM1 
compared to PC (CM1 vs PC, p=0.024, ANOVA Bonferroni) and in the gut although this 
difference was not statistically significant. 
Comparison of var expression between the tissues and peripheral blood showed 
a different expression pattern as in the diagnostic groups described above. There were 
no significant differences in var expression within the tissues but Group A vars were 
highly expressed in PB compared to the tissues (p=0.011, ANOVA Bonferroni) (Figure 
3.6).  In our previous study (Montgomery, Milner Jr. et al. 2006) using msp genotyping, 
we have shown that some circulating parasites are also detected in the different 
organs, implying that the genotype of the parasites is common to tissues and 
peripheral blood. Some var gene studies using peripheral blood have found an 
abundance of both groups A and B in children with mild and severe malaria (Kaestli, 
Cockburn et al. 2006; Rottmann, Lavstsen et al. 2006) and the expression of var gene 
group C can be similar between different clinical malaria diagnostic groups (Rottmann, 
Lavstsen et al. 2006) as is the case in this var gene expression analysis.  
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Figure 3.6. Transcript abundances of var gene groups in parasites found in the tissues 
versus peripheral blood. Transcripts are shown as proportions of the total number of 
var gene group transcripts for parasites found in each tissue of each patient. The box 
plots outline 25th and 75th percentiles, with the median indicated as a line inside each 
box and the 5th and the 95th percentiles are illustrated by the whiskers. Outliers are 
indicated by the open circles. (ANOVA; *p ≤ 0.05 after Bonferroni correction).  
 
A major drawback for this sub-study on matched tissues and peripheral blood is 
the sample size. Because of the difficult nature of post-mortem studies and the 
imminent end of the parent study, we were not able to recruit more patients. For this 
reason, the data lacks statistical power.  Apart from that, we experienced a lot of 
problems with the blood samples, which thankfully our collaborators discovered to 
produce poor quality RNA perhaps due to drug contamination, circulating toxins and 
other material released from dead parasites. We have struggled to get consistent and 
meaningful results in trying to use it in our genotyping and var transcription analysis 
which makes the results from this data set unreliable.   
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3.5 DISCUSSION 
Cerebral malaria is one of the most dangerous and often fatal complications of 
P. falciparum infections in African children. Over the years, much information on the 
relationship between clinical malaria and var genes has been collected using in vitro 
and molecular techniques. The present study aimed to analyse the proportion of 
transcripts belonging to var group A, B, and C present in various tissues and peripheral 
blood using the unique resources of the clinicopathological study of fatal paediatric 
malaria in Blantyre, Malawi. We used qRT-PCR to measure var gene expression in pRBC 
sequestered in the brain, heart and gut in children who died from cerebral malaria and 
children that died from other causes with a concurrent P. falciparum infection.  
As expected, the quantification of the proportion of var gene groups in gDNA 
indicated similar distributions to the 3D7 genome in the parasites from different clinical 
presentations and tissues. Therefore we conclude that the differences observed in var 
group expression were due to transcriptional regulation during symptomatic malaria or 
due to receptor regulation that then “chooses” certain pRBC expressing particular 
transcripts to sequester, and not primer bias or DNA composition. Our results are 
directly comparable to those from equivalent field studies on peripheral blood and 
extend these observations to sequestered populations of pRBC.  In the var transcription 
analysis, we found major differences in var group transcription between CM1 and CM2 
patient isolates, with var group B being significantly more highly expressed in CM1. 
However, we observed no significant differences in the proportions of var gene groups 
between isolates found in CM2 patients and parasitaemic controls. Group A was 
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prominent in both these patient groups, with group B being the least expressed 
regardless of tissue.  
The infecting parasites in CM1 patients showed quite distinct var expression, 
the proportion of var group B transcripts was higher compared to CM2 and PC patients 
and group A were down-regulated, particularly in the brain and gut. The number of 
children in CM1 (n=5) was the similar as in the PC group, thus offering the same 
analytical power for comparison and yet the CM1 expression profiles resemble the 
overall genomic 3D7 percentages. This result clearly indicates that there are other 
factors that are influencing var gene expression in CM1. It is possible that CM2 and PC 
express a specific subset of var genes that are skewed from the overall genomic set 
because either 1) the parasites have a specific transcriptional regulation pattern, or 2) 
parasite transcription is not skewed away from the genomic – but a subset of parasites 
are chosen to bind based on receptor expression on the endothelial cells.  
One of the clues to the unique var expression in the CM1 group was HIV status 
of the patients considering that the majority of the patients, 80% (n=4) were HIV 
positive. Unfortunately, the total number of patients within the group was small and 
lacked statistical power to perform within-group comparisons.  However, we were able 
to compare total HIV positive individuals (n=8) versus HIV negative individuals (n=12) 
and var gene group A proportional expression was high in the HIV- patients while group 
B were upregulated in the HIV+ patients. This confirms our findings that the up-
regulation of group B vars in the CM1 group might be influenced by their HIV status. 
The HIV influence on var gene expression was hinted even in the small number of 
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children in which we were comparing var expression between tissues and peripheral 
blood. Although there was no significant difference in var group B expression between 
the HIV- and HIV+ patients, group B was significantly expressed in the HIV+ patients 
compared to group C. 
The differences in vascular pathology between CM1 and CM2 are striking. In 
CM1 cases, patients have a heavy sequestered load of pRBC in brain microvasculature 
but no haemorrhages, thrombi or other vascular pathology. In contrast, patients with 
the CM2 variety of cerebral malaria show the same levels of sequestration and have 
significant vascular pathology (Taylor, Fu et al. 2004). In adults, HIV infection has been 
found to be associated with severe forms of malaria and increased risk of CM 
(Chirenda, Siziya et al. 2000; Chirenda and Murugasampillay 2003; Grimwade, French et 
al. 2004; Kamya, Gasasira et al. 2006). On the contrary, another study in Zaire showed 
that there was no differences malaria incidence between children with progressive HIV-
1 infection and those who were HIV (Greenberg, Nsa et al. 1991). 
 In this study, all the children were similar in age and there was no difference in 
parasitaemia at admission or death in all the diagnostic groups. This is in agreement 
with the trend observed in the main clinicopathology study where there is generally no 
association between parasite density and disease severity. Our results present strong 
evidence that HIV plays a role in influencing on P. falciparum var expression. Therefore, 
it is possible that HIV infected children are at risk of developing cerebral malaria 
because of an increase production of particular molecules implicated in both diseases 
such as nitric oxide synthase, ICAM-1 and VCAM-1 (Mannick, Stamler et al. 1999). In 
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this case, the upregulation of var gene group B in CM1 infections may be a result of 
altered host response encompassing elevated levels such endothelial receptors and 
immunosuppression, considering division of the samples by HIV reactivity showed a 
similar upregulation of var gene group B genes although var gene group A remained 
highly expressed in HIV negative cases.  
Expression of both var group A and B genes have been found to be associated with 
severe malaria (Kyriacou, Stone et al. 2006; Rottmann, Lavstsen et al. 2006; Kalmbach, 
Rottmann et al. 2010; Avril, Tripathi et al. 2012; Lavstsen, Turner et al. 2012) which 
could imply that both these var gene classes are favourable in binding to endothelial 
receptors of the host and therefore likely to be involved in sequestration of pRBC in the 
brain and other organs. Recently, other independent work has confirmed the up 
regulation of domain cassette 8 (DC8) var genes by parasites adhering to human brain 
endothelia (Lavstsen, Turner et al. 2012). This is also consistent with the finding of 
Claessens et al (Claessens, Adams et al. 2012) and Avril et al (Avril, Tripathi et al. 2012) 
which supports the idea that parasites expressing DC8 and DC13 var genes have a high 
potential to cystoadhere to brain endothelia and other tissues.  
The lack of variation in group var expression between organs in any diagnostic 
group was unexpected.  Histological studies on fatal malaria in South East Asian adults 
have shown few differences in endothelial receptor expression levels between organs, 
except for CD36 which was sparse on brain microvasculature, although heart and gut 
were not specifically examined in these studies (Turner, Morrison et al. 1994; Silamut, 
Phu et al. 1999).  A study on paediatric malaria in Ghana also showed staining for ICAM-
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1, VCAM-1 and E-selectin in association with pRBC in brain microvasculature of fatal 
CM patients (Armah, Dodoo et al. 2005).  Both adult studies showed limited 
upregulation of endothelial receptors compared to non-malaria controls apart from 
ICAM-1 and E-selectin.  This may account for the homogeneity of var expression at 
group level across organ sites and in both CM2 and PC diagnostic groups, and for the 
high proportion of upsA genes which are more likely to contain the DBLβc2 domain 
combination, previously shown to mediate adhesion to ICAM-1 (Smith, Craig et al. 
2000).   
An alternative explanation for the same var types being commonly observed 
may be due to certain var genes being preferentially transcribed, either due to 
switching at rapid on-rates, slow off-rates, or both.  This phenomenon is reviewed in 
detail in (Gatton, Peters et al. 2003).  If certain var antigens are more likely to be 
expressed by an individual parasite, and there is no specific selection for var antigens at 
the tissue, then they will by consequence be more likely to be detected in studies such 
as these. In P. falciparum research, post-mortem tissues and true animal models of 
sequestration are scarce. The findings suggest a similarity in antigen expression 
between tissue and peripheral blood.  It has been shown that the same circulating 
parasites end up sequestering in the different organs, hence peripheral studies may be 
indicative of the sequestering parasite population (Montgomery, Milner Jr. et al. 2006). 
However, var expression in the human host is massively diverse and tissue-specific var 
gene expression occurs (Montgomery, Mphande et al. 2007) and yet it is the same 
group expression is observed despite different pathologies between CM2 and PC. This 
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could suggest that var gene expression is indeed structured and hierarchical (Discussed 
in Chapter 1) and the possibility of var gene selection depending on the environment 
and/or demand of affinity of receptor present in that particular tissue cannot be ruled 
out. With 60 variant genes encoding the expression PfEMP1, antigenic variation 
generates a wide antigenic repertoire (See Chapter 1 for details). The var groups are 
broadly classified into groups and subgroups; therefore, it could be that different genes 
belonging to the group are expressed. Perhaps these groups should be placed into 
smaller classification based on structure such as the Lavstsen system for easy 
identification and comparison.  
Susceptibility to severe forms of malaria is attributed to a combination of both 
parasite, through sequestration, and host factors, through induction of the immune 
system (discussed further in Chapter 4). Therefore, what should also be taken into 
consideration when performing such investigations is a complete knowledge of the 
expression pattern of these host dependent factors specifically triggered during a 
clinical episodes that might play an equally important role in parasite sequestration as 
they could be used in the development of prognostic test that could be used to predict 
the outcome of P. falciparum infections (Oakley, Kumar et al. 2007; Oakley, McCutchan 
et al. 2008). 
 The potential influence of HIV and sample size has already been pointed out as 
one of the drawbacks of this study, such that the results should be interpreted with 
caution. Nonetheless, in their study Lavstsen et al. 2012, indicates that parasites 
expressing specific var genes mainly belonging to group A and B are likely responsible 
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for SM and therefore host immune system is likely to recognise these var genes first. 
This may be a result of particular adhesive domains binding to endothelial receptors 
with high affinity, and warrants further investigation of the full length sequences of 
some of the dominant antigens in order to identify their different binding domains, 
which can further be used in adhesion assay to identify host molecules they interact 
with.  
 
3.6 CONCLUSION 
In conclusions, the present findings suggest that different var/PfEMP1 may 
influence disease pathologies of cerebral malaria. These results also suggest that there 
might be a certain order in var gene transcription, in agreement to what was described 
by Recker and others (Recker, Buckee et al. 2011), that predicts similar var gene 
expression in the tissues regardless of pathology. This is also the first time, to our 
knowledge, to show an influence of HIV status on var gene repertoire of sequestered 
parasites. The question that remains is whether HIV is affecting P .falciparum infection 
dynamics at the level of the host response, transcription level or host selection level. 
Although patient HIV status may have been overlooked in previous field var gene 
studies, it should be something that should be considered in the future. As we have 
seen from our data, host response in HIV positive and HIV negative individuals are quite 
different. 
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Chapter 4 
 
4. COMPARISON OF HOST RECEPTOR EXPRESSION AND CYTOKINE PRODUCTION IN 
MALARIA AND HIV CO-INFECTION 
4.1 INTRODUCTION 
The sequestration of parasitised erythrocytes in the microvasculature of vital 
organs is central to the pathogenesis of severe falciparum malaria. Mature 
trophozoites and schizonts are removed from the peripheral circulation (Bignami and 
Bastianelli 1889), due to adhesion of the infected erythrocytes (Miller 1969) to the host 
receptors on the surface of vascular endothelial cells, leading to sequestration of the 
pRBC in the tissues. The consequences of pRBC cytoadhesion and sequestration to 
disease pathology and the host cells receptors involved have already been emphasised 
in Chapter 1.   
The parasite-host interactions described above illustrate a complex web, with 
clinical isolates having a plethora of host receptors to adhere to. Some vascular 
receptors such as CD36 are common, present on varied cell types and expressed at all 
times in a wide range of vascular beds. Such receptors are regarded as constitutive and 
their expression is not related qualitatively or quantitatively to severity of disease. 
Other receptors such as ICAM-1 and E-selectin are inducible (Berendt, Simmons et al. 
1989), their expression is modulated by local environmental factors such as 
inflammatory cytokines (Cotran, Pober et al. 1988; Ketis, Lawler et al. 1988; Wellicome, 
Thornhill et al. 1990) and their upregulation in cerebral vessels of CM patients suggest 
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involvement in cytoadhesion (Turner, Morrison et al. 1994; Brown, Hien et al. 1999). 
Whilst the distribution of these receptors in human tissues is not uniform, reflecting 
the phenotypic and functional heterogeneity of the endothelia (Kuzu, Bicknell et al. 
1992), some receptors such as ICAM-1 and CD36 work together through synergistic 
behaviour to increase overall binding efficiency (McCormick, Craig et al. 1997). Such 
synergic traits significantly contribute to increased cytoadhesion, especially endothelial 
receptors that do not appear to be up-regulatable (Petzelbauer, Bender et al. 1993).  
Limited post-mortem studies have been used to investigate sequestration and 
the expression of cytoadherence receptors in vivo (Turner, Beckstead et al. 1987; 
Ockenhouse, Tegoshi et al. 1992). These have demonstrated the widespread 
endothelial activation that occurs in fatal malaria and the major receptors involved in 
brain sequestration. So far, such studies have only been performed in adults. 
Considering that the major burden of disease occurs in children who have limited 
immunity against the parasite, and the inflammatory response can have a profound 
effect on protein expression, receptor upregulation might be different in children.   
 CM pathology is also attributed to local cytokine release that potentially 
contributes to organ specific pathophysiology as seen in the brains of fatal CM patients 
(MacPherson, Warrell et al. 1985; Pongponratn, Riganti et al. 1991; Turner, Morrison et 
al. 1994; Seydel, Milner et al. 2006; Milner, Valim et al. 2012). There is compelling 
evidence that the inflammatory responses seen in the brain in cases of CM involve an 
increased systemic production of pro-inflammatory cytokines, especially TNF, 
lymphotoxin, IFN-γ and interleukin 1β (IL-1β) (Pober 1988). Cytokine overproduction 
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leads to the upregulation of ICAM-1, VCAM-1 and E-selectin by cerebral endothelial 
cells.  This in turn facilitates the adherence of pRBC in blood vessels (Armah, Dodoo et 
al. 2005).  
In sub-Saharan Africa the high burden of malaria is an important risk factor for 
other co-infections such as HIV in adults, malnutrition in children and non-typhoid 
salmonellae (NTS) (reviewed in (Feasey, Dougan et al. 2012)). In African adults and 
children, invasive strains of NTS have emerged with an associated fatality of 20-25% 
(Feasey, Dougan et al. 2012). NTS co-infection has been associated with high malaria 
mortality (Berkley, Bejon et al. 2009). The association of NTS infection with hemolysis in 
SMA patients is well established (Mabey, Brown et al. 1987; Bronzan, Taylor et al. 
2007) and in murine malaria models (Cunnington, de Souza et al. 2010; Roux, Butler et 
al. 2010). 
Parts of the world with high malaria rates also carry a high burden of HIV 
(reviewed in (Hochman and Kim 2009; Hochman and Kim 2012)). Many aspects of the 
relationship between malaria and HIV remain unanswered (Hochman and Kim 2009; 
Hochman and Kim 2012). While it has been shown that malaria infection increases HIV 
viral load (Kublin, Patnaik et al. 2005), it has yet to be demonstrated if this translates to 
higher rates of HIV transmission among populations, even though it has been shown 
that HIV predisposes to frequent episodes of symptomatic malaria in children and 
adults (Grimwade, French et al. 2004; Cohen, Karstaedt et al. 2005; Kamya, Gasasira et 
al. 2006).
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Table 4.1. Cytokine production in HIV and Malaria infection. 
Cytokine HIV a Malaria b 
TNF-α, TNF-β ↑ MDM, U1 ↑associated with CM* 
↑parasitaemia  
= anaemia 
IL-1β ↑ MDM, U1 ↑ associated with CM* 
IL-6 ↑ MDM, U1 ↑ associated with SM* 
IL-10 ↓ MDM, U1 ↑ associated with SM* 
=parasitaemia,  anaemia 
↓CM  
IL-13 ↓ MDM, ↑ MDM  
IL-16 ↓ MDM  
IL-12  ↑associated with SM* 
↓parasitaemia 
IL-4 ↓monocytes, MDM, 
↑monocytes, MDM, 
PBMC, U937 
↓parasitaemia  
=parasitaemia,  anaemia, CM  
IFN-γ ↓monocytes, MDM 
↑U1, U937 
↑ associated with SM* 
↓parasitaemia  
= anaemia 
a cytokine data generated using  in vitro techniques, reviewed in (Kedzierska, Crowe et 
al. 2003);  b cytokine data generated using mouse model, reviewed in (Angulo and 
Fresno 2002); * cytokine data generated from humans, reviewed in (Hochman and Kim 
2009). MDM, monocyte-derived macrophage; DC, dendritic cells; U1 and U937 are 
MDM cell lines   
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Co-infection of falciparum malaria and HIV seems to be mutually detrimental; 
HIV increases the risk of clinical malaria with the greatest impact in immune 
suppressed individuals. HIV infects and depletes CD4+ T lymphocytes, putting patients 
at risk for opportunistic infection and malignancy. Like malaria, control of the HIV 
infection and pathogenesis is regulated by pro-inflammatory cytokines. As a potential 
means of affecting disease course and outcome in other infections such as malaria, HIV 
affects the systemic inflammatory response, causing activation and/or immune cell 
apoptosis as well as pro-inflammatory cytokine (Table 4.1) and chemokine elevation in 
the plasma and lymph nodes (reviewed in (Hochman and Kim 2009; Hochman and Kim 
2012)). HIV dysregulates cytokine production pathways including decreases in pro-
inflammatory cytokines IL-12 and IFN-γ and increases in anti-inflammatory cytokines 
such as IL-10  (Yadav, Fitzgerald et al. 2009). In addition to cytokines including TNF, IFN-
γ, IL-1β, and IL-6 are increased in brain tissue and cerebrospinal fluid (CSF) of patients 
with Acquired Immunodeficiency Syndrome (AIDS) (Buckner, Luers et al. 2006). 
In malaria infections, TNF-inducible cell adhesion molecules are up-regulated, 
providing pRBCs, uninfected erythrocytes, leucocytes and platelets increased 
substrates for potential adherence when they are expression of the appropriate 
receptors (see Chapter 1). Host platelets and mononuclear leucocytes appear to be 
involved in the pathogenesis of both human and murine CM (Lou, Lucas et al. 2001). 
Thus, through inflammatory mechanisms described above, HIV can influence the 
upregulation of adhesion molecules on endothelial cells, which may compound the 
adherence and sequestration of pRBC. However, the full extent to which this 
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inflammatory response in HIV infections exacerbates pRBC adherence and 
sequestration is not known. The previous chapter considered the possibility of HIV 
altering the host inflammatory response, such that changes in endothelial receptor 
expression in turn affect antigen expression in malaria. This chapter uses RT-qPCR to 
analyse post-mortem tissues to ascertain and compare the expression of host genes 
involved in apoptosis, cytokine production and endothelial receptor expression in 
malaria and HIV co-infections.  
 
 Objectives 
i. To determine the expression of putative sequestration receptors and cytokines 
in the brain, heart and gut from fatal cases of P. falciparum paediatric malaria 
ii. To compare the distribution of putative receptors and cytokines in paediatric P. 
falciparum patients with different clinical presentations of cerebral malaria 
iii. To compare receptors and cytokines distribution between HIV and P. falciparum 
co-infections versus P. falciparum infections alone 
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4.2 RESULTS  
4.2.1 Clinical and diagnostic details 
This project utilised clinical samples collected under the parent 
clinicopathological study of fatal paediatric malaria and a summary of the patients’ 
clinical details are given in Table 4.2. The full description of the clinical samples and all 
methods has been given in Chapter 2.  
 
Table 4.2. Summary of the clinical details of patients in main study. 
Diagnosis Agea HIV+ 
 
Time to 
deathb 
Time to 
autopsyb 
Admission 
parasitaemiac 
Final  
parasitaemiac 
CM1 75.6 ± 40.6 4/5 20:58 ± 16:55 07:49 ± 03:06 382,990 ± 07,769 66,142 ± 120,250 
CM2 61.6 ± 49.4 3/11 09:32 ± 09:56 07:15 ± 06:26 247,837 ± 34,794 210,011 ± 350,186 
PC 34.3 ±23.3 1/4 13:34 ± 07:32 10:01 ± 05:20 87,624 ± 57,274 79,668 ± 78,700 
a months, b hours:minutes, c parasites/L in peripheral blood are given as means for all 
patients in each diagnostic group 
 
The overall mean age of the children was 57.2 ± 37.8 months and there were no 
differences in parasitaemia at admission or at death, or in the length of time to autopsy 
(Chapter 3, section 3.4.1). Patients were recruited from four different malaria seasons 
between 1999 and 2004. However, because of limited resources, only about half of the 
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patients were selected for this sub-study from the cohort and not all three tissues were 
matched for all patients selected in this analysis.  
 
Table 4.3. Clinical details of patients 
 Case no. Diagnosis Tissue HIV 
status 
CM1  Sequestered parasites in the brain   
 38 Clinical CM
*
   brain, gut - 
 74 Clinical CM  heart + 
 84 Clinical CM  brain, heart, gut + 
 79 Clinical CM  heart, gut + 
CM2  Sequestered parasites in the brain 
and associated pathology 
  
 28 Clinical CM brain, heart, gut - 
 55 Clinical CM  brain, heart, gut - 
 60 Clinical CM  brain - 
 61 Clinical CM  brain, heart, gut - 
 62 Clinical CM brain - 
 63 Clinical CM brain - 
 78 Clinical CM  brain, heart, gut - 
PC  Parasitaemic Controls   
 31  brain + 
 65 Coma of unknown cause with 
hypoglycaemia- Reye’s  
brain - 
 77 Gangrenous bowel brain - 
*CM cerebral malariA
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4.2.2 Comparison of receptor expression and local cytokine release in the diagnostic groups 
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Figure 4.1. Transcript abundance of each cytokine or receptor in the post-mortem tissues of parasitaemic children. Description for 
each cytokine or receptor is given in Table 2.4. Transcript abundances for the brain (A), heart (B) and gut (C) are shown according to 
the diagnostic groups; Blue is CM1 (n=4), Red is CM2 (n=7) and Black is parasitic controls (n=3). The tissue available for each patient 
that was included in the analysis is listed in Table 4.3. Each ΔCT value was calculated relative to the average of housekeeping gene 
GAPDH. The mean with a standard deviation is indicated by the cross lines (ANOVA; *p ≤ 0.05 and **p ≥0.001 after Bonferroni 
correction). 
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Comparison of production and expression of 12 selected cytokines and 
receptors (Chapter 2, Table 2.4) in the clinically different CM diagnostic group was 
conducted using relative quantitative PCR with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), an enzyme that catalyzes the breakdown of glucose for 
energy and carbon molecules, as an endogenous control. Data analysis was statistically 
challenging because of the small sample size in each diagnostic group.   
Surprisingly, most genes, with exception of ICAM-1 and TNF, were more highly 
expressed in the heart and gut of CM1 than CM2. CM1 group had the most patients co-
infected with HIV and therefore possessed a degree of immune suppression, the level 
of which unfortunately is unknown in these patients. There were no significant 
differences in expression of the receptors and cytokines between the diagnostic groups 
in the brain. Although, there is an indication of elevated ICAM-1 in CM2, the sample 
size was too small to draw solid conclusions. This could also imply that the physiological 
responses to malaria infection are similar in these patients, irrespective of severity of 
disease.  Both CM1 and CM2 are severe (and in these cases, fatal) forms of malaria and 
inflammatory responses to pRBC occur even in the parasitaemic controls. I have 
already pointed out the possibility of the presence of HIV in some of these patients 
potentially influencing cytokine release, and in turn receptor expression (discussed in 
Chapter 3). Because of the difficulty of the nature of post-mortem sample collection, 
there were not enough PC to be included in this analysis for the heart and gut. In spite 
of this, we observed some tissue and/or diagnostic group cytokine/receptor 
differences.  There was an indication of CD36 elevation in CM1 and ICAM-1 
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upregulation in the heart of CM2 patients. In CM2, the expression of ICAM-1 appeared 
to be elevated in all the tissues but it was significantly higher in the gut (p=0.002). On 
the other hand, there was a significant increase of neural cell adhesion molecule 
(NCAM; p=0.037) and apoptosis gene -1 Ligand/CD95L (FASLG; p=0.059) in the heart of 
CM1 cases. NCAM has been recently identified to facilitate P. falciparum binding but 
the parasite ligand for this receptor is not known (Pouvelle, Matarazzo et al. 2007). 
FASLG is a possible indicator of increased production of an apoptosis gene FAS, that 
also aids in regulation of the immune system.  
The cytokine/receptor expression pattern in the gut was very similar to the 
heart. Three receptors: CD36, PECAM-1and VCAM-1 (p=0.057 in the heart) were 
elevated in both tissues in CM1 but only PECAM-1 was significantly increased in the 
heart (CM1 versus CM2; p=0.034 in the heart and p=0.050 in the gut).  PECAM-1 and 
CD36 are widespread on tissue endothelia and other types of cells, and they have also 
been implicated in pRBC binding (see Chapter 1). Surprisingly, an increase in the 
expression of glycoprotein Ib/beta polypeptide/CD42c (GP1BB; p=0.034 in the heart) 
was also observed.  This molecule forms a part of the GPIb-V-IX system that constitutes 
the receptor for vWF and mediates platelet adhesion in the arterial circulation, and an 
increase in vWF itself. The presence of PECAM-1 indicates endothelial activation and 
inflammatory responses to the presence of pRBC. These physiological responses also 
trigger the upregulation of VCAM-1 and vWF which are early markers of endothelial 
activation, especially in vascular disorders (Zeigler, Rosenfeld et al. 1996; van Mourik 
and Romani de Wit 2001; Szmitko, Wang et al. 2003; Eikemo, Sellevold et al. 2004). 
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Interestingly, these genes are associated with platelet-mediated binding of pRBC, and 
therefore potentially contribute to cytoadhesion (Bridges, Bunn et al. 2010).  
  Although not statistically significant, there was an increase in TNF expression in 
the brain and heart compared to the gut (Figure 4.1A and B). In malaria infections, TNF 
is detected in circulation during the erythrocytic stages of infection (Grau, Piguet et al. 
1989; Kern, Hemmer et al. 1989; Kwiatkowski, Hill et al. 1990) and has been shown to 
have both beneficial and detrimental effects. High levels of this cytokine have been 
associated with malarial pathology such as fever (Karunaweera, Grau et al. 1992) and 
CM (Grau, Fajardo et al. 1987; Kwiatkowski, Hill et al. 1990). TNF has also been shown 
to have anti-parasitic activity by inhibiting blood stage infection of Plasmodium 
chabaudi in mice (Clark, Hunt et al. 1987) and rapid clearance of fever and parasites in 
humans (Mordmuller, Metzger et al. 1997). However, tumor necrosis factor receptor 
1/CD120a (TNFR1), a crucial receptor for TNF-induced neurotoxic processes, was 
upregulated in the heart and gut which could imply regulation using an alternative 
pathway. 
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4.2.3 Comparison of receptor expression and local cytokine release by HIV status 
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Figure 4.2. Transcript abundance of each cytokine or receptor in HIV positive versus HIV negative children suffering from cerebral 
malaria. Description for each cytokine or receptor is given in Table 2.4. Transcript abundances for the brain (A), heart (B) and gut (C) 
are shown according to HIV status; HIV positive in orange also shown by the triangles and HIV negative in green also shown by closed 
circle. The dash in each sample population represents the mean. Each ΔCT value was calculated in relative to the average of 
housekeeping gene GAPDH. (ANOVA; *p ≤ 0.05 and **p ≥0.001 after Bonferroni correction). 
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There is some evidence that HIV infection might influence the expression of 
host receptors which in turn might determine which pRBC can sequester (discussed in 
section 4.1 and in Chapter 3). In order to explore this possibility, the levels of genes 
encoding for 12 selected cytokines and receptors (listed in Chapter 2, Table 2.4) that 
potentially influence HIV and malaria infections were compared against a housekeeping 
gene between HIV positive and HIV negative cases.  Of the 14 children, only 5 were HIV 
positive (CM1 n=3; CM2 n=1 and PC n=1; Table 3.2). The PC group comprises children 
that were HIV+ plus another disease that was their cause of death. In order to avoid 
conflict of interest on malaria effect on cytokines and that of other diseases, only 
children in the CM2 and CM1 groups were included in this analysis.  
The pattern of cytokine/receptor upregulation in the tissues of HIV positive 
children was generally similar to CM1. This was not surprising as most of the HIV 
positive children had a CM1 diagnosis (see also Chapter 3, section 3.4.4). 
Cytokine/receptor gene expression patterns were also similar between the tissues for 
the respective HIV status groups. CD36 was upregulated in the heart and gut of HIV+ 
patients, with a significant increase in the gut (p=0.0001).  In agreement with data from 
adults (Meroni, Riva et al. 2005), expression of CD36 increases in HIV-infected children 
and circulating monocytes regardless of antiretroviral treatment (Meroni, Giacomet et 
al. 2005).  
Genes encoding PECAM-1, VCAM-1, vWF and GP1BB were prominent in the HIV 
positive group in all the tissues, as was seen in CM1 above.  Expression of TNF was 
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significantly increased in the CM2 cases in all tissues, (p≤0.042 for all tissues), in 
agreement with Emmie Mbale and Chris Moxon (personal  communication) who 
showed increased TNF in the sera of HIV negative children with severe malaria 
infections compared to children with severe malaria and HIV co-infection. 
 
 
 
 
 
 
 
Figure 4.3. Comparison of TNF plasma concentrations between CM children who are 
HIV-infected and HIV-uninfected. In 80 CM patients with malaria retinopathy, TNF 
concentrations on admission were higher in 69 HIV negative patients than in 11 HIV 
positive children: mean 53.7 units/mL vs 29.8 units per mL, respectively (p=0.03) 
(adapted from Emmie Mbale and Chris Moxon) 
 
Some of the observed gene upregulation was localised to a particular tissue or 
diagnostic group, as in the case of TFRC which was higher in HIV positive cases in the 
brain while low in the gut of HIV negative children (p=0.041 and p=0.031 respectively). 
While the upregulation of NCAM and TNFR1 was similar in the brain and gut of both 
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groups, it was significantly raised in the heart of HIV positive children (p=0.049 and 
p=0.016, respective of gene). GP1BB was high in the gut of HIV positive children 
(p=0.007) while NCAM and IFNG were also elevated in children in this group. 
 
4.3 DISCUSSION 
Despite the high mortality associated with CM, an understanding of the 
underlying pathogenic mechanisms has been slow to evolve and there are still grey 
areas requiring investigation. Some of these areas are unable to be even roughly 
investigated, because post-mortem samples from patients in whom CM was 
established prior to death are rare. Over the years, several hypotheses on the parasite 
and the host side have been developed to explain the pathogenesis of CM. The release 
of plasmodium toxin (glycosylphosphatidylinositol), systematic and local cytokine 
production, the upregulation of adhesion molecules by tissue endothelia, and the 
consequences of sequestration i.e mechanical vessel blockage, ischemia, acidosis 
haemorrhage and excess production of nitric oxide have all been implicated in CM 
pathology (Newton and Krishna 1998). 
Areas with high rates of malaria also carry a heavy burden of HIV (reviewed in 
(Hochman and Kim 2009; Hochman and Kim 2012)).  Initial cross-sectional population 
studies  to determine co-infection dynamics found no significant differences in 
incidence or severity of malaria between HIV-infected and uninfected individuals 
(Chandramohan and Greenwood 1998). However, recent work suggests otherwise, that 
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during co-infection symptomatic malaria incidence and the severity of illness increases 
(reviewed in (Hochman and Kim 2012)). Both infections are influenced by pro-
inflammatory cytokines in control and pathogenesis; however, they differ in the 
mechanisms by which they respond to physiological changes in their host environment 
(discussed in Chapter 1) and it is not known if the inflammatory response initiated by 
HIV affects adherence, sequestration, or disease severity in malaria. 
In the previous chapter of this thesis, some evidence was provided on how HIV 
might “influence” P. falciparum variant surface antigen expression.  This chapter offers 
some support to what has previously been speculated, that the induction of adhesion 
molecules on endothelial cells through inflammatory cytokine release may compound 
pRBC adhesion and sequestration in malaria, thus intensifying CM pathology. In this 
study, the expression of selected cytokines and receptors (Chapter 2, Table 2.4) was 
quantified in the brain, heart and gut obtained from pathologically defined cases of 
fatal CM and non-cerebral paediatric malaria. The CM patients were further grouped 
based on their HIV status in order to permit an extensive evaluation of the role HIV 
plays in paediatric CM on the local production of cytokines and adhesion molecules in 
different tissues. Due to the difficulties of obtaining post-mortem samples, a small 
tissue size for the different patient subgroups poses puts this study at a disadvantage. 
Therefore, this study is mainly descriptive as there was not enough tissue to allow 
extensive and exhaustive analysis. 
Firstly, comparison of cytokine/receptor expression in the CM diagnostic groups 
confirms what previous studies have shown, that cytokine/receptor activation occurs in 
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both fatal malaria and non-cerebral malaria and is tissue-specific. We speculate that 
this might depend on how function of a particular tissue is affected by disease. Several 
studies in both children and adults have already shown how HIV influences malaria 
prevalence and epidemiology (reviewed in (Hochman and Kim 2009).  
The major variant findings are individually discussed below: 
4.3.1 Adhesion molecules 
CD36  
 HIV also alters fat metabolism and distribution regardless of antiretroviral 
treatment (Dube, Stein et al. 2003). CD36 is one of the receptors implicated in 
lipodystrophy and plays a crucial role in the cellular uptake and metabolism of lipids 
and sugars (Aitman, Glazier et al. 1999). Increasing CD36 expression would seem 
beneficial to the virus as it uses lipids for propagation. However, it may be detrimental 
to the host as in HIV infected individuals fat distribution is impaired regardless of 
antiretroviral treatment and the upregulation of CD36 may contribute to pRBC 
sequestration.   
The role of CD36 in CM is questionable considering that brain endothelium does 
not express CD36 and recently, pRBC binding to CD36 was associated with UM (Ochola, 
Siddondo et al. 2011). It is proposed that the source of CD36 in the brain is platelets 
and inflammatory cells, especially monocytes and leukocytes that have been shown 
accumulated in brain tissue from CM paediatric patients at autopsy (Wassmer, 
Lepolard et al. 2004).  
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PECAM-1 
PECAM-1 is a glycopeptide adhesion molecule implicated in pRBC-platelet 
adhesion (Treutiger, Heddini et al. 1997; Heddini, Chen et al. 2001) and was elevated in 
the tissues of HIV positive patients (Figure 4.1). This is in agreement with data from 
(Eugenin, Gamss et al. 2006) that showed elevated levels of soluble PECAM-1 in the 
sera and brain tissue of individuals with HIV encephalitis. Therefore, PECAM-1 
upregulation may not be specific to CM but rather an indicator of brain damage. High 
levels of PECAM-1 offers an explanation for the accumulation of platelets in the brains 
of CM patients (Wassmer, Lepolard et al. 2004) and the upregulation of host 
mononuclear leucocytes and monocytes involved in the pathogenesis of both human 
and murine CM (Brown, Rogerson et al. 2001; Armah, Dodoo et al. 2005). LFA and 
PECAM-1 have been shown to increase HIV infection of human umbilical vein 
endothelia cells (HUVEC) by enhancing HIV absorption (Scheglovitova, Scanio et al. 
1995).  
The presence of high PECAM-1 in the brain is very significant as this receptor is 
involved in the migration of monocytes from the vasculature through the blood brain 
barrier (BBB) into brain tissue. In malaria infections, PECAM-1 on its own has never 
been correlated with severe malaria (Newbold, Warn et al. 1997; Heddini, Pettersson 
et al. 2001). PECAM-1 together with CD36 also acts as a binding site for microparticles 
(small fragments shed from plasma membranes or activated platelets during CM 
infection) present on platelets (Combes, Taylor et al. 2004; Faille, Combes et al. 2009). 
Perhaps its action in facilitating cytoadhesion is enhanced by acting synergically with 
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other receptors as its upregulation also coincides with upregulation of CD36 and 
VCAM-1 within the same tissues. 
Furthermore, the binding of platelet microparticles to pRBC contributes to their 
cytoadherence to brain microvascular endothelial cells in vitro. Sequestration may be 
further enhanced during HIV co-infection by facilitating the release of platelet 
microparticles via platelet activation (Wang, Zhang et al. 2011). 
 
VCAM-1  
In agreement with (Wolf, Tsakiris et al. 2002), elevated VCAM-1 was observed in 
all three tissues in HIV-infected children.  VCAM-1 binding to pRBC is extremely low and 
is not associated with malarial disease severity in African isolates (Newbold, Warn et al. 
1997). Therefore, in this case VCAM-1 is potentially acting as an early marker for 
endothelial activation. 
  
ICAM-1  
There was a slight upregulation of ICAM-1 in the brain and heart of CM2 
patients although the results were not statistically significant. Because ICAM-1 is widely 
expressed in the brain microvasculature affected by sequestration, it is thought to be 
the likely main receptor for pRBC adherence in that organ (Berendt, Simmons et al. 
1989; Graninger, Prada et al. 1994; Turner, Morrison et al. 1994). Unlike Wolf et al. 
2002, who found a systemic ICAM-1 increase in HIV infected individuals, significant 
differences in the expression of ICAM-1 between HIV positive and negative children 
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were not seen in this study. On the other hand, ICAM-1 binds to PfEMP1 variants 
containing the DBLβ-C2, which is found in all three main var gene groups and very 
common in group A (Kraemer, Kyes et al. 2007). However, in vitro studies using HUVEC 
infected by HIV have shown that virus replication is arrested by adding monoclonal 
antibodies to ICAM-1 (Scheglovitova, Scanio et al. 1995), suggesting that ICAM-1 
upregulation could promote increase in HIV replication.  
 
 4.3.2 Cytokines 
vWF  
This is another marker for early EC activation triggered by inflammation and 
liberally found in circulation. It is upregulated when the GP1BB receptor that forms part 
of the GP1b-V-IX, complex is induced. In vivo, vWF biosynthesis is limited to EC and 
megakaryocytes, which mediate platelet adhesion to the site of vascular injury (Stel, 
Sakariassen et al. 1985; Ruggeri and Ware 1993). During P. falciparum infection, vWF 
levels are elevated in both CM and UM patients (Phiri, Bridges et al. 2011) and the 
accumulation of platelets offers the opportunity for pRBC to bind to vWF strings via 
CD36 (Bridges, Bunn et al. 2010). In accordance with Drouet et al. 1990, we found an 
increase in both GP1BB and vWF in all three tissues of HIV infected children. There was 
more vWF in CM1 compared to CM2, implying more vWF release in children with co-
infection. 
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The notion that HIV actually infects EC cannot be ruled out. vWF levels are 
elevated at all stages of HIV/ AIDS (Drouet, Scrobohaci et al. 1990), an indication of 
endothelia involvement during HIV infection. The presence of HIV infection brings 
about endothelial damage and the resulting inflammation stimulates vWF release. 
During both malaria and HIV infection, the endothelium is chronically exposed to an 
imbalance of cytokine concentrations and consequently the normal endothelium 
function may be impaired (Zietz, Hotz et al. 1996). Raised vWF plasma levels do not 
necessarily imply endothelial damage but merely its activation or stimulation (Pober 
1988; Blann, Maxwell et al. 1995). With the lack of vWF release in the tissues, these 
results provide some evidence that vWF plasma levels correlates to its level of 
expression on EC.  
 
TNF  
TNF plays an important role in the pathophysiology of both malaria and HIV 
infections. In advanced HIV infections, TNF is essential for virus replication and 
therefore is upregulated (Griffin, Leung et al. 1991; Naif, Ho-Shon et al. 1994). In 
contrast, Mbale and Moxon (personal communication) found in a cohort of retinopathy 
positive children almost two times the amount of plasma TNF in HIV- hosts compared 
to children co-infected with HIV (Figure 4.3). The patients of this study were children 
less than 5 years of age with CM confirmed by retinopathy with or without HIV co-
infection, also enrolled at the malaria research ward at QECH in Blantyre, Malawi. On 
average, children with CM and HIV co-infection were older than HIV negative children 
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with CM (p<0.01). The disease course was prolonged in HIV positive children with CM 
but their short term outcome was not affected and TNF plasma concentration was 
higher in CM children who were HIV uninfected, compared to HIV infected CM children. 
This coincides with the significant increase of TNF in all the tissues in vascular 
pathology-associated CM2 hosts that were predominantly HIV negative, and reduced 
TNF production in HIV positive individuals.  
In malaria infections, TNF has both detrimental and beneficial effects; 
detrimental as it has been associated with malarial symptoms such as fever 
(Karunaweera, Grau et al. 1992) and CM pathology (Grau, Fajardo et al. 1987; 
Kwiatkowski, Hill et al. 1990); beneficial because it has potent anti-parasitic activity and 
is associated with rapid clearance of pRBC (Mordmuller, Metzger et al. 1997). However, 
the role of TNF in malaria and HIV co-infections remains unclear. Although there is high 
TNF expression in hosts with either HIV or malaria infections, co-infections seem to 
significantly reduce TNF production. One of the receptors that TNF is known to regulate 
is ICAM-1 (reviewed in (Schofield and Grau 2005; Marsh and Kinyanjui 2006)), which 
provides some explanation of a slight increase of ICAM-1 in the brain and heart of CM2 
cases (Figure 4.1) and lack thereof in the HIV positive individuals. TNFR1-deficient mice 
exhibit normal susceptibility to P. berghei (Grau, Piguet et al. 1989).  Conversely, HIV 
infections of monocyte-derived macrophages induce TNF secretion through TNFR1 that 
enhances HIV replication (Esser, von Briesen et al. 1991; Esser, Glienke et al. 1996; 
Esser, Glienke et al. 1998). In accordance with this, a significant upregulation of TNFR1 
was observed in the heart and gut. However, this TNF overproduction must be short-
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lived and viral load-dependent because infecting macrophages with HIV show 
reduction of macrophage ability to produce cytokines, leading to lower TNF levels in 
the HIV positive patients (Ludlow, Zhou et al. 2012).  
Pre-treatment of macrophages with TNF prior to HIV-1 infection results in 
signalling via TNFR2 or CD120b and leads to inhibition of HIV replication (Herbein and 
Gordon 1997). On the other hand, TNFR2- deficient mice develop protection against 
CM (Grau, Piguet et al. 1989). We did not see any significant differences in the 
transcription of TNFR2 in the tissues or the diagnostic groups and it is not clear what 
role this receptor plays in the HIV and malaria con-infections, except in this case, to 
suggest that HIV replication is not inhibited.  
 
TFCR and FASLG 
  Soluble transferrin receptor concentrations are considered to be a sensitive 
indicator of iron availability in the tissues (Ahluwalia 1998) and have been used as 
measure of iron deficiency in anaemia of chronic disease (Ray, Ndugwa et al. 2007). 
Iron deficiency is suggested to protect against malaria parasitaemia and clinical malaria 
in young Malawian children (Jonker, Calis et al. 2012). There were no significant 
differences in TFCR upregulation in the diagnostic groups (Figure 4.1) but in the tissues 
between HIV-infected and HIV-uninfected children (Figure 4.2). TFCR was up regulated 
in the brain HIV-infected children and in the gut of HIV-uninfected children, indicating 
that in this case iron deficiency might not be universal in co-infection but rather tissue 
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specific. Other examples of tissue specific responses include FASLG, which was only 
significantly higher in the heart of CM1 patients. In both malaria and HIV infections, 
FASLG is a marker of increased immune cell apoptosis triggered either from within the 
cell or by signals that are elicited by binding of extracellular “death ligand” to their 
death receptor, most of which belong to TNF (Pinti, Nasi et al. 2000). Soluble FASLG is 
extremely elevated during acute falciparum malaria of non-immune adults and 
decreases during anti-parasitic treatment, suggesting an association with T cell 
lymphopnia (Pinti, Nasi et al. 2000). The FAS receptor is known to mediate apoptosis of 
lymphocytes during acute malaria infection; this is in order to achieve balance between 
pro-apoptotic and anti-apoptotic mechanisms comparable to the situation in the other 
infectious disease like HIV (Pinti, Nasi et al. 2000).  
 
Other influential cytokines 
One of the clear ways that malaria and HIV interact is through local cytokine 
release from inflammatory responses due to immune system activities and the up-
regulation of adhesion molecules. There is a scarcity of direct evidence for local 
cytokine release in human tissues from CM patients mainly because of the difficulties in 
obtaining post-mortem samples. Therefore, most of these studies are descriptive as 
there are not enough samples for extensive and exhaustive analysis, as was the case in 
this study.   Another influential cytokine that ought to be included in future studies is 
IFN-γ which is known to increase the binding of pRBCs to EC via PECAM-1, possibly 
through redistribution of PECAM-1 from endothelial junctions to the cell surface 
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(Treutiger, Heddini et al. 1997). As already mentioned, PECAM-1 contributes to changes 
in the BBB permeability and enhanced trafficking of HIV-infected monocytes into the 
brain. Other essential cytokines and receptors that play key roles in both HIV and 
malaria infections are: IL-10 (Yadav, Fitzgerald et al. 2009), IL-1β, IL-6 (Pober 1987; 
Buckner, Luers et al. 2006) and lymphotoxin α would also be worth investigating. 
 
4.4 CONCLUSION  
In conclusion, the presented results provide evidence indicating that in 
paediatric CM the upregulation of adhesion molecules might be further influenced by 
the induction of cytokines such as TNF. However, there is some indication that the 
presence of HIV influences patterns of adhesion molecule expression, which may result 
in the manipulation of the immunopathology associated with CM. It is hoped that 
future studies will include immunohistochemistry to explore HIV influence on cytokines 
producing cells in the issues.  This analysis is limited in that it is not clear if the gene 
expression is coming from the tissue (gut, brain or heart) or from monocytes that are in 
that tissue. More effort should be put in developing models that would allow further 
investigations of HIV/malaria interactions and responses in immune cells and 
endothelial cells in vitro assays. 
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MODEL 
 
 
 
 
Figure 4.4. Proposed model of the regulation of pRBC cytoadhesion and sequestration 
in children co-infected with HIV. The presence of both parasites and HIV elicit the 
immune and inflammatory responses which result in endothelial cell activation and the 
release of vWF which binds pRBC through platelets. However, production of 
inflammatory cytokines by HIV-infected macrophages such as TNF is limited. As such, 
ICAM-1 is down-regulated on the brain endothelia as the TNFR2 receptor that interacts 
with TNF to upregulated ICAM-1 is also down-regulated. Instead, VCAM-1, PECAM-1 
and CD36 are upregulated due to endothelial activation. In the brain, PECAM-1 is used 
for monocyte migration across the BBB. CD36 is also upregulated on HIV-infected 
macrophages and potentially mediates pRBC adhesion. The upregulation of arginase 
due to RBC, depletion of nitric oxide, reduced ADAMTS activity, and platelet activation 
which causes EC to massively upregulate receptor expression on their surface, and 
release of microparticles that all provide substrate for pRBC adhesion.  
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Chapter 5 
 
5. DIFFERENTIAL VAR GROUP EXPRESSION IN PLATELET-MEDIATED CLUMPING 
ISOLATES OF MALAWIAN PAEDIATRIC MALARIA PATIENTS 
5.1 INTRODUCTION 
As previously discussed in Chapter 1, one of the most important pathological 
characteristics of P. falciparum infections is the sequestration of large numbers of 
mature parasites (trophozoites and schizonts) in the microvasculature of vital organs 
due to cytoadherence of pRBC to host endothelia (Rogerson, Grau et al. 2004).  There 
are several adhesive phenotypes that have been associated with severe outcomes of 
malaria such as the formation of rosettes, sequestration of pRBC in the brain or 
placenta (Miller, Baruch et al. 2002), and formation of platelet-mediated clumps (Pain, 
Ferguson et al. 2001). pRBC adhesive mechanisms that do not utilise endothelia are 
supported by post-mortem histological studies that have shown pRBC accumulating in 
the microvasculature (Wassmer, Combes et al. 2006). 
A precise role for platelets in malarial pathology is mostly speculative; however, 
pRBC can form mixed clumps in the presence of platelets in vitro in which the platelets 
act as a bridge between pRBCs. Whether platelet-mediated clumps occur in vivo 
remains unclear but may account for the significant accumulation of platelets described 
in brain microvasculature of Malawian children who died from CM pathology (Grau, 
Mackenzie et al. 2003) and thus contribute to microvascular obstruction. Interactions 
between pRBC and platelets might also lead to platelet activation and release of 
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inflammatory mediators that upregulate expression of adhesive molecules that 
facilitate cytoadherence (Srivastava, Cockburn et al. 2008). Platelets are also known to 
mediate pRBC adhesion to vWF strings (Bridges, Bunn et al. 2010), are believed to have 
anti-parasitic effects in vivo and are able to bind and kill pRBC (McMorran, Marshall et 
al. 2009). 
P. falciparum clumping phenotypes vary between clinical isolates, and the 
ability to generate clumps in the presence of platelets is significantly greater in CM 
isolates compared to parasites isolated from uncomplicated malaria patients. 
Significant associations of the clumping phenotype with severe malaria has been 
reported in Malawian (Wassmer, Taylor et al. 2008), Kenyan (Pain, Ferguson et al. 
2001), Thai (Chotivanich, Sritabal et al. 2004)  and Mozambican patients (Mayor, Hafiz 
et al. 2011), (although not in Malian (Arman, Raza et al. 2007)). The outcomes of these 
field studies were affected by using different experimental methods to assess platelet-
mediated clumping.  
Although the molecular binding mechanisms between pRBC and platelets are 
not fully understood, three platelet receptors have been identified that mediate 
clumping: gC1qR/HABP1/p32 expressed on the surface of diverse cell types including 
endothelial cells and activated platelets (Biswas, Hafiz et al. 2007); P-selectin expressed 
on the surfaces of activated platelets, especially in combination with CD36 (Wassmer, 
Taylor et al. 2008); and CD36, a glycoprotein receptor expressed on the platelet surface 
(Pain, Ferguson et al. 2001; Chotivanich, Sritabal et al. 2004). The observation that 
most field isolates can adhere to CD36 and yet this receptor is not expressed by human 
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brain ECs has been a mystery, and CD36 was therefore thought to be unimportant in 
cerebral sequestration. The accumulation of platelets in cerebral vessels suggests that 
CD36 mediated cytoadhesion in the brain is possible through indirect adhesive events 
(see also Chapter 4). 
The parasite ligand for all the receptors mentioned above is unknown although 
PfEMP1 is the likely candidate. The parasite ligands for CD36 binding are PfEMP1 
variants (Baruch, Pasloske et al. 1995; Baruch, Gormely et al. 1996) encoded by two 
major subtypes of var genes; groups B and C (Robinson, Welch et al. 2003). Binding is 
mostly via the most N-terminal CIDR domain (Baruch, Ma et al. 1997; Smith, Kyes et al. 
1998; Miller, Hudson-Taylor et al. 2002).   CIDRα-domains bind to CD36 whereas CIDR-
α1, β and γ domains do not. The CIDR1 of var gene groups B and C (full description in 
Chapter 1) are the CIDRα type and therefore their var/PfEMP1 variants bind to CD36. In 
contrast,  CIDR1 domains of var gene group A (full description in Chapter 1) are mainly 
CIDR-α1 and their PfEMP1 variants are known to not bind to CD36 (Robinson, Welch et 
al. 2003).  
DBLα is another domain of the PfEMP1 that has lectin-like properties that 
enables binding primarily to RBC bearing A and B blood group oligosaccharides, and to 
other glycosylated proteins such as CD35 (CR1) and heparin sulphate-like 
glycosaminoglycans (Baruch, Gormely et al. 1996; Miller, Hudson-Taylor et al. 2002). 
Cerebral malaria has been linked to DBLα1 expression, rosette formation and adhesion 
to ABO blood group antigens (Kyriacou, Stone et al. 2006). Blood type A or B antigens 
are also implicated in pathology through formation of large rosettes and at higher 
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frequencies compared to type O, and the fact that rosette formation correlates with 
transcription of lectin-specific binding domains of PfEMP1.  
This chapter is intended to identify specific var gene groups involved in platelet-
mediated clumping using P. falciparum isolates from the peripheral blood of Malawian 
paediatric malaria patients. 
 
 
Objectives 
i. To determine which particular var/PfEMP1 subtypes mediate platelet-mediating 
clumping 
ii. Identify ABO blood groups associated with platelet-mediated binding 
phenotypes  
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5.2 HYPOTHESIS 
Clumping isolates will express group B and C var genes and non-clumping 
isolates will express mainly var group A variants 
 
 
 
 
 
Figure 5.1. Schematic representation of PfEMP1.The α-type CIDR region (purple) in var 
gene groups B and C binds to CD36 receptor while the α1-type in var gene group A does 
not. 
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5.3 RESULTS 
5.3.1 Patient characteristics  
Parasites were isolated from a total of 100 P. falciparum-infected children 
whose clinical details have been provided in Chapter 2, Table 2.2. A summary of the 
characteristics of the patients are given in Figure 5.2. The children were male (41%) and 
female (59%) with mean age of 64 ± 37 months.  
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Figure 5 .2. Characteristics of the patients by (A) Sex, (B) Blood group and (C) 
Parasitaemia 
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5.3.2 Standardisation of the platelet clumping assay using P. falciparum laboratory 
strain HB3 
P. falciparum laboratory isolate HB3 has a known clumping phenotype (Arman 
and Rowe 2008) and we used it as a positive control for the occurrence of platelet-
induced in vitro clumping of pRBC. The assay uses platelet-rich plasma (PRP) as a source 
of platelets and platelet-depleted plasma (PPP) to control for potential pRBC auto-
agglutination in the absence of platelets. When pRBC were incubated with PRP from 
healthy donors, clump formation was observed after 15 minutes with clump sizes of 8 ± 
5 pRBC/clump (Figure 5.3B). After 45 min, the clump size increased to >15 pRBC/clump 
(Figure 5.3C). After an hour, the clumps become gigantic such that the number of pRBC 
in a clump could not be counted. 
 
 
Figure 5 .3. Clumping of infected erythrocytes in laboratory isolate P. falciparum HB3. 
A clump is defined as ≥3 pRBC in the presence of platelets. Clumps formed in PRP at 5 
min (A), 15 min (B) and 45 min (C). 
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5.3.3 Platelet-induced clumping of P. falciparum isolates from Malawian children: 
Uncomplicated malaria versus cerebral malaria 
The clumping assay was repeated using P. falciparum isolated from 10 
Malawian children (Chapter 2, Figure 2.3) 12 years of age and below whose clinical 
characteristics are described above. When incubation was performed with PPP, no 
platelet–induced clumping phenotype was observed at the end of the kinetic study 
(Figure 5.5A). When the same experiment was repeated with PRP from healthy donors, 
there was no clump formation after 5 minutes for most these patients except isolates 
from patient ID 3, which start clump formation after 10 min (Figure 5.4). For most 
patients, pRBC clumping started occurring randomly after 30 minutes, with small 
clumps averaging at 4.7±1.6 pRBCs/clump, with no significant increase in clump size or 
frequency after incubation for 120 minutes (Figure 5.5B-D).  
 
 
 
 
 
 
 
 
 
 
Figure 5 .4. Distribution of clump formation in three patients with uncomplicated 
malaria 
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Figure 5.5. Clumping of infected erythrocytes in P. falciparum paediatric isolate. The 
clumps (white and black arrows) are defined as ≥3 pRBC in the presence of platelets. 
Clump assay performed with PPP at 120 min (A) and with PRP at 0 min (B), 5 min (C), 30 
min (D) and 120 min (E). 
 
 
Platelet-mediated pRBC agglutination is known to be time dependent and is 
associated with disease type and severity. For strong clumping phenotypes, clump size 
can get larger. The reason only minimal pRBC clumping was observed for the patient 
isolates used here might be that although there was high parasite burdens in some of 
the children, their diagnoses were uncomplicated malaria, and hence not severe 
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enough to select for clumping phenotypes as shown in previous studies. The assay was 
repeated on a CM isolate (donation from Karl Seydel, Blantyre Malaria Project), in 
order to confirm that most of the patients that were recruited in the study had a 
“poor” clumping phenotype.  
 
 
Figure 5 .6 Clumping of infected erythrocytes in a P. falciparum parasite isolated from 
a CM patient. A clump (black arrow) is defined as ≥3 pRBC in the presence of platelets. 
Clumps formed in PPP at 120 min and in PRP at 5 min (A), 15 min (B) and 45 min (C). 
 
 
For the CM case, cell aggregation was higher than observed for UM cases with 
the clump sizes being larger, with an average of >15 pRBC/Clumps within the first 15 
minutes of assay (Figure 5.6). After one hour, the clump size increased to giant sizes of 
>30 pRBC/Clump. The clumping behaviour of the UM isolates used in this study, while 
not ideal, was necessary due to limited SM sample availability at the time of collection 
and was considered adequate to test the hypothesis. 
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5.3.3 var gene group expression in platelet-mediated clumping phenotypes of 
Malawian paediatric malaria patients 
RT-qPCR was used to quantify expression of the three main var gene groups: 
upsA, B and C in P. falciparum isolates from 65 Malawian children (Chapter 2, Figure 
2.3) in order to distinguish platelet-mediated binding pRBC phenotypes that allow 
multicellular aggregates.  As hypothesised, there was a slight increase of upsB and C in 
the platelet-mediated binding isolates while the upsA were relatively low as shown in 
Figure 5.7 (A vs B; p=0.023 and A vs C; p=0.044 respectively).  
 The three main var gene groups were quantitatively analysed in laboratory 
isolate 3D7 gDNA for reference (see Chapter 3) and in parasites isolated from PB before 
culturing to characterise var expression in the unselected population. The upsB and C 
were the most highly expressed groups in the parasites isolated from peripheral blood 
before culturing. UpsB was also highly expressed in the parasites that were not able to 
bind to platelets (A vs B p=0.036). 
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Figure 5.7. Transcript abundances of var groups in pRBC before and after the platelet 
mobilisation assay. Transcripts are shown as proportions of the total var expression in 
the platelet-bound parasites, wash-off and peripheral blood before culturing for 65 
patients. Box plots of proportion of var groups A (red), B (blue) and C (yellow). The box 
plots outline 25th and 75th percentiles, with the median indicated as a line inside each 
box and the 5th and the 95th percentiles are illustrated by the whiskers. Outliers are 
indicated by open circles. 
 
 
This was not surprising considering that all the patients included in the analysis 
were uncomplicated malaria cases and did not have the clinical symptoms associated 
with severe or cerebral malaria. Therefore, it was expected that upsA would be the 
least upregulated as they have previously been shown to be associated with severe 
disease (Kyriacou, Stone et al. 2006; Rottmann, Lavstsen et al. 2006). Var gene 
distribution in the patient samples was as previously shown (discussed in Chapter 3); 
with upsB being higher and upsA being the least expressed as expected for var gene 
distribution in the 3D7 genome.  
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5.3.4 var gene group expression in platelet-mediated binding phenotypes of 
Malawian paediatric malaria patients by ABO blood groups 
var group expression in the platelet-mediated clumping of Malawian isolates 
(described above) was also used to ascertain the role of ABO blood group antigens in 
this phenomenon. The study cohort showed similar distribution of the three main blood 
antigen types;   type O- (13%), A+ (23%), B+ (29%) or O+ (29%) (Figure 5.8). 
 
 
Figure 5.8. Distribution of the main ABO blood group antigens. O negative 
individuals did not have either A or B antigens on their RBCs, and the Rh factor was absent
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Figure 5.9 Proportions of var gene group transcripts before and after platelet mobilisation assay of P. falciparum obtained from 65 
children with different ABO blood types. Transcripts are shown as proportions of the total amount of var expression in the platelet-
bound parasites (A), wash-off (B) and peripheral blood before culturing (C) and by reactivity to host blood group antigen A+ (n=17), 
B+ (n=21) and O+ (n=21). Box plots of proportion of var groups A (red), B (blue) and C (yellow). The box plots outline 25th and 75th 
percentiles, with the median indicated as a line inside each box and the 5th and the 95th percentiles are illustrated by the whiskers. 
Outliers are indicated by the open circles 
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In order to determine if platelet-mediated pRBC binding is blood antigen group 
dependent, var gene group expression was analysed based on the different blood 
groups. The most significant differences in antigen expression were found in the blood 
types A+ and O+ in the platelet-bound parasites where upsC (p=0.027) are highly 
expressed. In A+ hosts, upsA were significantly downregulated compared to both upsB 
and C genes (p=0.047) in type O+ hosts (Figure 5.9A).  upsA genes were also slightly 
upregulated in blood group A+ hosts although not statistically significant in the platelet 
bound pRBC. This is interesting considering both upsA and host blood type A+ has been 
associated with severe disease, but it also contradicts the hypothesis.   
Similar trends in antigen expression are observed between parasites not bound 
to platelets (wash-off) and the pre-culture parasites (Figure 5.9B and C). Therefore, 
there are no significant differences in var group expression in blood type A+ children, 
although group B are significantly downregulated in the platelet-bound population 
compared to in the other two fractions.  UpsB are also highly expressed in blood types 
B+ and O+ children (A vs C; p=0.034 and A vs B p=0.004 respectively) but in all three 
fractions. This study provide some agreement with previous studies that consistently 
suggest that blood type O hosts of falciparum malaria infections tend to have milder 
disease than type A hosts, who are also more likely to develop severe clinical outcomes 
(reviewed in (Cserti and Dzik 2007)).   
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5.4 DISCUSSION 
The main finding of this chapter is that platelet-mediated clumping is a common 
in vitro phenotype of P. falciparum isolated from Malawian children and is not only 
restricted to severe forms of disease but is also found in uncomplicated isolates, with a 
less pronounced phenotype of smaller clumps formed over a longer time interval.  
PfEMP1, a parasite protein expressed on the surface of pRBC, has been identified as the 
major ligand involved in binding to CD36, a major receptor implicated in platelet-
mediating clumping. The present study also demonstrates that upsB and C PfEMP1 
types are not the only VSA likely to be involved in platelet-mediated clumping, as 
hypothesised. There is a possibility that a range of var/PfEMP1 are involved; platelets 
have several receptors for clumping including P-selectin (Wassmer, Taylor et al. 2008), 
CD36 (Pain, Ferguson et al. 2001) and gC1qR/HABP1/p32 (Biswas, Hafiz et al. 2007). It is 
possible that a wide variety of receptors on the surface of the platelet would be 
capable of interacting with more than one var/PfEMP1 and their different binding 
domains. In addition, PfEMP1 is not the only parasite ligand on the pRBC surface, 
therefore the possibility that other variant surface antigens are involved should be 
considered.  
The study expectation was that group B and C var genes will be expressed by 
clumping isolates and non-clumping isolates will express mainly var group A variants. In 
accordance with the study hypothesis, upsA were downregulated in the platelet-bound 
fraction as expected, but they were also low in the non-cultured fraction (Figure 5.6). 
Contradictory to the hypothesis, there was an upregulation of upsA in blood type A+ 
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hosts in the platelet-bound isolates (although not statistically significant). This result is 
an example that highlights the complexity of the interaction between the parasite and 
the host. Besides parasite VSA interacting with platelets as described above, the 
parasite can also form rosettes by interacting with the ABO blood antigen groups.  This 
is interesting, and is contrary to expectations given that both upsA and blood type A+ 
have been associated with severe disease and the patients in this study were all UM. A 
substantial percentage of isolates from children with high parasitaemia will express 
DBLα1 var genes (Kyriacou, Stone et al. 2006), characteristic of upsA, which bind to 
blood type A and B antigens to form rosettes. Unfortunately, the static adhesion 
conditions of the mobilisation assay (Chapter 2 Section 2.6) used in this study does not 
allow a separation of rosettes from clumps.  
Host ABO blood groups play a significant role in P. falciparum antigen binding 
(reviewed in (Cserti and Dzik 2007)).  The results of the var gene group transcription 
analysis of P. falciparum isolates from children with different ABO blood types suggests 
that all host blood groups support platelet-mediated clumping of pRBC. Isolates from 
blood type O hosts showed abundant expression of upsB and C while upsA were the 
least expressed. As it has been previously shown that blood type O individuals suffers 
less adverse disease, lower expression of upsA is in agreement with this finding. 
However, the upsA potentially contribute to rosette formation by binding to blood type 
A and B antigens. 
This study was faced with three main challenges: firstly, the plus system of 
counting parasitaemia only provides an estimated parasite concentration and relies on 
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individual judgement. Therefore, parasitaemia could have been underestimated or 
overestimated, especially for individuals with relatively small numbers of parasites. 
Although the use of UM isolates only provide a partial var/PfEMP1 representation, 
mainly dominated by expression upsB and upsC, it also provides proof of VSA diversity 
and their intricate interactions with the host, at the same time displaying a pattern 
governed by both the parasite and host factors that are consistent in severe or 
uncomplicated disease, even if they are not happening at the same level of significance.  
Secondly, using the platelet mobilisation assay has a drawback.  The assay 
selects for platelet-bound pRBC using a static adhesion technique. Therefore, not all 
pRBC that are capable of binding to platelets will adhere once platelet-binding 
saturation is reached. All the non-binders were collected as a “wash-off” after the 
adhesion which would still be represented by potential platelet-binders and non-
binders. The assay does not also allow differentiation between binding to platelets via 
CD36 and clumping considering that many isolates can bind CD36 but do not clump.  
This leaves two fractions: a clumping fraction (platelet-bound) and a mixture of 
clumping and non-clumping pRBC (wash-off). 
The identity of the transcribed var in each fraction can only be intuited from 
their group.  The ideal approach would be to design specific primers to the different 
CIDR domain types and use reverse transcription PCR to determine the individual 
sequences in each fracton. However, our group has tried this approach and several 
attempts have been made, including seeking help from other experts but so far with 
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very little success. Because the CIDR regions are so variable, designing primers specific 
for these regions has been an insurmountable challenge.  
In addition, the optimal stage for RNA extraction for var gene expression 
analysis is at ring stage for it is at this stage that maximum var transcription occurs. 
Because of the nature of the assay which necessarily uses trophozoites and schizonts. 
RNA at ring stage was obtained only before samples were placed in culture. Therefore, 
although there is less RNA, the var expression analysis on these late parasite stages 
forms provide information on var genes that have been “selected” for VSA expression 
and also avoids “contamination” of non selected VSA. 
Lastly, P. falciparum has been reported to switch var expression between genes 
at variable rates in vitro, hence the necessity to grow the parasites to maturity for the 
clumping assay makes this approach susceptible to var switching.  In this case, the 
transcripts at the time of culture might not be a true reflection of the in vivo isolate. 
However, this is only likely for a few isolates that were maintained in culture for more 
than two cycles to attain a parasitaemia high enough to perform the assay. 
 
 
5.5 CONCLUSION 
Platelet-mediated clumping is a common phenotype of P. falciparum isolated 
from Malawian children, as is expression of var gene groups B and C in uncomplicated 
malaria patients. This phenomena might be significant in a field setting as it might help 
identify pathogenic ‘traits’ associated with parasite isolates prone to form clumps and 
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characterising these phenotypes in terms of their adhesive components and the 
receptors they interact with on the platelets. This data also suggests an influence of 
ABO blood groups on platelet-mediated clumping of pRBC.  Overall, other researchers 
interested in investigating clumping phenotypes should consider carefully designed and 
standardised experiments for consistency. There are several aspects of the clump assay 
that have been poorly characterised, one of the important points, which has also been 
overlooked by previous clumping studies, being the selection of platelet sources  and 
the effect of blood antigen groups on the outcome of the assay. In order to avoid 
unspecific agglutination due to blood group antigens platelets used for each clinical 
isolates should be matched for blood group antigen or use universal donor blood types.  
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Chapter 6 
 
6. FINAL DISCUSSION 
6.1 Introduction 
Malaria is an important tropical disease with P. falciparum being the most 
virulent pathogen, responsible for the majority of morbidity and mortality in children 
under the age of five years in sub-Saharan Africa (WHO 2011). Aside from young 
children, pregnant women are also at great risk (WHO 2011) with consequential effects 
on maternal health and birth outcomes. Several malaria control interventions in Africa 
and other malaria endemic countries have considerably decreased the number of 
malaria cases per year (247 million cases in 2006 to 225 million cases in 2011 (WHO 
2009)). However, despite such efforts the overall number of deaths attributable to 
malaria remains unchanged (WHO 2009) and Malawi in particular has not seen any 
decline in childhood malaria over the time of most recent, intensive intervention (Roca-
Feltrer, Kwizombe et al. 2012).  
The clinical presentations of falciparum malaria range from asymptomatic 
parasitaemia to severe anaemia, cerebral malaria, multi-organ failure or death. One of 
the major contributors to pathogenesis is thought to be the cytoadhesion of infected 
erythrocytes to various host vascular receptors resulting in sequestration of the 
infected erythrocytes in the post capillary venules, obstruction of blood flow, and 
subsequent tissue damage (Medana and Turner 2006).  
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The parasite protein implicated in cytoadhesion is PfEMP1. Its prominent 
position on the surface of pRBC makes it particularly vulnerable to recognition by 
antibodies produced by the host. PfEMP1 is encoded by the ~60 var genes found in the 
parasite genome. Each var gene encodes an antigenically distinct form of PfEMP1, 
allowing the ligands to bind to multiple endothelial receptors (Gardner, Pinches et al. 
1996; Chen, Heddini et al. 2000). The extremely high level of PfEMP1 sequence 
diversity is a highly effective strategy to avoid host immune evasion and parasite 
clearance by the spleen (Looareesuwan, Ho et al. 1987; Anyona, Schrier et al. 2006). 
var genes are divided into three main subgroups: A, B and C and two intermediate 
groups (A/B and B/C). These have now been associated with different clinical 
presentations of malaria as discussed in Chapter 3. 
Areas of the world with high rates of malaria coincidentally carry a heavy 
burden of HIV and in such areas malaria-HIV co-infections are common. HIV infects and 
depletes CD4+ T lymphocytes, putting patients at risk for opportunistic infections. 
Recent data have shown that HIV-infected individuals have more frequent episodes of 
symptomatic malaria and malaria increases HIV plasma virus load (Kublin, Patnaik et al. 
2005). HIV affects the systemic inflammatory response causing activation and/ or 
apoptosis in a variety of immune cells as well as elevated levels of pro-inflammatory 
cytokines and chemokines in plasma. This alteration is a potential means by which HIV 
may affect disease course and outcome in the other infections such as malaria 
(reviewed in (Hochman and Kim 2009; Hochman and Kim 2012)).  
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This thesis mainly focused on investigating the contributors to cerebral disease 
development in P. falciparum infected children by: firstly, using post-mortem samples 
to examine var/PfEMP1 distribution of parasites sequestering in the tissues particularly 
the brain, heart and gut, and investigating possible association of the var/PfEMP1 with 
different forms of cerebral malaria and parasitaemic controls. Secondly, by comparing 
the distribution of putative sequestration receptors and cytokines in the same organs. 
Thirdly, investigating var/PfEMP1 and cytokine/receptor distribution in Malawi and HIV 
co-infections and lastly, the investigation and the role of clumping in clinical disease 
and the ABO antigen group plays in this phenotype. This chapter provides a summary 
of the highlights in this thesis and ideas for future work. 
 
6.2 Major findings 
This thesis provides three major findings in relation to var/PfEMP1 antigen 
expression in relation to clinical malaria disease presentations: 
 There was no difference in the var gene group expression in tissue populations 
between vascular pathology-associated cerebral malaria (CM2) and 
parasitaemic controls (PC) who died with non-malaria causal, with the var gene 
group A being highly expressed. var gene group B was highly expressed by 
parasites isolated from children with cerebral malaria with sequestered 
parasites only, with no vascular pathology (CM1). 
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 There were no significant differences in expression of the receptors and 
cytokines between the diagnostic groups in the brain. However, most genes, 
with exception of ICAM-1 and TNF, were more highly upregulated in the heart 
and gut of CM1 than CM2 cases. In agreement with another local study 
conducted by Mbale and Moxon (personal communication) using children 
enrolled at the Malaria research ward at QECH, TNF (measured by ELISA) is 
significantly upregulated in CM2 cases in all tissues, (p≤0.042 for all tissues). 
Interestingly, there was some evidence that in malaria and HIV co-infection, HIV 
has an effect on the pathology of malaria. P. falciparum antigen expression in 
the CM1 cases, in which the majority of the children were HIV co-infected, 
showed the major var antigens to be group B. This is the first demonstration 
that HIV exerts an influence on var antigen expression or selection in malaria 
infection. In support of this, the pattern of cytokine/receptor upregulation in 
the tissues of HIV positive children were generally similar to CM1, with genes 
encoding for PECAM-1, VCAM-1, vWF and GP1BB  being upregulated in the HIV 
positive group in all the tissues.  
 In agreement with previous studies (Wassmer, Taylor et al. 2008), the P. 
falciparum clumping phenotype is common in P. falciparum isolates from 
Malawian paediatric malaria patients and it is mainly associated with expression 
of var groups B and C. However, there was no strong association between a 
particular ABO blood antigen with uncomplicated malaria but it was shown that 
var gene group A were more likely to clump than the group B vars. 
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6.3 Implications 
The data generated in this thesis has some implication on the following:  
 
6.3.1 Implications on future var gene studies 
This thesis has demonstrated the same antigen expression in the tissues of 
children with CM and PC with two possible explanations; 1) a specific var gene 
transcription pattern which would support strict var gene regulation and transcription 
(Discussed in Chapter 1), or 2) immune and inflammatory responses leading to 
endothelial cell activation (which affect receptor regulation), hence parasites may be 
selected to bind based on receptor expression on the endothelial cells.   
 The advantages of using post-mortem tissues is that they provide a snap shot in 
time of what is happening in the tissues. These results also support the hypothesis that 
P. falciparum antigen expression is not influenced by level of parasitaemia, but rather 
by the host physiology and immunity, thus only allowing a restricted number of 
antigens to allow sequesteration to the microvasculature. However, obtaining post-
mortem tissues is a challenge, hence more studies on var genes are performed using 
PB. Investigation solely of parasites isolated from PB may only contain a subset of the 
var repertoire, with sequestering parasites showing different expression due to 
differences in EC receptor expression as mentioned in Point 2. 
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6.3.2 Implications on HIV and Malaria infections 
HIV has already been shown to increase susceptibility to malaria, bacterial and 
other viral infections due to an impaired CD4+ T cell response. In co-infections with 
malaria, HIV has an impact on the expression of certain receptors on EC that in turn 
influence the sequestration of certain parasites. One of the possible means of 
accomplishing this is through reduction of cytokine release (as shown by macrophages 
infected with HIV (Ludlow, Zhou et al. 2012)) such as TNF that plays a major role in 
upregulation several receptors involved in parasite cytoadhesion. It is through such 
mechanisms that HIV can also affect malaria pathology. Unfortunately, there was lack 
of information on the level of infection of our patient’s level of immune impairment. 
This information would have helped us to determine the severity of 
immunosuppression needed to influence malaria co-infection.  
In the long run, this also has implications for malaria treatment, especially in 
cases where the aetiology of disease could be different and therefore treatments to alleviate 
CM may need to take this into account. There are still several unanswered questions 
pertaining to HIV/malaria co-infections. It is unknown how antiretroviral treatment 
(ART) might affect malaria pathology. In Malawi, the ART currently in use are the T30 
treatment regimen (Stavudine, Nevirapine and Lamivudine), which has adverse side 
effects in some individuals. Fortunately, T30 is being slowly phased out to the 5A 
treatment regimen with less adverse side effects (Tenofovir, Lamivudine, Efavirenz for 
adults and Zidovudine, lamivudine and Nevirapine for children) (MoH 2011). With the 
realisation that HIV/malaria infections are common, studies on the interaction of 
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malaria and HIV from an epidemiological perspective and the effects of coinfection on 
treatment and other clinical outcome are under way.  
 
6.4 Study limitations 
 Most of the real-time qPCR data was generated from post-mortem tissue which, 
due to the difficult nature of isolating parasite DNA, contained substantial 
amounts of human DNA contamination, which is almost impossible to get rid of. 
All samples were run in triplicate or duplicate and a melting curve was added 
for each PCR plate run to ensure consistency in product formation. Using probes 
specific for each antigen type is ideal, however it was extremely difficult to get a 
consistent product in the post-mortem tissues either because of the high 
human DNA contamination or primers were only designed from specific 
sequencing. As such, RT-qPCR was performed using SYBR green fluorescent dye, 
which is not specific but binds to any double stranded DNA.  
 Post-mortem samples are hard to obtain, therefore the sample size did not 
allow for extensive and exhaustive investigations of VSA and cytokine/receptor 
profiles. In addition, for the HIV positive children there was no data indicating 
level of immunosupression to pin point how HIV infections could potentially 
mask host endothelial receptors and distribution. Nonetheless, there is a good 
indication that this thesis has provided some preliminary data to be used in 
designing future studies on the role of HIV influence on malaria infections or 
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vice versa, and makes this study unique in the questions it can ask of these rare 
samples. 
 
6.5 Future work 
This thesis brought to light some important issues and generated potential 
research questions warranting further investigation that, if addressed, would 
contribute to the better understanding of malaria and HIV co-infections. 
 
6.5.1 P. falciparum and HIV co-infections in children 
It is inevitable that malaria and HIV co-infections occur in sub-Saharan settings 
where both infections are endemic. This thesis provides some evidence that HIV 
potentially influences CM pathology through selective endothelial cell receptor 
expression that are used for parasite sequestration. However, the molecular 
mechanisms of how this is achieved or at what stage of the HIV infection would have 
greater impact on the course of malaria infections is not clear. Further investigations 
could be designed as follows: 
1. There was no strong evidence that parasites isolated from CM1 patients 
expressed different var antigens than CM2 or PC cases. These cases were more 
likely to be co-infected with HIV (OR: 12.00 with 95% CI (1.06-136.98) p=0.057). 
Further within-group analysis of the different HIV status was not done because 
of the limited availability of patients in this group. A larger sample would allow 
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patients to be subdivided into HIV positive and HIV negative within each 
diagnostic group to allow within group comparison of antigen expression. 
2. Parasites can be easily isolated from PB of patients with different clinical 
malaria diagnostic groups, with those HIV-malaria co-infected further groupd 
according to their peripheral blood CD4+ counts as follows;  high (>500 
cell/mm3), medium (>250 and <500 cells /mm3) and low (<250 cells/mm3), to 
determine the measure of immunosuppression causing the most impact on 
parasite antigen expression. It would also be more clinically relevant to have 
patients on anti-retroviral therapy to allow the assessment of ARTs on parasite 
cultures or malaria drug resistant development  
3. It is likely that HIV and P. falciparum interact as they both provoke an 
inflammatory response from immune cells, with subsequent effects on 
endothelial activation. The effects of one pathogen on the other could be better 
understood by utilising co-culture techniques. The binding efficiencies of pRBC 
isolated as described above can be tested in vitro on different receptors and 
using PCR techniques described in this thesis to identify and determine the 
specific antigens involved host-parasite interactions. 
4. The consistent upregulation of certain cytokines and/or receptors due to the 
inflammatory response such as vWF and VCAM-1 have been used as markers of 
endothelial activation in other diseases. A correlation of such markers to in vitro 
pRBC binding ability maybe a useful tool as early markers of pathology. The 
cytokine/receptor expression was not able to be compared to parasitaemic 
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controls due to limited samples available for this group. A larger sample size 
would allow an extensive analysis of other cytokines and receptors such as IL10, 
IL6 and IL12 and IFN-γ that were not included in analysis presented in this thesis 
and yet are crucial in both malaria and HIV infections. 
5. The comparison of antigen expression in the tissues versus the PB was not able 
to be performed due to the poor quality of the DNA/RNA obtained from the 
samples. This is an important experiment as it will determine if dominant var 
antigens in the tissue are the also the most abundant in the blood. A proposed 
study would be to select another set of five HIV negative patients (to eliminate 
the HIV influence on parasite antigen selection) who have CM2.  
There is an in vivo phenomenon between HIV and malaria coinfection that 
would be difficult to investigate in vivo but some insight can be revealed in in 
vitro experiments. Monocytes or macrophages (either HIV-infected or not) 
could be exposed to parasites and measure their cytokine profile. After that, the 
next step would be test adhesion capabilities of the infected cells with EC to see 
receptor expression differences that were brought on by the differences in 
cytokine profiles.  
 
6.5.2 P. falciparum platelet-mediated clumping assay 
The clumping phenotype is common in P. falciparum isolated from Malawian 
children and is associated with CM. In this thesis, a platelet mobilisation assay was used 
specifically to identify the var gene group associated with platelet-mediated pRBC 
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binding in UM only. The analysis in this thesis did not include CM samples due to 
limited availability. A proposed study would be to repeat the experiment using the 
platelet mobilising assay using 40 UM and 40 CM isolates to compare var antigen 
expression between clumps and non-clumping isolates. Initially, the DBL regions would 
be amplified by PCR in order to determine the sequences in both clumpers and non-
clumpers. The DBL tags can be used to identify full length var/PfEMP1 and/or used to 
design specific primers for amplification of the CIDR domain with fewer artefacts of 
human DNA contaminations from using PB. Alternatively, the experiment could initially 
be conducted using a laboratory isolate such as HB3 and use qPCR to test expression 
levels of their known, sequenced genes to look at upsA vs upsB vs upsC.   
 
6.6 Concluding remarks 
In summary, the postmortem studies in fatal paediatric cases in Malawi 
revealed that var genes expression and distribution in the human host is complex but 
there is a clear dominance of certain var types in patients with cerebral malaria 
regardless of the tissue from which the parasites were isolated. This study also 
indicates that var gene transcription is not skewed from the 3D7 genome but rather a 
subset of the parasites is selected to bind based on receptor expression on the 
endothelia. Both the host and parasite may influence cytokine production through 
inflammatory responses, which leads to upregulation or downregulation of various 
endothelial receptors. As a result, receptors like PECAM-1, VCAM-1 and vWF which on 
their own may not be adequate to cause adverse pRBC sequestration, in large numbers 
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may act synergetically and become an advantageous trait for the parasite to cause 
detrimental sequestration.  
The findings of this thesis have highlighted the synergic relations that exist 
between P. falciparum and HIV co-infection. There are several questions that still need 
to be addressed about this microbe relationship at molecular and epidemiological 
levels. Future studies can use this thesis as guidelines for further research in 
malaria/HIV co-infections.  
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